var title_f22_39_23152="Allergic child";
var content_f22_39_23152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Allergic child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 264px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photograph of a four-year-old allergic child with \"allergic shiners,\" mouth breathing, and \"adenoid facies.\"",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23152=[""].join("\n");
var outline_f22_39_23152=null;
var title_f22_39_23153="Atypical nevi";
var content_f22_39_23153=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68734&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atypical melanocytic nevi",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple melanocytic nevi on the posterior trunk, some of which are large in size (&gt;6 mm)and/or have variegated pigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Clara Curiel-Lewandrowski, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23153=[""].join("\n");
var outline_f22_39_23153=null;
var title_f22_39_23154="Adult ADHD screening tool";
var content_f22_39_23154=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Adult ADHD screening tool",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 491px; background-image: url(data:image/gif;base64,R0lGODlhXgLrAcQAAP///8zMzPLy8kBAQMDAwAAAAICAgPDw8NDQ0KCgoJmZmXBwcDAwMODg4LW1tVBQUGBgYCAgIDMzM7CwsJCQkDw8PBAQEGZmZkxMTBkZGQAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAABeAusBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5urtuCQa/vw2/LggMAwQlBAMAwy4EyEjQzDrPRAVDzUANDSwHCCINCT3hJ94mCAcryivXTOQv0u0yBjUGEzzoQQsMEIMIBBQYPDuQbcWDeybWFVQnzYg8ejmqDZEHZGEPiwmXAXi3gyOJdSWOqdOYgmISjyzk/5l8AXEGgx4ifxQ7BJLZgwERKIjYx0DcCAQWjB2AwIDBPYX0JhSFkO5BOgjcoCYQt2ABTmhEB5AUgUDrgAUAFnxDABZAgqJgD2iNMCFBga8Alg0teg8BhAcMHuy0GgHZ2QEMvk0Nm+BBArWAv5E4mzessQHpql4tUcAqg3TFtKYbMTguAMRsAWSGDICAsQgtRRhjkHYtQq6rfY7YhxpAhAgDEPwNbJYChAUQLAxIQNYsX50Asm41/iCCuLlGRYNNcDy5cNlAjQFQym+zCNN49Yp+nO6aXaL9FvsGy9MnT3oGikIMqPWb5L7S43pFp5U357dgVYYTZuSRkFkE3GiknP8IXw3oWG2ltYbTBASUZVdYfBEQHoMGAOZNUMvExwBE92nYGGivibafdcMVUpMB/RxgAQAUQIQgCSLV+FkEpYVITwTpGKDTQQ3kBMCMw7Q4gV4UlGXSQT3Ghcw6XYkAgS8WAqASjfQcwKNp6fCmpF6bLckMPVoR0MADyBRpIJCifbaTTmNSFiRYcCaQngjNXGNAlnn2Y0GQqckJQGB/ckXCZjJ+9FKczZSplwFs/aORQjHO2KQIJsH42aA6ehmlp43WNEJMcArpaJjfBKplaZfFlSKlEyCgo20NUCAeAlXGxeujItVZE5hsbsQjCSpxs4BOrp56zwHcXLPpq1oqS4H/aYom902icVoQFZ3iKMVqtcyAJVKvucUVbqyIZjlCsRpGaciLEF0DmFYWNBQsNMcgBdI6NVKQwDGTojnlMjGZ1M46IimEG04GEBABBBSUN4K9/D6j0b5RInCTdklC85ZWFBU0wVoGy3vxd8cIdy8JfZY2ccUEuGwMSAt1OEC+ElPs3WcQkLxoBA8YwE0zHr/czL8+ciql0zBDdExM/Tb9qqkMHszyRxs/Y/My1+CcWjP37qyMNM0AIzUyDS8DUpHReqXwymfW3N9WFESwgE8YQ93OL14WzY1a381MqJfptJ01tQwjk3bKIPVrOLIrYy0IvU4PkCKOyEDpK1IzlaZX/1d6Fa1TyFEmTNnWinM7wgFL9rOl57lFzrbWFnyD1NNa/jyC6wikCvly7SyJ7Qkxfxb78VufSYKui8P+wJ4APIDcShXy2Ezuo0LEtPOvqh61ah4jVLvVYS/3dOjxjmA7806DtOz4suL42rRCkn17lCBF1zsKW6rbo04Qjp6ET2RQW9oCeJQA5ChvehuxgJ4WZztqmSlHZVGV4p4mPeoNSgQzslwgMPcqpXCjVpwzi1Mk1j3bEOAAhlFNPxIQgW0Nj0Z6IcCTTrcMn1nFWMhAwAQohMMjNcBihTkACyuouNwd4IeoCwtTDuDACHKDAsGD1gBuiKwjxpABOvFIYcxyDf8iQg+MGxGHE4v2vBz2xYziEYH1yGggcQCFRplCBxQhErzP7O5V0NNhCTzFwiQuEX2i4dHPDJOOvsBQNvISCRrJEbbLwI1+JtyObiBzgATADW5ZLNL+1rEOCLQEOAegYgm8ZTHnTRKSFODGHKWVw3b8zQC6Ec2MnCICOFqpANx4WgWB+cjqHeaTN9rgMXw5AlMyox8iBERxRNAZjSzpKz8TCzUHAJX8DKYBQZNNxD6jkcFoc5odcksJhlK0ZazJMBYKGgR4Jc90nAxN2+zmNLV5TrCQjjpmoYpiaKSVKopuADoZGMUEmh8chVMETxyA55qpuWXYhZvpiCiUPLbQElj/5U/0xOiibnKyRVnlAd8YygAa8M/piFNzxakmn4bTKa100yzc5EZMfaKRDqXIY3oBZ4sMVBZtavQebiNasRYjm2suIB0Dg5KGlnpPgYRlLP4014ooUNAS3NMzAf3MSVN0TanNVJ1gnYpGEbCmn9STmnHs506+UYCHiuYBOcQrNOR61YsyZVEdMgBmysILErB0O+prXmF5cNiS0q8K0bTBPYrkuyc0NrElEJgKYsKOxTZhTSI9wTQ9qwPQ/pWpVxjtDoKG0iqYtrLnUAE4XYBZ0tr2trjNrW53y9s1cHZ8+UiIbAgAjIH6QkjBfCwKGvId5sZgG0JwbnB18NsnXMMc/wQMpkRu4MnS0A0G0GUIDLBW3RUMI7jlRQJjYlCoF6zktumNYgkY4C0+QYAAsWPQtc4CSfCVJCHOhQFGdrCS9NbAwEtIHwqWFmAZdDeAAm4vgMe7HAQjL2W8Y8IH2UuD9+JiNWWhT77SKo5fZGc5xZiff2MYEy8llxkSdU5YPeMWuHCGKgyA0Kn4Ys+lNBI3A7ULXq40GcTwZjeCqU6NCXvi7fiYqB0aj2bi0qFYSRIwZWHM6ApEgvcwQz4M4vGD6MHXawRnOEi2DZAHw52/lsiwMSKTXsSyZC2JmQQgLsFtcrM3w6TZnBkiZ2I2creQBA0/RhbMamzYZG4WuT+1iv+NdKLMGMJScwHNseMCoiwieiw50WYpikVPkyCg0UU0d2nMobAMtcJuJjChE8ktnVfeZYUuGyXl7KZhlpZBJW8lvzjeQDllLdsE6XSFAtOhwlW6Nimyl5PKVKtPBY1UVbFm1zK2WWR3NHMh49W8glOroEo96IkGXXS1lrCFqREFG8pMj9O2Bpm9yk7WMF6yvlixF0U++qXpiNCmNb2L5SapVnjgzn53wXhXpzmKhlEhtMC1enUlmGVKiRInALqpRXAeFQAz9YMWILv0JXaltN8evoXO8qU/ag1DviO40Y2y0bjfjW1tvzYB4IhmtNXV7VJWc1/XojSyAZjnY4ikVgr/vyf073yNcQhzHL6I2xK7vYzaNucTPW4ZuJ5v0N1JAxlEgg10dpeATYb5BZ2QEcCcTd3f0Ah70xRX9GssrMJaq/tdlYZhui8qaEaXF6VQBnexaZ1aesfLOPO2t8xlrIIrZ/tizX2Mls8a5rpcC7J/t/ZTDbsZiKrXtA8foWPRzcSPitdCKriOj5OAe3+0pQnOlfo4ygt+FtTLMShPXMLi3lkjwJ9OZl16s19NI7C3Guq/o3utPc8Aum9tvhOYGt7DHYS6m3vef3b3kGz/9dmndcaI7h2Hu9t1g4RIYEAifMT7zlb1LaA4rkE7S2XN+imvRSD7Ekr81LABW+Q8jNRl/8gxE8NARVbWJhBAPc8kMypER0b0MyZmRzNCOc7jSDHkG4YSSVqDSqrkRHsENaxEAgOIgZBUE69ULcW0e26kJvWlEynIGZzkSQhySbeUS3fkQ+2WSJ+iR8uggQTxIy/EYs43Ag0gQckBLMgwgsQnAvvXEEAYEyCofVHigUPCQ95XhVOkE1MogIdhdr+xEUuSUO4mSqIxK9D0JRqBTNGyE1vIDKlUQ7FUPcOnQkqkhvfXgtSSLrrwUdp0T9qkDB01GEBFAjdVPZ3kFRWzE1oRQyWgJzllJRXVSwF4Y2sVEtQkDkLlEyqVXPuEVU7YVS01Y9ZUiVyBVxthVz9BWEelJf92xU9bFIg3oROtuBgSdRR6xSCZeInvBFBg5VOj2Inf9IqgeHbpUCFzhVj4NGOzEYvD1onapCLwFFZ8xVUIBTTT2GXFaI06MYqEiIpyRRDchA4kZVFMJk+fZ1M65Xu5CFYEdY3WeA9lpYs4pU9FZR/OCFZ82Fu2kH/8uAQD9o8CCQS1NZBJ0BkGmZAKuZAM2ZAO+ZBNEITD5gRK9GLqUABbV5A58BZQwJGb5Y85EHgqUJEMApIzIJI2oENo4mEq2QIteQMGUAANZgIkGRcmCZHqVQB1JQUv6ZIYWRoT6QMa15EaiZJBYJQn8JJISV03qQIt+Q8oUJMXKWHsJZPO8JP/ojGTOLkEO2MBH9QV+/AWP5MAFqCTvOQxZulkBWABuNQiXUEcCFUVh6KTMsYABYAbKrKWlpZId/mTcBE8OskbalEAxsAeX+GVz/EAeumEEbCYcLEmgTlsSrGW9GCXdykOA7NAlVECxXCZKhKWpCGWf3mNp1IZd5lSEGCWY3mY+WJ06bEAOmkBRbWWZcknZekfqnGXCFMZiBkWmoNSMLSYvsmI5ESYcGF0C9CbeEaX/YWWBcAmP/lDmdmY/tQiQ3GbDQCbi9mTtkmY/FGdMMiczCCTb6kiVBGbYGGXePlDYVGWvDSdm7mVQ9AAdZWa4qBDqGGXVTQVFVIAzGIBQ8QA//QpEIXRkiqpQ8IBFvc1AREwI6kZgEFBAKmZIl45ARTwkxyJABHjFrrnnzq0m7+xltVTABMQk1j0nATgC1qyDIpJIdG4EYSZonqxoA06nltUlsNmAX2hmP9wl/Hhnys6l09klaWZABNAmNUDoBdqaTH5FXppl9tCIUZnK3VlGtLinxMQFIb4FisZojNidMaAliUKpCIZeEZ3LRzpmrBZgc2EXzVKAg0aoC0ZeE1qADjakql5LWxiD8pQAD1afViqpXZJECSaHG6KJDJpoD/Jp1P6oCtJIxh5pJPCpTgqn0IQk0PEkYqaGh5TlhipQ4SFqe7zkweKlV+mk2FDqrppl/9Vt5ktyZFD0ZgciaRBWqZ2124rdZutxZFraorjOSuW6SdWGZPSsKmbGqRuQUOmV5LMupYksxXEGqTRejKo2qeJYy8jU5ujKjXtYKYqgas22ayPkqbd2inB+hHxWRp+KayOk6gYOkCIVa3caXT4cg3JmmN8cq7EeqzUqpPPgJXeyqzRGq2WCgSyiqoNcKwjoKN/igDxmSuFuhGgqq4Rg5UXKliB95Qo+gzJNbGvyqKFOqvjupvMqqUH8JzQAn0iCqvU0ZgOdKEIAbEYy67jKQ0OCxZHiqb08LGfsZZAiiPtQF9H0hfP8HlWyZHE6rAPIAwyaXTXOqIUsl0Uy6zhipL/JvucNvm0tEquVOuEGDmYBvKwc0qz+/qTWupHz8m0/5oaLfoM3/YWm3mxYFu2YKGSSqu2Skl/rie0AyuTUlmwOXCk9yWhlaGwIMSWRleZlZGcR8iWQUOfb1GWFTsfz5mc5kGY6VlX0JcaDdohGAqywMGRihm6JBuusIlpJCoxm6alaVo0LWqEXgkjCFW5tdm3DUFf8eEtx+qRqQlMIYGRoxsWXHoXMHO0IUKehEkpMsmhlrsdPrpAYcsa4Vq18nC6r5uaEWCZI0q602uUF/oAzbucVZEv61qzNduSsFk0OZG8jbm2JHCkqAG9I+q739u8xAq5O4ORDjsi7bu/5lJG/5W7mbbLnYB7A1ylGF0xT245VFyhFen0GdZID9mpFfLITQMDl7JhFQvYUxIFwTY1bEnzwHABQ1s0wkHTpMOZwlwFJRGFTXGBszcxUeBgFZrjmxuMU4Kxj2I1jubZwzbGoSZwUqZYGLdoi98AFwOTw+CbLh1yw6UBeAbVIXOmET/EnqHoOSrVJHJxwrxKxcuhwUGzThFcntKZLklcniqEUVFlFbzCwN8BxSyzJ2C8DEmMWESGmRLFxjA2xdBGmnV8xm5cwI5AHZ5rUGYwoXhAyGcqyIwcBcogUf11Bh2MB4/siI18yZicyZq8yZzcyZ78yaAcyqI8yqRcyqZ8yqicyv+qvMqs3Mqu/MqwHMuyPMu0XMu2fMu4nMu6vMu83Mu+/MvAHMzCPMzEXMzGfMzInMzKvMzM3MzO/MzQHM3SXApqA3NSS0AS5mENcwLWuAAWuTjrFTX2kAPTFXxa4c0sEFlO6B2LuB3f3EvvLC7gkBrXdF+loXbJ1c0vpkoQ5UAT8M7uTE3wOgL1rJVB0F3LFWDYBQMWVl37wIBBoM44AJXMR5pWUBABSQjPsIDV8FvXHMRI6HOzJ3mDNEUNdAIisWHIojFUydDMBSOpdNIjsQIVZywbkZzOlZ0jZgKxshMhbRonBBYwkqIfBNOdZFA3sm03vdOGhdO/019AvR17aQT/CJ2UASbRKK2VvxU6RoDV9QAhcFNMF31zj5ANjoYf5pRj7SVBcZQV5nGPUlJnwLco/XHEKQogPrcOoEYdmWZq/lNRZKkdc/06kJYZBqTXde1V4rEpSmRV62QazqWiCztG5ZJ+i1PDKKBiLAzZNMnZEDXQ6LcTYFZRvzJllRZmDgJqfQZJYoEiqPVmZ4ZjBkQdOIEcIhZEBXLbhngdbQZV69FlmFZDgsYbXVEfzCFjiD1oeMZqNPIYY8Fl7uNMiRQZVTRPO4EM7SFlBkQWHeLar0MU0cHdW1HcTLyzp9Elid1AYTgIZk1vwfYoE2kmHzQt7sYxK5GlFKMYHfc073Vd/86036QCKiTHKQvwQtWF31gkRwUIcVGy3/V2KANlYOVl3QH3QUdYNNAwDBJjTxaQ3+fwEo2CdVlNgi924eNURHFSuIizbRQ3f8W23//GOdzyeWhCb+xnI8IgbbGGDIGy41wjAtbGDJWCI/f5EvsNL9H2KUrEognHbxDu483yWMmJaT+jgUfIJUAOcJ9SGhk348+3I1yebe8yJQtX1PQA4EPO3i3ROoLFcxZZcRWnOkxE0iUQDgs0f3LD3wyiFZyCE+Khd/pDNXReXnYuYxShUhkLNnnuFVZCgyk04pjYTOJQ07ATH/0weH5qhC0rDoyOKxMk4iMNM8xV6fyQYYzzNf+DBzEul5FCU16S4zPjoziR8xgsJ3r6Y3XG0HJN9z0WoTp6tyW3ruhCAzNTd+tPZ9kbcRlKkSKIkyS0/kKA5249086LIyWWA+wR01OsTqct3QdmrTUKtKxH0h/NFz9DN30oUFKuh3X9bSx0JYHqVz4MQlegbgLqXn7XQ34pAIiPHuqRDkLkvk5+QmYQ7Vhd5lP9noW/02AnWz90Az+hPWvrXu0p1EGxrjWRMyu2vjYQvzY/zj4Ll4WNMvFHshlIEu+tB1u8d+sDjexLsxwUk0wpYn4qY/HvYj729+BH8nOHR/IZzQff3j04yKbbEUegUkvGcof7M4Kz8SzOZIV6bgL/CwMkUE9IDLRCxyIPA9j0QEMPYdgAY0hH6wD1JqCjL8ZZ+1hrimEmIERFX8hV4HONC+D07RU84o72Ed4QvBR8b0/HM6h0r2SGQrTqUpRKned9zHR4itNHsCOgmhQz/YcMrxT5P+5CxdTrJdYPUO9MnmL1Wmj4bSQzGgckZhiD9CMxUVEo9JkemVQrc6ROIJH4dnhIJsD5l04Pa0TwoD8MvhgICClXanVSw0YBrzFOPqURXAVSV6WMHwF4ssGNy59YJAFQ0K8zN6VQwUQShRjdWsGJTUyOkzhN0G8CGtjA5zzvKnL+ze+Exa8mNCxYMwZD/+D8KEAxP+EVZZEu5F0W/wAIAoAoNsswGIeYDM8EDONhugACDRACr4lInSiAxW4kIt5yqlHCR7QtRIbBa/IYLA5NUQwwQT1nrSq4KEJEAQ2cD7A1wq6pXxBwmM6nuQaUPhAamRg8fRkwENjRvBidnIhY/cGJRJhBZh1cffXZ4EAsMe1tGt2hqGwhPEBQtAFFbiWkScrO0tba3uLm6u7y9vrWGhj8DhP3DpgVJ8s+ICo7P0MXDzTnBhe/NER8JhN0RX+Dh4uPk0e/laNLom6n48K2w8fbPume/+I8ICcbUMv7/wMMKHAgwYIGDyJMqHAhw4YOH0KMKHEixYoWL2LMqHEjx44eP4IMKXIkyZImT/+iTKlyJcuWLl/CjClzJs2aNm/izKlzJ8+ePn8CDSp0KNGiRo8iTap0KdOmTp9CjSp1KtWqVq9izap1K1ddDQiADSt2LNmyZs+iTat2Ldu2bt/CjSt3Lt26du/izat3L9++fv/e5cPLQIHChg8jTqx4MePGjh9Djix5MuXKli9jzqx5M+fOnj+DDi16NGnOwgYXiNBoNevWrl/Dji17Nu3atm/jzq17N+/evn8DDy58OPHixo8j/x2hwOldhJt3jS59+rDnvaxTz659uyzszplzDy9+undd5cejTz/1PC726t/DR+re1vz49u/3rE9LP/7+/mXy1x14/xFYIIADfgf/nYELMmhSgJLUV0IQdxTQDy4DFDDLVyoQgOAtBXjjCwLNEGahJBvCgWEvBOhjRInJqNihgrrIOFCNzxyAYYaSgGgHAYIN0+MzKuJywI+3vBgPkQsUZqIyRgpGpDgjyiLhMdFQCUCSvzwIx3wIWFAAAwxUuGUuUnpZIQA34iLkL0SaKaCFaObiJoRqFkMlm7zs+U+fxVDAnJM9/smLnTDueEuhaTpJjooIFMAMO87cSOc3loJpwQL0DLljnKjNiKSHRjxQACAINEAYBMulYUCYDOxwAASvNvAoFiMgsBwDC3T4AJkDqIAAhprCISaGwNpAZgQ+sPDCFGYkEOYACajK/6oIZKaWQK5ixgJDAUxSYgcEhT2gAgXLacqkBVcyEeZyiEyw3LJqlCrmDgbIO4EJVqARQ6/WeiGvDwRgG2Kvv5qi670D8HHrF4sAAMQOJhyASQHEDtGFCUYcDKIKTF4cBQ5cQGDDsN1uy0ACspKrQo/KhritvTBAUGq4OaZ2KL6pvbBAmOVm7LMFbagbphtXsnBvvjCbHPIK7uK55rRHI+JzpKYgfQwLCUCQQAP1wqrlqzuoqGy3FhPbDbPTiD3zvvmMwDSGQvvA8tWBoJDaDtG2HDG6C/A99QilTnCkEcIusBwsYgarrA+IIxw4tQWs+m0i7rYBzKjtbS5CYWmiEP8mAoFSMIEFDAAwLgUEMIPhARFoM0KtlCfQYQSGmArA6QSMCzEAPBMWhQURsF7ADgxYECh0BCzHD2GhG586AfFaMHvXjBSQwARiAvCABRMESkSkBFCbQGoGAAnpIeOySDnBBVhcOBHmQ0BAMBgycEyMIBY/AaT1k+kAw5teyUZgO9xRAFLMiIAF3JA9SMFvXEDaXhZ6RDjCCIFIaDogmYRggMJhCA0FKJzldtc72WGoft4Dn+V6NC4UHI4f5nvA7zRVKhqWanV2op/9DKC87dEwheqKmPvIpCU1lYiHwXihMEw4QvXxLmoH4B7yDvDDSB0RESUijGoSQDgCEIF0pkP/nYpemLnujRCDUyQj/MR4Om/lzwxM9BYEhrjC8GFPe9xrAhhNpUDy8aN5/ShMmCzQjwOGqWa5G2CpRnS+DjJPUM9zlfGUR4BViCpU9Onc7xIlBSRW6FgDMBr3RoChUlnoRTWSke0GQCboCIl/4KmRAA/lrU9qEYnYylCcNJihi50ARA14Fdx0NsIsEiZ/71IXDF1nykTtTxgySuYA3gUz362SOS8q0RTriKF4oc4IsDOfD2IZA19ybJbg+YJhfkQ5Jn0lNa700IuAeazf+WtUslpOj8z5u3DayZlc2JGK0OlMFW0zlPAzoDpV80rCOCtqqasQ5W55y4TaD0/MFIYo/40WzWJ1wYXGq2hHM2SpShH0l+u65zMHagPvFQZ9xCSbJz2XoUDRkKEczRAr1ckPn1oUo9sDkScyeR1OYuhUqQJl/8Kiu3BW7FhYdJGasmmAP4IFSPi0Q6QgFYXtCaGWIXJpFrOoPJyVFXvXauAAwYKAA6SqVA00ZkQvKSiwVAwWy6FAqZYwu5bWCKyWxGsDKDCr6InAqoHqWfQYEAEG8BVDCiqaCN44xSAudIM+VeBSEeHYx9pgfFmlKiLayqKt9olwW/VnKe3UVxK8FnkWLWhmeXnMEr1WDTXC6o8gmtZHXCx6sW2gb7eIJy0kzlRfBMst+2RZLG7vm2gsHHNPOv8gdJoWGUSS7fAcmYK4Xsyi4oRfhwwGnmh61QumsmpQmWok3JXLcALSpOY02SExkSmjuZze+RI3hEjhqxsmzZ4RcKpDaYKHTBAwwANgeTsyvQB5hqgeAJCHR1J9awIYxanViPgAQAyUwZZjEgpqxrwFuAp1FrDAVWUnpp39aMUoPkQLRDyB7TEAD1LaX+iqN0xNGYIAFlgw8oBk1WHm+I1ELEBhC6OPBhSmgExagGrH9djP6XRNzFEfjJfcBgUzGDovIrEBarZV9XWrVAt44Va3Oq412wnHeADilGeboRl22HzrapKcUYDmClMuzFDO8bvgIC/gPqDOetaRfrnQYML/be92/v1oIL6lWt2lBriSjoB4ccUtO/+3xDkNsZp1x2LJnjjFaFyA7wjjq2Nm+aMSLjJ71axhphpiEN9a1BHpux9OcmJCSTvaDnhXBzdcwRMbqxXQRCArP09NWHVrhQ4YcQUqONsE1W6Wlth1hkwMe9jaHtmzoUMDGK7gCi4QAxZU8AWGGeELib6SlbIAiRqsCR/9GsHGhKXuItTbiieoNq6iHW0cZIEELVDDwiWxHDMAAd/PpsDGCv64qbFg3rE6wRIEngNkDBvZY4BBqxrubDnc6lYkFxcKVG5AfXvhCoCoeMWnAIGRdXsBEst3CxZGQ49XW94m0IfqRgAJEE9B/+daY9e9F2HsSPRbcAUeOR1A/HQhVNxLC6d5F7xI9YHi4DTCavnKTNDul2J76mm3eMZMVjdt70Dabkf7BMJ9jCREQu6z6BJVfd2ggwzaP8uZFEssdRK+jwDxfwcIt/EjLL+jJOsqUXyvF2/5y2+E8pTHPOc7DxDNA9vzoh/950O/d9OTPvWqHwfoIb/618N+H6i/k+tjb/vbV2P2aVJNcnrv+98DP/jCHz7xi2/84yM/+bVp3lHrB5jnQz/60p/+9CtEfbVY//poyb72n8/97pPl++Dny7hq33fcb6SmA1G/QNjPEfcDBP4ZaT36NSJ/f9xfHvm/yP7h0X+K0F/9Yf/E/6UDAaKDAUoEApKDAj5EAAqgRTCgOERgOExgQ1TgN1ygQjjgA1JEBkKDBz4DCCKECCoDCRbEBnJgAo7gCoqECRaDCw4ECqYgRMBgkLBgSNTgL+Rg6Zlf4uneDBrEDvaCEBrKSBDhLhxhPMggEFrgDRZEEsYDFLaJSCwhEy4E/NkPIFDLAWpIMARDi+QCr8nC/dWbVg1DlnxKCeIC67QANYCMWzmD+yGAAWQOtRDeMOAMeZkhMVShFSYE/BHGMRkeBs5Ch+yZRNHID/5OLWTKINyOMhAJihCiLZgPoRHYH03RWNlglVzMEgxPNAyWIm5SD34SKfrhPwBiYWgDkcT/S7bkSBQIixC04rxszfXUgvuVV+XJTNhgARA0TdoICsaxzSzIn6o4294oDMmkULRYQKyMy9VIzrDlwDKuWBFQUtici9OM4S2EiQpMUQOZDTPdy9jQjM2AoRHAH4YwC3gIi9PUItd0QQ7AgdWUS8okANO0I7FAjscYFaic4kOk4pQ9ShHBTwBB1P+8D4V0kS3gopi8DyLMIflgUWE4ghORUApQkQXc4SLSwn2BiBD8EQN5jqb8CpPg0PeETyQ5j5qETElikRvByvhs4TbWQi4OVBRNi/ncTpOVzhuFzA0xJC3MEBrxgUVy0bQwyY15yBU9gPXgZBOtzwhxUO6M4lGZ/+I/RuGvCdhyHJEyVQg5OVZXVlOZICIxFuJhnMY+UWSbtdIr1Qj7VBQt3B/rhMm3YNRW1VMM2FOPwAlLxkBeessJhMkwiQnc0GRHugmGgMWACElJtZktFUstiA4WtaU24QmU3RyTqdVFVVVDzdNPIRjk9SFWEkQqutPnDBYBVAyIWE5qUkijRKYslBeTMIAKqFY/dQFvxZMwbI/o3CIjLoH5/MExMckO9AhgZld7IcJx+uV0hQVciVgDHSYtdCNXNdCNCMlyLWdIaWJszoKVXaJo9VbUkIkFjJoIDFdZ7ZZ47qaWiaYoVh5pXqFW/leG/NiMIUK98MF9Blka8shZxv8AmUSBmrGZm4BZg93Iof3mfgwZ7kwAkqkaXjYnmZmZrQEmYEaaI6aakv0nJZ6P4rhnZbEYAmSof/nTgs4CBEknoC1Yg22J+RBYvEVKnb3Inx0oaIZoVfqjfCoE/A1bjnRBwElNAamB2WVByAWlLCCOyRwDJrRcFLgc0CGA3hUdilaJHtTPGSDcEtyKNKaB19UAKlCBlxLbyvHcH7Bbwk1nR3ZCM+jdu/HB1Zmpy5llLeAAiEkpkkLZisabzK0Au0zBz1HblBrcGZ2eKW4ej5aDFH5IOwxekuKgEyqD+XSLP4ymoqKipE4JulnpRzAqpDqDCeyhEsJnomKqBGpq+xn/YapmXqnC56mOw6d26vqt6kHIKjlcKqz6H6vGX60GIRW66lXqKjjcap3+agvy6vwF67CWZrLin68+IbAi6qsyazQU65rSKrLaqrQeFe8p37eCa7iKq2uAiLiWa7ie67j+Rrp+K7uq624wH2o43/jRa73a673SRQE4wL7ya7/6678CbMAKbMDq68Aa7MEi7L8WgAIwbMM67MNCbMRK7MRSbMVaLMMu7MVq7MZSbMZy7MeCbMhGLAYsa7UGRAEIQMqq7MqybMu67MvC7MuibMzSbM3abMsWQADo7M7ybM/67M8CbdAK7dASrc7mbNEibdIK7dEqbdM67dP+7AWUrMmi/+LNWu3VyizWaq3WMi3Ueu3XIm3Xgu3YGi3Zmu3ZBoDUTquwUm0Jbu3b3uzMwu3cyiza2i3Yiu3dOm3e6m3fCq3aWmXbVi3dEi7Lym3hFi7f+u3i+qziMu7SPm7k+izg7qjgRiHiYu7hYu7cOq7k+m3nei7Pgm7ooi3lJojl6t/mJq7qEu7oku7Zum7oxu7rgq3pmge1om6QsC7dau7uYu3s0u7XAm/kDm/wOq3t5h7b5q4v9K7vWm3zOq/NFq/xNu30Lq71Um/RIi/nKO/yGkr0bi30gm/MYm/2Em356i36mi/Qbm8/eu+iju/vxu/Vqu/6/mz9oi3+2u/Otq+Ovv/vAs7v8wZw3O6v3eqv2R7w/vZvfeXCjbUDtYyqVxgqNHRvMngNx8BmCw6w9G5wzSbw/n4w3hbw2S7wr9FXjjTDATDAHiaKNexD/ejLMHQDqioDGvjCMEpBBQ+GDutgB9Os+PqwAITw+g6x1xYx9ZbwoaboKFED73SolpyG/TSDm54BO0CwHUAW+RzCfvqQN44IP0hCDwUpHcJBAxSBkawA+iQWCZghk5GxGlAAGZuxszUDtVjIPf5IA+jxDqRKGxxAEbwVDIAPILiwHcNBIDeACujxmqzJAWiYGq9JqiwCqlAAICwyJVPAEtiP/0hgEMMsEPvwEVOvKO/tCJttEs//Vy3gcIXxSFgsmJYwQ4NV2A58j+5sAwpMwBZHwILhCz8IS92hDvN8UOyMAF+Bkb8wgIaFSDasQMng8iFwpAuPwK5Bc93xzlVxGrKlDj+snZbcjv2MCa8k8xRIDRcgQhvWERRvczf4js51z4C+QLmiwfTEjqAkcxzwThRYwxi8sjFLnrV6ctYGNM6aMgKPMCnTLirTnir3A68UixfCUOy8zhCUzs01QDiRQDhNgDMjwgyvM8GARTz2QwTEaQxAwCKsMCNE2I9odMl4ioK89BkYVoCe848QzyUZTBeUmQic9LV8hUjDACIIEBRnA1j4otGVi68AQD0LhiMHGEdaQVDb/wFxcVRHxwBJlzMFDjTObrXhFjTZIrTShjXpKnSa+NoqgzE6Jp4wJEqGbDQE1EoMG1AXzDDbeHQOeOFPm7Nal/MwrvIXIEAw07Ve5nBsWkPNgE8McA0zC3MwnJFHu7Bfh/ReDyMvBZIXntHrNIEOANQZRMDqQPOO1HUzWLZUz7Bod2ccdvXKgnIHjzXpvnbRxrbklvX50cIqc4rnrPUsqwHqqDANUZnvDLUbQKlV83RzGAlQjwBWz7A7LzU7LORwv0NM87U1oHZlufMwdRzH6PRpOLc23HVNJwtRa6SzwQEDlIsVpAF1s82OUJxUB7Y62/VVl3Qnr3bKtvYGz7bk7v835H7119a2D2pSquxy5mD0NO92LhvCIuTdQrkIFqQ02wjQB6kwkY2Icq9Ajl1BbwuCJJxL4kE4H9QMBOSYYQtDzZjdEZS3G9zOzY0Ciz1yRnf4UlMZ8cAACtyzNSRAixOpFORULXNkrjCYjb9ThOO4s1R1Od+jHtj3fef3APf340Y50E653wZ4Kc6CkcChG8wINSyyj3xCIq/xiVBDIIP5GaimHQAyO5jxHxvQqEqzbnGMHpthM3w5i7i5mo/CacGBkcCVVsmXnwcyqqS5GjQ1n4+CYJi5l6tmIDMZNVBBoV+yF5MAiZ4nQN+3EGe6EP+3CBdwlfftlcfnLeTKRlr/xOuYekzU1CrTgmEZwjm6baY/eQCDet/Wuuh2uteKepegCkjkuU5YiJkrSqFrtaxv+q3fLbKXba4/7a7j7v/qwqzPr7THr7Ln70Eze7NPbTswVximdXsUYgYDAy/0cUk0wAT737Efe7Y/rbVb+ylv+zjYsDqv4SFASp3sXajYAyMs5y68TuFciri7Abo7w2CfrLrLOruX8qcrvNI6u/IGcp73lu+4wRY7NiRbESSPwM2pplB/cTM8smCoH7W88pq8Mcf/cTC4qcuk8QRLcYYHOrVk8iEXliXvsRq88YgE57dTywugvBGUe2IFPZc73Ru7GIt0w8unscDHupOve8Mn/627Qz3SPjwxzLfn8MM9J943G0IC+GKOaE9KmxIKQNma3E68fAw9szypcLMweBEYQSnZlw5IS3WGrBkY9QODsY4w9HKZr85RmxIzpLMh7ArBKDOLI8KCsXPq1A+vnIDGGz45/444J37jkw8zbEo60aEwo/06d3OxO33CT71sY/voD23VD8PVQ/V5QvZp3BkzXLOLuH5WS7iGETnQZ7M1RAB1lXZi4UHdd88cGJo3cppHA/3kpIhQE1cB9XSFNYxNGzXDZHNhG0Hzp/RLM/Ny835shndR4zT8Grvom75/g/D4/22884LqX/dcUz8voYDKy75uh3eugHa/s786a5M1WP+DCvMKCEAGMBBAATRQFDXAe8IoMcBvwiQEapcvahiRTMMhIRI06GqwoK1Y5AVptkJSKHtRjchg4gkOi8cngfmMTqvX7Da74I7L5+tC4I7P6/f8vv8PGHhnJ1ho+Ed4qLjIyHdhRSZmABlJ5rPFQ7Fgs+UUk8AEcGDjOcNU4unD89IQ8eIUQTTq1DmiKvqygAXAgJDCALAF4xPTY4IA7LlA8RIxWtJgMSoaPX3gCbPcPCplUP1yEAv+xLMFLT1eqU4GR+f+XgcvL5/YaH9fWI+/P8jv/x/g0a51kwaug4FjwQAmBSAsYOACxgELBiaUegFhgIEHzJoIMfWiBAIkD8T/rcL4QOGIkQseBkNCgMECCAxsmUDxQEQEXzAm1GQwIVioGzUfnCShESgATw1kagxpIgESCBCWahyA4IgBnr9U/ng1wsBVBCxd9oBAwVzUqVUPuq0yLy6ddnLrvgGIF5++vIv28v37R+DbpZQGwyB7gGeBBkSeHCBwoEHExowjwpCsRRRPBKMYJx7V+LBkywQom3g8GgDnYC+yTrPx2BrXwyZCk5gAmZXlYJaJPebqmZVt3jCIYE6RW8tw3olbWyMw2/A6unarn6FuvbpfwNz3bO+OCLz4PYLfFpQ+5ij69ezbvyUWacICdO7r2zeMPXvd/Prjfh8P2H8A5iHggACV/+fWefctd1+DDg62WiXBPUhhhT/0Zx1/GMJToIH/dDggiB7ig+BBClqIYooqrsjiihpu6M6LMM4h4oj31CgejjYuUiJBhbXXwBdkjBBki/cZJF2RDSKpzm9GsifjjHFEKWUbOu6oyJXcaYmlID2qc2J7wogBEn4WJiBkevWNWZ9669RE05PoUVllPHVy2GWAeerB5Z5+fFlJmIYRoMRjqBBhkTdfbUGokJIloKgoFKQFmmaENgYpAbvxVlFrUziHgAoQQNZAEJsupgQrFKTaAE+P3WCAbTQQ6uqqEZVKwSiJXQpGqQnwcMCk02iaKqy2wSenW3TeicayzJrRp599RP+bF7XS5gFoJIK+hQMBk2o1gTMALEBAuNwIBUACDxDQ0lI5UFDDATmEe9NLFYn7QKxPVRGrUhTgxoAJAzAwACgaHTFBAptUQW7AACRMgAgj3fAAACLQEFRxFiQQbgMHFOxTqwMkDAy44h4G1K+iRICmuAU0bMLFI0t0crLKPhsjznNdC5C1PfPsT7ZD/jhYC8WdcppFJqEbAW47LPVRum3dolYrYJHzwgQVByOWLUI6MVJ0X0HdGgUZ8SKwprF4O9QWy6hbmggXx1Qa0jZAICQKCufyRTetlAZv1r3YPJizzxrOrM9AK+4P49IKPca2ynKC9EhpOQySFUmQHUMq9ar/VQvWQslLrghQeAIK0d1Y/MAEgScAgdVaeUE5WF1PMYAIpqplzFeeONHN7MUORfhBiN95fJ2OS7u8XkDzA7kkRL8ljihqeR4DFdXPEjXsUGWPtNWcZwGAJqET44Q1R61eDhMWaPMNLke/0DooEpkODu8w4P2V1hgF5Tf6TENsxatE8qp0QCk1b08LtEcDsRS9MEjuID4xAFrUMpKNLI0KZUlG1Eg3n8/ZDQIpqQk5HAIR0tHEJlpAglQ20hbyOYGECmHCfKbxQqpw4n1ns5hGOCIvEfRCf61BwgJ4kLseri6HbVkAAQuYHp3RSIpyeCCWrNiX5+0jgmCY4EFQoxnn/yDnM6xpjnJ0kxktyMsXp9nMABugjSowRiKawkyEkGM9sRlnMpxx1WycBBuyzKYytNGVGx1Tm8NwZY/548odoWhAKk5Jkm7Aoo0seQhMGoiLT/AiFOEUQzE4RCGvGRskT4lK6SRwRquEkSYN9EpBxHI8nCTF9FDJmCfCpjRhYFAqfwlMclDSSsO8ixadd61ZiqeWTbhlMJ8JzWiup5UboiaGlJkjnmGzO8x8hTOlCc5wilOYxVSDNfuzze6kkw/r/Es3CcOkccpznsE8p37smZ12/kWfBDrmPd7pSXoKdKA2w2eGymlOf95ImwptBEC/SdCISlRFBtUOQtPAz2oxtP+hPIKo9OI50ZCK9D4VtUtJ98NRRmS0Hyk9xEMjsJCYynSmNK2pTW+K05zqdKc87alPfwrUoAp1qEStaQEqgNSkKnWpTG2qU5/q1KNCdapUrSpTCyCBrGp1q1ztqle/CtawinWsWcUqWc+K1rCaNa1sbatbvZoBj0qwIaWpq13vite86nWvfO2rX/8K2MAKdrCELaxhD4vYvBbAAYxtrGMfC9nISnaykl0sZS+L2cxCtgAK6KxnPwva0Ip2tKQtrWlP21nOona1rC2talsL29jKVrQYkGsXbTvS3OrWeBdtVm+v09IsbTS4XsKtLUG62+QqN4q/FcBJ5bLSnyWTuIX/eChyl4td7D7XP811LnXzMdzv/sm4zbxuds+r2+3OQ730EG8gohvdoJHXm+ZFr30nyl4OdTe+jQuve8kzX3jed8DLze87DByj/4Znugp2RIADSuAI0xPBc9lvg6fl3wsH5MEBlrCH67lfC2uYTxm+sHU/jGKCUniKzeUvP+A7YmxxuL4prjEqV1xFEceYpczb8R1ObOMggxPHk2yxj3nsJxeTaMZiQEBGFjAKHEiwOL50CzJGpstKsImkDkJBkT42AApcGU3qQIEZ1xOhCNHYQkSupI53DGMfAxkME/DFTF6RJvKNbz2tQ5d0tmwfN0EpBV/QBP2CoqRIlGk9xEAf/xTbTEwjHznOO56zGLYgLzCsAmwx9cUDRhE7i+3GJwyAQGIsQDAIWKBg42JADlRDQgZs7TILIZgoaKKU4izMyQ9ztalJcIM8n0Ah4sLBwLKy66pceQCltBjBUICATbCgYKjGyibADBQnqmZhKFB1mEPBbBtQgGBYUQ25T00wBFQb2E5+gKy1QG5hPwjSb3hzjCkdY0uHAX8AeMCpYoqEftemYq1rBTMs8ARxGYAZl2DCqprBGAaMYnAw6DMVHh6OJ1jABWgBgMKZsTo5josZ09DaREahC49HOZSGBh/nGt7vjiAA5i7v9xfUZQNkfK/YVWk0EWYgcV74Ah3YqBC97f/0WyUjs8dyZvIYpNwE22x6BKtAwaooAAoCzNrPVKD5wBZigbp9j3xdJwKyghAOQ2mhBiGX4Uoe8HWLHfwxq477MH6OLuxR4SQ0L1PZSSGEEhCg7rb2+aKQFjoUHd2c9h4xvkesbxvgoJSxEh3Z6IPwmRN84TkHRjAq5vWMrX3sY6NCn0kwyI0p2/NaL0bRXT8CC7CxBq2YQFViIgZigETvbH9N3/3s8XB1MvCl8fzdx14mwTPh9fMOsaR9/HgNR54ozf605WcYlraUOl07SThkHvAFH0zsACF7WFbsVnFmiCVdnz4CGCCwmGZ8/ws7acC+3A4A2R9AISGpHgOYkWj/5VMxT0MFvGcxm9AAtpcr/BcD45cuBSBsIxEZ4vB/hGZzowB+58I7+pcvKbJ4GNV4GhZ9JuZ0YFBDC8EKxANswSYKXTMNlfcxvZIRQqJtVhEUWjMAUBZtufBHJLQ36ZI7m8J+lzGDa4cWwsYEZKZ5P2h7EqEQp9cEI1MDO0hm4+ILO3gNuRMqDwB+C7N8MxMNYTABSXEaTxgUCMCFqpGGU7gw2oaGVLFmquR8SXdkATCCDTZ9YrAuuYUsycV8D5MCNYMekPExVdYmc9hbSrdQDFZpJRgJPyhSKnBe1vd+A/AAWXYQ8DIzHoiIF6WIDlRieOiIQkaKv/SBvvV8cBaK/wqWh6XoioRzitcRghd2h6w4im9xHEUXgIOxi6rUHoJmIYBmGI8UCX0IYi02iw1Wi//VimAiBLoob27Ri2YyaEYijINhjGOQjabYiQj1iY2wjO7VjJUwbQiwEQMQAcxAhcTWEeO2EHbGAAF3GJugMOjYEYfRaeliNptAEwPAAzggEyExhlxRef9SPgBEbKOwbChHbKGBdTegfq62Em04GzHhblvzEAsRLEKSAMwAkAvTGutGar8mbgQTdr1WaqV0Za9WUN1YTt+oUqvIjLeYIM9YFRORdzeZeZ4neJ5XkTVgQaKAcDawh61nAE2DAC0HbUzAPy+THOWzCZaIeifgAv/awHMk8AX+cxiu4HFkcQrnR3rBEHSDMw3LgHtoM3MYkWfE8HGdt3OzcI/yg5MtiYypeG8yKY40aSLPGDUFGDWeEw75sht+aUqmBATE5zswhY5UBwYzF23AMJTBQ3g1QHN3R5hQQ0R+5gNjuJhdqXNHuRDy+D2MMhSeQ5qwkRH+CIsuWUwwmUWMmG96SRB8eXicc5hjxy5cOXoXYQOY93J4ZwAgWZgwQBFJuRFjMwXGN5rEoy7803ILl5kYpHAjADsL8AXBmXvHwHpb5zk693lE2RHASFGsOUyuKVywCXmyqQ5m04J9CZRRI4F/gwBfoG61w5v7k32cQwED6GXigAD/ALRvwGBwyDkCFVgklQkDLMAKLdAKkuEMRxAa0hkZTxEO4vI3qiF6F+hx85dzznChsXAA4AeeD7iadUmHk4aX4jWOkXAAGREkQsKG6QKjWUOG+2eJs0GFMwobLiijUTiGrZEREOALKvgwHSGkIcGCNtpnbiicGHGPWreH5aMRNdgaFAmER/gK9+hkWphzaagCrPYEYxicvvClwhaiUliiSZeMChaOKqqeFIJogrhbafeK00SelGSemZSi37WiDpIRl5hdrlOndmqiiViHbcqnbzqoi6p4dypJeWoIiEpdfcqoldogsQgta/pfkkpclCoGxxEJwhgh4pkCQrge0/gk/wlgqk8QIaqqDmaYXo5KRZAKXugpfYo6JOYljLqnLXEYCahqJK5ajEQgrPERiKs6UJjqXJrqXpwaXJ4aBuVobIMDkDXAQeUWkrb2MugYZQQzOOXYAwO5kO7yjiuohPS4j632aldmND3ha1GWrv3IBN7qhQlphQaTg62mkepma9pmABIZEvYKAxQnUspqsIe6p5OKq5EjBCVXMQWgkKOzMU+ge1VJcllTMcznlHQKO955C2RTgEj5cB5nf0ERGTbQlkdZZ0qZDoMTf9oAH6xWlgxndtDxlVQ5ck0QSiFlsMwqXs7aUtDaRUKAhnHnbpUXEyzZO7CnhnGnsVowmdizOv+X+XUDEHYUEAHWWTt5h5iuB3b1QjbE0C4PE5osNAS/w5icI6KxWqieiLC2SoK+CmG5+gKy52dJuXGDlxNgwKuXN3t7VnrKKbVXQ7UZSmhK651G2bVWtzUf6wSb6ZPTCQUl8JwgdzXjklw9a5eOl7CdurBiwJ4TwRn8ZwAHEA5gmTtPkIFMq3/8F7pVMLAAmADxKQ719xSXWX4r6wIcgbIc6gn7GQyM+xJg+7jQcTLx+RSrCw0MajQhR4w8K6tSRKuy1LnP+rlh0KIDIDJdKKUzg4Vr2xpryIJLeG0u2gNOaIk3SIZCgaU52hNwB2U4OBBlyoKvUDA8oBLaloRf4ET/+EqPufOQaFgx2galZle/VDpSmnui0Fe9QXu9ArWND9IqZGup+BG9OjO979XAKSW09ITAKNIAcEeSFXwzbeuNb8t0jSi3HUbCLcxbJvySKJxkR9bBLmzDkQTDrSnDDETDD3zDP8xcarq5IrjBHFXDQIzEMnDBOJPBgAC0HOzDSSzFCmyoKAq3orjCvirFSUzFbmvFKRybWbzFYzwdS3w4O5wnTTxeK6yYReXGbwzHcSzHc0zHdcxTUmVVeazHV7XHfdzHa/VWgSzIZwXIg2zIZXXIiazIEhBXKzwqiQXJkSzJk0zJlWzJlxxYlqVZm8zJm9XJn/zJrzVbo0zKqyXK/6WMyqmVyqvMygpQW2JMxrEcxInos9/1xEYcxbLswl18wl88w00Hy7oszBeSw+WJxl2ixn1wxMNsqbwcw77Mw8A8GHPLzDfszDoMzWncw8FczbF8zcaczci8zdPMwt28qN+Mp8d8ReNsHuVsznWKzo+qzjuSzA7Gze88xWacOPN8SeycIO6Mz6UYz7PKzyNSzwB2zzZASA9juGcSKUkSjfWhxe1RrMFgiMo10NJb0B5y0HqQh/v5r18gL0I4de5hQeXSpG5xjb8oJ2c30RKV0Ri80bDkzybiTMPCBBGjaR6hBZXHGqohRpKnKPKSFt3iArhiSLzyBISyfilQLJfhKv/EGimMJEfF0gCr8gUTbD3G4hhZsRWa8SrpEikjMymXmymtcdXMoNSQEtHjFNNMPNMhUtM+AlJaJ3rK+QN1ZToboXUFOnRBQR8hUREB0wq6AxMzRzL2Yi7iti78FxMWMRTi4z0a4RPEOxBO6TAQIzFciXMyk6FH8C8tcASFN9gCsy4OQTaeTQKtQ0L3sn+jQi4R9dZnHM7rLM3tDFIWlCaxzS9B8BTiknHLYHuxo5xNkTU9VxtMGSt0k5lGQwUQkDEQEa5oY9wPUxVtR6BlczYOs7yA0zY2dDmd4XlN6AM4aSprEzhe19fNJlCzvc+1Tc9zDSYeNZdLIXU8XXXWHTv/IyOcp+l1uuMNmdk+kxsaA1kyOc12l4t/JOQ6NQA7stMFT+1nuDN66MKrUxDh4ZfcUKECLICs4eTeyBPXANLRMpbQ6RCGPHh9fv0LovBuCwCFQnkDUbnhFoMFagcFEIcucSSnMCXSQ7k32M20A55/8CNAW9s6mAbkNG5uUBM/z1DjJVCWLw1JIa48Iz4eJY4HeZgTR5kmeF0MZFNBuRZmqgGxnZSD0l3eFDEBQfSvYJnj6VIUtOcUBoG1UfgQHJcTJgS7qZ0SKDgu9MFEOzQT1hoKYpHnSPGvQeEEg67eXd59KqbPIg7f/Xzb/xxProEQBkEZEREblzEsYTBHQf3p/6qRG2ZEjK1yZpoiQbsw6lqQGpyARsHQR+DwR9Cx1FjhRwrdGKGSHMcBSKuB6gr5lMk66Vde6QYt34GCWxI4UnRqMysNz8eOQFieTZdu0/UVKrl1ZsnS7RVs5dWe7By97NoC0AEtZOGuQNYOHlr+Y7m8IhWN7tCk7qzE7upU7kND5SkSwbn+JIJGpNg47cWczuNO09hO16cqGWS6cEm9FcGSKz3tKEFSur4ikGUt8bqh6mRK8beiBLZx1VZN8Q5fKxFfRl5tAg1QALhOLEEBKR4f8btSeSrP8g3/BBYP1hcN09S+7gYv1wg/31T+rzKB2FJmMgtge9TZ2JsQ0uMGM/+rHTH0uPTuIhMF+C5TmDJHodlhARTj9hKh7TEsIxUaiATmsgOpgtl4EzhFXzJl/6BWwDEBg/HwBtkvYWvaxfP27vMknu+R485BaePFJ3ZFoD1Oc5tMu+bBVxpA0BaX2W1505hm854vMETg/YNam3xgy7QxMDcBwzuZ4G/vF90Rx967Ve+udO9b0vcftR6pAOCMYTd7dwW2eTW8qjlO4AmODwVHweCBY5rLtzlkk/lhHnIokDtJAPvfAyz/agEZ6nPSXrB5j/p7n+WrP1dCLwT8huMwtz20H7bauaHjkPuTz/mQ3+eXKQ1b0DpaCd0197Gb3203/vnp8KPZ0BEPGvD/bCvEC6yKIBCII1maJ5qehdq6LxyTV2EAN57ruFHvPxBgsAEODIiBgSAMbgMCgAlARBYLhpBYuA0Bg0FyMq1eszdpF7ClGiDbHOSx+AojBnDUsoA0vRD+zZaUF9QABIUal1bRUdJS35MfBQUYQ0JOA8OczWCQ5ydoqOhogYDpKWqq6iprK2upa6zsrCqLzC1uboqtbq8Kr2+w8AkN0aiQz7FOQ0PO0kERwg0C9IH0GRQA89nNNkIDATQOQfZ2tHZz1M1BuMUOAbX0EEE6E8L1ND6U9bQ4vTo6btPCnZvirxm4dDr+FVTm8CFET7BoUaxYyyJGjMCGcRy2sWOvjyBH/8oo5rCHsYgqV4oi8ODOJU9pzvRhafMmzpwQJ2bsGYunz6C1SBLNJbIojKNIl85Idgylzqg2lygMYm4dPqlat3J9CFQoWAFfwwZVyvSs2bMr1LJtmlIU1K5y59Kta3frWLI98+rV2PZvgLSAAw9Wa1JZ3JsNYnZjTDfh3ciSJwfh27ei5cu0BBf22HnX56WHnzq12SlKk5meEsRU3fLlgAWUZ9O2m1mzrNu4XXEOHdK3id7Ab40elRgiAQPZmCSXJsVcAuUIKRiI+SccdAPpvk0SF91xotrix0fVvfvV+b3DiQpn2379i+JwS5984JKThQQTIoBLbeMlEzZMkAABSP94AUYDXYAxAQOFPDCBgXsQsEA2qJF3IYYqmZdeKhtyeMp78LkQIlMkioiCfKEc51AE1URgIQALUICGdi+aMQUFgKQxRCY3QEiIhS+Jw8UAQ2Z4JJISfWiRh0uaeOJaIj4JpVsn0afMG4kMMo9/W9oQxwSU3MglTUA+B0EE/DmRJJtt7tDkh3ByOCWVI9BJ0p1UpgjKisoooQ0WgzxIYwM2dvEGjYoc4A4ACcgWiRTiLEBEVm5aeqSc6WV6Xp5UdtrRpyLu+UmfxzAYRh57NJFoHFd8KQcdBNiBQBd3XNEMpE08gEQE19R0KbAXbrrbsLiFKuWJx643qkxXKsOOONb/3INVQFM0IOMZ8XQDhTng4EBNQc+MEyy55BWr2bmXKbveur606xuzQZS6FQRWFFkuvvmGkm5f/Or1rm8AG1VnMPECMa9W7FSoL8MN4+AvWRCHJfBnFN9i8WAG/4Cwwx17LJXEYIUsFMaDlZwUwb5ovAPHH7v8ckQjl7UkZim7m6zNuqysQ8sw+/zzJzL7JLR6OQ+MrNHEOUvq0kA7/bQORGcktV9JX4yz1THsnEPPUHsNM9VM0kzRyX+VPWLWWjct79pfu+1y2JiNvVnaMZzdwt1nbc1D22/73XDcZM89S95oYV13C3tzUUAEXzj+OOSRSz455ZVbfjnmmWu+Oeed/3v+OeihS15ABaWbfjrqqau+Ouurk9467LHLnnoBEth+O+6567477737/jvwttcePPHF+z688ckrv/zuGfTNcgEQkDM99dVbfz322Wu/Pffde/89+OGLPz755Zt/fQEOqL8+++27/z788cOfvvz123+/+/Tjvz///fNfgAICKMABErCABjwgAg8IwAQysIEOfCAEBYiB5/GMgn+7YLACt5nB5YaDNCscCkCIFMUh4y0YPKG+NEg4D/KGhXE6HOJSQMKuobCGSVJhB124Chx+EIYxJIYF+WZCGxLRTTxsoQ4vkkRi+fCHJZhhEIsoxdkcsRVVRM8SjdVEJ44AikOcIv8YzZVFVFxxh2NE1xa5GAAvhrGNGSqjEs8IRyYiTY1PjGIJ3ajH8cyRjGc0RR/RWEc7dhGPNNwjIrUSSED+USyN/FcaucjGRFLyLot05B8vCclBEnKNhmzbBKCQACwsRAxRWA45fkWX00iFH/sCAriAZJWqsGQxHbskLh8ZsUg6cZJASIAFiFCdhUACEqmMDCujkkwgZEkHkZDlwb4IEVs6LJeZ1OXEePlDX+4AAbEhghF2wCgGkFIQDHjAOafBgC9AIzYDaFEOKBCTBFDgABAgpxhYs6YcEOCc6QTAOjUBAHnegJ4xIid4rsBOOFhgAAlAQEAvAdF3NmMLB3gAYxD/YIF1+uGdogyoNNI0gKwMYAIjnei9GPSFSyxAGgiQzUsblSPZXMESU1inmnAwygH8iTbWlCM2RabNGHITEww4wEweQEv7TIhCLonCUQEaUmgkAAJqaAa2vmWjXlGnCC9KQzOhCo0/iUMJ/bxBg7oKgJyu4wZZLVMR1uGOkhahon5wZjYcCoAJPCCue+2ra9RAoQPAs6oAsAA0FAQFKaAhAhNAgFr5Q9cDVEUcfK3NT8eoyV1ykpBFxcFIbySEhQ10CBOYwBAQMYgnEKChPG3CG1zD2iY88wlgJaYToHCHAVgACr2CqBfWyduFmfSdKRmEPb+wBQpUISbRsypec2sh/wQ84LWifdgZXLtOL5lpVf5xgnB7y9wFgIe61vVpIzMb1KkNFXGfdcIX0tQa0nqzSAcYwAOcY8yz5iC2b0nAri7xICfQahH8NCYF+gqkqpLXC6bUARUSe9w+PAAR4VmMTaMX1RzUdrFNsIB+rxuIM5ASroq1UKIcvIxROgbEMKJiemO83qG1t27v5ZoxHmCkG0SAlAyw0WqhwABE2NK/O0hTQXUsq0b1NQFhDXKCoxCBfaQJGgxqxmO1Slk8aLUIFW7Ucpvx5S0kwUgYbaeHD0uNOQzUqkbK0pC1cQkQX/RL9WRziq+8V8iK2cI3oDOb0XvNQc+YvZ214411GpMGqP+SCxamgGymEOmWFmEOA+6DPnVwCJ0aIh18MCmEJy2NTVBaCH7ma2yMlABDEJRrJb1oSZuAaiL0wQrOeEBfKR1Tb2JUNsmtSk0OYGkxUPcPNmgArh0l6UYxBtULOMCsIYxfZQsaqIQuNJNqnLZE78A+dCHsjiupCKepd4mbzeah1cjtHFB7LmES9w8y/bNyJ/HcQk23JD8pTXjz2yb01qG9SabtrK273wb3ioytje1s47uX+lZJYKu1GnLyE64RYWUsf/DMm9x3ADPSEHneElbbJFyzC68afERYlILLZIgR1wFio2Zx5Khy4zuwOUsgPeKYhVzmk/m3CwNeloFbjeX/8hIQOSEADZHiw574BHNsdFqA2PQTnQpm0BHaWdBLMPoLsql6OjXKUY3zYcpTcJw8oEABMaw9B1hX+lobt4Cp0xShU4jDP+GwztiSMyX3BS20kw4NXUcaBwot0oSmYdUkMIDWN7jnAEZeF6CzUOg0bvg2Hx6RLsDTAIhwTVcJu/P+knisUzV1eLowYMZG9U845/AlLuvtp+ocv17ISuc/b+DIgqP1WdF5IrxJ4BxglMlrTSwicqUDSdUz5pMS/u0TAXzJ04XyHrR80VLeySohBo84HkSKQZtXKIwcUfvtgxSMbH4YReL14rdQltYw0jIwCq4pfsNrhxtkDmeDzMKc/zAhgB9tpZnbxZedHRZS/V8iPBP1zYX1cRD2GZr2bZ8IGF00AVcUANZbDFj0lR9cPQEGPpX6lcn+uZ90SUHMHdafGQBkGYCCqdMZaODO0dU4GBP/jRjweZ4OONaLhGBfKZ+WmUGh/EgOIsIWMCBlPODgRCDKsQsFVqDmQQTnhUPx5YhfMRk72MjIWUADsIMNTtlFXUKvMNp/fJ53SdeZyVR0SYGBtMHjYUGh+BmPUeElpAEXBh6WPYJ04UCUEcAWFAozsFVBFUBMgGHxHYKw/UqEkaETmB0gAqL09ZUfJmHJZRETMtwEUqAFxhvX8UFM/Bq7ddo+FSALipo2eCJNHP/CJdgTbCxbjLgUrkGTW7mUr92BAViWhUFApTQAKjKbj+CBs1mDKboaqGWgty1D/fGiXmlDshVeQbFaTPxIDB5jH9xBMUqGEs7NJdYM5hFVFDbMN8TIvvGYy7wc0GTj2Gwj2RBd0mwimzABl3mCt3yMjvkNOn7QyWGiEz6hOx6cP1ZGJZpbPnJjJm5fP/4jQvZXQNbbQK5jN7rXN3bFMpkjclCLnKmEK30CaWkcFAxbv92jkzQk3TykjUUkV0zkODrE+l3kxTXaDzTg+4kBJMIbSMaJSBIOOxrNQX4L2knaHWDCF4xdTdWhDRweO0QaAkAXDkAeppGTbDhZbEBAQz3/1FPOQQTkonDpwChxlFQ61ETZ1EvBBN01ilPeAAWsU2/lQE+JW03OyU3mRk7mzE7ewOxJogV8HA6sXhPwXhcw32E1w6bxYaTJ3+NdwkqigZu5w/RFDTSEmF8tSh583BtAHwQ8FCltnBvyW1tqylv+RFzazFyGh5Y02vrlX291QXHZQRaA2w0mggE0jnGFhwDeyBH2nw6gk3LASHJF3ovFFmzaQRo8U/F95EICXGfyxmemTGimoDskU2k+WBZEmBDmh1LuIZk5o2yi33ctoG1CGAVwoaBYmCDURGw5Y3BmA3ayZXEG3XFaUXISTGi2oVUl05f9pJ491hAsIpe5AS31/+Efmh0CiMEdUkER3N9ASWJY3SJh3cOLXBQiONmL3WGhQEGALqLZGYTBbSantOcrvGedhCZSgUFjpicrUlsw6tOqqWKSbYxDTSYf6OJe4YE1xlSmVWOL6gAl0KA1whqoxdQv2kBSGoI0mJQBlFqpaeZ6Vh6H7pCH6olJXsjrNcCQuqQySGmMJuTkJen1LelQkOS2Pel48OIPIJshhJtDkCncYakDaikEcmmHNCmUhKaaZiibLqGbkhGcnoiczimSXpsl3imI5KmogCmfFmog1Kk2AiogCSp87KmhUpKGEouiigWjLguhPuqcRqqxTKrKlUCnkoSjYuoeaSq6cGqlDv9HqIqqG5GqupiqlxLcpaoqQrJqv7hqQXYSFMGm6Owqr/aqr/4qsAarsGbO68yOsR4r7SCrsiprsS6rsz4rsiIP80xr70grtV4rtuqO86Qk9EjP+XwruIaruI4ruZaruX6P/viPut5Puq6ru87Pu8arvNbPAkWQvd5rvd6rvu6rvk4Qt1bQv8oqcfqpQCrqp9rJE3pSwAqRwD4qrf6Lre6jJsZqw9IpwTKkwZ4qcKRqxRbRw0ZMxA7HwYIEx3asDX3sxIQscIxsR5SsyaIQyoqMygZMwrrsy2JQzJLMzIYGy3KEzd7s3+TszGTsqxYdxQJtIgnt0OxsxdQsmCoMOez/FXR2RXTQUpWCR04cgFrx00Y6zcLmhNLuBdN2Rs8Ow43JyhDYgBFYbZZQpHFIzwSk5ygs0014HGqlhNtOg9wqE5U+RPthFzYiajqObWGUrTCcrSoVyJvwABEkx3JMQz9opXYwwoyM0j8kSD1Fg+O+wxD0QYKAh5UWaEFNLkBchTYUADxkh4FEgQFkmTZ4HlU1CC1VbT+E4zjA7uj+A7jwAz8wg5RaQ3NobebiwDZQ1jlQQwOgrjQUwOdakuDiI9HeqmeBKdo6Rok9zPS0oX28hFQdloAayYLIbgQgwWsqhzcNSKDYwX4YSYJNyKowAGr9SqEUlFWFL/mN2zjUQHT8/4dy4EH7stn5jlId5CZotW6DBNcy7lVaJV//2oDyoYFTou1+LACEpMRlneVAPQo56K9g9VPX4sXzhmT0SqxBgmkDhFIsuhVp1UDn2gA8iZ6MQAgE9AjxktKPACESkEOD7B8OqAkbmhIDAJsYyK4NW5WRkV4WzK8Z+HAT5LAHsxIN3zB4JFg6KPGJMVZqQNf+nQZk4hcvikEkxB/+Vl8I2+QIi6zTfm0eBQ0PrDDjiuYWyDCjxe2BlQkQGkLa9sce7pwUdFgBAtdsHjHgkokZlCb5agcrzSbOIRUDWEAoVaMDp1mKbbEqNUhljhKawfEYr+nFGucZr2waW8kXiYMSv/+iz5nBn/SIEeQaB8pVQWkwjKxugdpgDzeDFGQVPOVA46wioyibIO8cjxiKC9tyExuDFy5fL8NyDljWAFhxJKPYdlKyDizAg1zUZd4vMKuxhpSxW34yzfIjmFLCazLG9Y4eajYe/DoBIiBAAeyYrQQxkCxK6xoBEpgVLRdU41UXoGzCDjAXD8QGPMfBPYncuLUKHozSbjFCPVNDMEHnO+MKaYmzTbVK45HlHJxhGkgzPzGKHEgXq6WeNscMN3OmN/NsKHefNIHDkETHOxBvOkAL8frDmFZILMH0FBCEK2VcN2jLGVjtdc1jT5tu6W6H7+70ZQ1EtBAEJtB0uEHGNCT/CKVoS+++9DXsbqVMQTdsx0EMNcl1MnuWdNOCsxrTkHR+DGtGRY44wlzkLdyM9IaCNdmeNGn8q+2a9VXjBDmYqVQI9dOE7dQQrsnItXF4H9JOkV9rBGADhuEWzNFK5AeDQtSuhNaG9MFIBmWXy2GLDVwXrmDPx2XfBFtvzGd7Qdt9gryxcWTA5DGcNqa4taRudmCLtShHBDuMAzRsLobyLjUszBDQ7l7xSE8P0+gayGRvpG/Hg0IkLzywLmMkh3VIz5AUbzPwA/MKN3NntW/v9DrsQ3cIhFBXd0wUGLdcQ21PNi1dx20TsBh5tZLCtmJ3tooQNo8hxFdt7zMzVo/9/0oS0FOtEcD6dvABAwgeDNlRFzCDFMI6Nbf+AlhTMVmDfwHp/tVAYYHOFQCFHDCD29p+iwnx2khVERZrwNMvA7jahVKDECgWOpSegRaCuOB9CItrb6p7mw1884l8CwFNubCLdJdY8YyBQdtrYnMwj5sj70AU1y/WvoFjbfBahdIkukYXKxUEiIGRLfmTGxhoDTEBUFuDjfgRJ8eAF8KWM5Us38gL2wgfxXipznhbLLbKNDYQLIqca/IDN9ptUcGMHLB/cZdLNFQdW8jrvQELH0ra2kBgWTJrRJX6FTpt6oBJAdeO2ICXK4omFIgNVNX82uI84NjoqbbzsveWsrl71P8403z2i6KVNPRInbPMIpwnSDuzXx2wKzeKMiPxhS5dNkjYDlDzBFhzNq9Vrjf6DurVUU85SPscIdshtqwaDhhJGqRyOVebyYH6W7Ksm/eCnLJzOpxKOo/SRb/YGwefHTyA2RmZQbuwFWwYkdyKLO4cFaT7GMA72mZFa9HlYI7bu5fBbeEomhsCIACAQFc0Eg+BEeyBwC9ACvKBC8rhvHP71Er7n1L7TVo7qTfLZ3OxUk+BVF+1OZRDOIBLORB1x3ctUOu0QGAD1xLvRl5Dx2f1OIT8yYd7PvBTUVdcQLBDzWekNjDEUm+3XlOixCeqqKvFtesMnAOBCR7cWetRZsv/zdAbjmyj9Eo8ttLfNRg1veA8fYlUPNuMdmHDrJq3qtYvRdHnws8GQQL49ENkN0Sk/WxENk2Gfa2OPVKUPS6kqhSwdmuuRBvwPEQkvSiQpzLUywIIYtLKPcTSfVHYvdKM9Y0X9zmg9zJPgqzTbk5zAzOwvRF8XPNyQ8YfQHQM7/sJ70FYd3T4vXI7h+ayIOmfgXVv8uEH/eAqPntw/cHcOIFLIm0hSLNbwn4UggG3wxS0M6RbAod3w/gqB/z+pBp8AT5AFgEcf26BeAKI+IVDgYAfFwcLgvpWQQU7uK29n3rKPvQCKsVH/VyrRJGXiWsYFiEcuVTtAWvIxr6/n7ED/1RFWe1i9ABegUCyAMCSAAVpGE2kGmSckikxkAMB2EA0EYQZYnCKGY/IpHLJbDqfUGZBQK1ar9isdqudcr/gMNYrLpvP5kJgzW673/C4PK6e2+/4vJ59KcCiKn6ASAQPFjc8K0eKADk8OzcmAw0QCxMAjDMxOY06nShICQwJQUc5jIozK4+MMq6PnDx+K38GnoO4ubq7g2Rov2G+wMNdxMbHX3V7y8zKzM/Qz31/gAaCuwckDEA3rSQJEDgEBxbfIxMPIwMD2ZmmOgsUJBHZmpue9p3oJBCXqiwuMFGj8erGJx4RPGUD0GAhr4cQI+IShswYxYrDLmLciMZZtI9vPP+CHElyzTRc1gbiirBgAYMDPAhEMIAgxgEGLRNiGuCyAY2aFBi8IGiEUwOcA/7kAyDKwIN8nAZAgGDwHwAI6RiolCqvhsFYNxCwdPmtiMSzaNPS4HhMI9sybt/K7VKyrsi6eJmdHJTyIRASB2oyvBVjHIKFDQgLDkyigc8dRw4XfgwZCQIdhAFI1iy4smMSCBrEI+RTB2PN2U7vuPVZrevXuuLO5SJ7djHbuOnmBXl3t287e6tdg028OJJKC9gZX84cdu3cVp5DpyJ9Osbev/Fgz86dz/AofZuLVwsz8/jz6KNUh74+d3vrFrs3k0//TXDw39Pr38+/f8T3tgE4m4D/8P2yXX1uHIhgXvdBEZ5/EEYo4YRrFUibhRdiGOCC2nFYX4NPPEjhiCSWSByBcqH4looagqEghy96OBKIToho4o045thLi1mwyJGPPOomIx1DdkdjEzbqqOSSTAJ5XZBXOAlldEUSWeVvRzKRJJNcdjmilMiA2daUbMWIoJlXLpPlElt66eab+olpEZnU0bkRmvThmWYeayrRJpyABlqcnMQQmpGd1+3Zhp6KApdfiAVEsM6klFZq6aWYZqrpppx26umnoIYq6qiklmrqpQVUoOqqrLbq6quwxgprqrLWauutrtKK66689sprARIEK+ywxBZr7LHIHgtsssw26+yz/9AKm8GjNRYAARDYZqvtttx26+234IYr7rjklmvuueimq+663BbgwLvwxivvvPTWa2+97t6r7778zptvvwAHLHDABShg8MEIJ6zwwgw3zHDBDkcs8cQUV3wwBtQimbGgHHcskaHAgGwgohUxyp3JjcbRZxJ/euzyy4CI3JGdMmOI8m83p+zGyki0DPPPQCNRcxo0kxymzjnr7J1KkDId9NNQo1A0nUMXmHReVyvN8yIbR+21x1WLEXYwRreFtNIkbW2Ez1+3DefYLk5ddkZnow2S2jGw7fbeXMKdjNxzG1i33dHgHYjTfCfepd8Zksk4blnbRfhHhmPSteKY4/j4bf+OB053ypGnXPmfByR3gigsF2ZeLggwMMAEneHyiGuiCIUk4rIbpMtmCVCG1uyDAg7l5gMOPrlel7Oc8QE6LWSAWa4MBdEDlwA/iPVoWeCQlrhfr3sunDDl+1nYv0b8GMJ7Dpfxx+8xesYUjGDETULnDcMQ69T0QDYQ+NS/ERNgAAMgEBgLuA4ChziBS0ahGaww4AFHaMA6XAeAA0BAgJcojPwQEI4ADjAbBkkA9BJQAJ4cYII1OeEAGFATb1gQg1cRzALGgUKmUKASNjjhJrbnOpx8Q4APQIABI4EAChQhAfJYIPRK4DrltGQAOpHgCr93ovTx6HwpYl/7+JS8nmX/bFIMkAcJHjC+Eq5jJgB4AGYgSL0WyKMcRqAHJuQBFhJQ4A8RSMxLAMBCI1APEgC4YwUDEgML+E8ecjRAV6QXPTUyxAWObIFAjCBI5mFiBOQ4QCRdYAAfXOYGDzgdBOenDQSIJRs1CZ8jbLcNQfbAdwsZDREAsI8/ls81WIyOFdXnIi1u8Q7vQxwnmPcYWxxBE6lwxR2NmINRkuARPKhjI5poAW6IwwgziKYnwvcC5sHEILJgJFHMOIAUkDMF3lAlARpQjvihYFLo/ENMbsBNFayjmuncpg4iYEqhTHEA1QTgGWFQx2xS0Tm71FAuy+TLX84hmEr44ycwkRlkwkB7/yQoxxDYqEgjtO6ZEJTm64wAC8IYNI0ZHEDs2AkOzdiuEKCYJDZpsL0CbM8bElXpVUThE5uuTZ4G8QEh7TjKU8jvmp8AhwkakcHIJJKgmLnBSZez0DpRjZcdaahDVdZFriFuAuwQYgz2d0z7XQUGBggHH8ORAH4eISGaPAEnxFLBAPoEdiX1ozwMcIME7E8mxynAY+Aayh6EJillLQEBD5DExe51IH6FSUBkYpAFOFamjyDhEikAQZms05CBTGMCQGiaCMjRrrTszCklCFVAPmCvBzVfQm2G1TOEjiS3VRRElQBWCAhGgkjQnQgryFcDOM80B6XELEsgGL5eAh0mRP+A/BYQOwuGUn4JkMr4mOJM5RbBBhAwoiliQIF1iLG8A5DHcI2Q3f+N8RboVW8RpNsYOB4hOQag7g4ekF7NPACC+p1jDKC7gO21V7z6pa91RcCcqgrAwQ5OFOi2qofdPsGRHaunjryxNwjPtrZj0CqFd9bVtXWVwR2jRJfIqjgPXxXEYhPxiJeGkhJn7sYRcnHnYBwMGc84ABbGsZBvpOMpRbhkPp5xkCOUiO5xeHVKuGUMNlPPv0SEEzCQspCLPDwe93jCP36ojQ83oiZzL7FP0PJEqwxlXGAZkENOApeDdOSjgTnMXO2en8Z8BBUyYAIv/HMDHzDA7OpEBA+IQBH/lAhIRbRuHdkggOvQGAMS8gQTAlSJFCkY6KZqZoiNoMqhFZgcnVyliS6F4naviYiwqNTPsROvDTutmenGzpgUuESumSJA+b1OpY9WTn/mfEUv9/LOeLYPn/W2hNeCppIukHQ2GLiPtFZQe67Mo5nl2FKMclgIX4mdLW8A7Xfg4ATVJii6IehOUIz0AKv+hFfIcYJNejQg/Cx3XsmrjpCa0iAQOEEBZuhNpqiVP8RuUZ3Nhuxkt2HJvSiKPvNq5k78s5pNJsAhpsgKlVhFpkTRJlKRWkdF1DF8KaAAS5YocVBImoHvXAdUrKnOfYNGpWQpRycHGlONTzC250m4Qo2d/4wkjxjiMXNITj95zYqzcKSF6YYtbPdMg3zbjvLraPR4sPSWH0TqX5/oDBogCpZfswYWeIBafZoEvwYcpThg+kQLSZM7QjC/iZX0hIROW6JvIbe8cTgckB6FSjBkApEFLMW7EQ7AohavYA8jQ05ggcM8QCWGhHceW+A7Z/OVu5I9QihJ2+jW8oCzO0i5T5yNRHN7JdSKPQBjkWDab/zVBS2QbGYu+Eh5tEAHCPBHDCRPdv/w3UILj0/DBQ/kZfN5fnz1LVO0W2sSJHgEfKU+LflbYPoOt3QD+CMC1C7rASO2EBi2CVZQ3N7xjR/ANfG+AuOfdSKkALp/0LB+w4LJwv/G9zhiNH3uVV75FTu0JEbS10BSkUo2kRwShXAfZjV+93dGR2GEVxwcxjENUBNglQRD9RAF5zbHJ4ET2CMVuFUXSBzr5TINwF8EhASJcRYTEIBtM4LwkXyFcoIOlYJx1oP7YYPWgYOf0yiAlyY86INIOB5AOB1CGDI6+EtHmGYHpWc1QoVn0RpMUAgmlIRUFYE3WIImuHyCF4VOgD1WeGbMkYGW4RPWxoXB82I7BoZUIoYOR4ZKsGn893k3kIAzxEQMJAJQRIM7kWgnwIeE0UNHZQ5QBIinJUAvaFoq5UEviESGRwL74IZVBIdGJodR8oRbZIdJMG47YAEUoAPohEn/2IZHDWBt5LAIqMhY4cBOfVZKaxMOByBYJYBI7fBY87CLmOBJN2eAmJgWS8genDiHRMh8JHaGJsaMclZ1cAYKsuhOF0cA7vBT4uBNHJZ9AWVWMbUK4AR20AR2Nxdvw/gxXhiEx1gFRRgN7VgloFg/gDQ7MxBwDOATUCc9+cAIfRReeURJRUUY17gCH7Vfk1SQMNUKCGB253gWxege60gdntg+8Sh6sBWN2SQplniPqXWNedN4AdEA1nIEqOdZ2PiNMEBYJ3BDgzQOhdUKqtGQavGQkBORDzaRx1OR87N+I0BfODBWt0BgB7BeVAQO2mdYSIBfAVYWP8kUJ+BdgEEV/45BFUdkFj4pkzOZjkxok+/4DF05JDqpH2qGlW5CkwHClTg5OWGZHsZEli5jlgOClnSYbGvplnYpZ1ppjBH5lcvAlx5Sl3cZmBUSh5u4l2lJOIApmHcJl3PRhIIzl3iWmIrployZInKZjMpIY3zxfJMpmJW5IpepKH7JIZLZmTL5mWUSmnsymgtSmqZ5jqj5I6qZJqyJIK75mpgYm3cym1dSmx/ifNfCLsI5nMRZnMZ5nMiZnOTyLwPTnPzCnM4ZnfgindRZnfoCMRaTndqJndrZnd7ZnRjjjIFQAORZnuZ5nuiZnuq5nuzZnu75nvAZn/I5n/RZn/Z5n/iZn/q5n2/82Z/++Z8AGqACOqD6KZ7TdyoImqAKuqAM2qAO+qAQGqESOqEUWqEWeqEYKioMiZsc2qEe+qEgGqIiOqIkWqImeqIomqIquqIs2qIu+qIwGqMyOqM0WqM2eqM4mqM6uqM82qM++qNAGqRCOqR2GQIAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Grading:",
"    </strong>",
"    Add the number of checkmarks that appear in the darkly shaded areas. Four or more checkmarks indicate that your symptoms may be consistent with Adult ADHD. It may be beneficial for you to talk with your family physician about an evaluation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from the World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23154=[""].join("\n");
var outline_f22_39_23154=null;
var title_f22_39_23155="Periorbital microcystic adnexal carcinoma outlined";
var content_f22_39_23155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86193&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Microcystic adnexal carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Microcystic adnexal carcinoma presenting as a subtle white papule beneath the eye. The palpable tumor is outlined.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23155=[""].join("\n");
var outline_f22_39_23155=null;
var title_f22_39_23156="Colesevelam: Patient drug information";
var content_f22_39_23156=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Colesevelam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=see_link\">",
"     see \"Colesevelam: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/47/35573?source=see_link\">",
"     see \"Colesevelam: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F154425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Welchol&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F154426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Lodalis&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691406",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower cholesterol and other harmful types of cholesterol in the body.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701858",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to colesevelam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3569698",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block or very high triglycerides.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have PKU, talk with your doctor. Some products have phenylalanine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696848",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take any other drugs within 4 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3572837",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heartburn.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Powder:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3501282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       to 1 cup of water, fruit juice or diet soda.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3572839",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take dry powder.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Tablet:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12340 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23156=[""].join("\n");
var outline_f22_39_23156=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154425\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F154426\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014381\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014380\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014385\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014386\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014388\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014383\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014384\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014389\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014390\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/57/35734?source=related_link\">",
"      Colesevelam: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/47/35573?source=related_link\">",
"      Colesevelam: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_39_23157="Haemophilus 1";
var content_f22_39_23157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72893&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    <em>",
"     Haemophilus",
"    </em>",
"    influenzae in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 240px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADwAWwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDD8P8AiW0udAuZra2nXUrcCMKdxXZ0Y/p7kYNdxo1xbapZIjQzmN1w8bHBJ68fjnPt+Vcp4KmtbaaSE/Z49m3zosAsxHVfqPT/ABrv5NES6eO4RxAkq/KiEDjHJHf9P/r/AC8nBaWsump7WLtzMz/PgkiFkltJ5SMu7aSenHU+uCOfTHGDWbqeuLqul3FvIrxScOEVd3Q8lTzkZ9dueuB0F/SLe5tvtYjs0NrEGKS43O28gsAffauQP7opNSktr5YIbmzNlLdqcjYN24AcnHUjpznr3zVXSei/z7mVJKMtTgPCmjvdauutCSWaSDKhCRhev+IPfrXQ+IzFrVhLHNOYYrdNwEbkhup5P4jnv9MVpWmmRWdhe29g/mJOvlSSJ1iLYXjnOOVP4jtnBoXhKOOwMEl0j2QyZJMNvAw3Vw2GX5jwVI6HrgglUbbm5bbeh2TqwlJXRxNn4xurW8sba3hjlSEFY9xIwTyMjPPH+e9egaFqWsfYjf6tPHN57BQqE4CnOMAA8/l/SvNtY0S00/U1ks42m2HKtzyAenT2z6c+uQI77X9WMccLKsSx4BGcZxnj6HOO9VNRk1yr7zrlhY1opwNz4iawsGpW6Wh3IyfMzAkrzyevPrk9evQ1yEN/dOrl5vmLn5nGMnH/ANf+X4aWk3LiaSWVI7ieUHLOBgZ46Hr1PIFWZNDuH2S2iRzGRctCMAhj0wD17+vU9anmjFcr+86aMY0fdaMO5ubq9s9txN5sZPIzkDnHX/POa7fwulve2dq1k0UssSkL5zkFQeScd+mevbqeTWd4f8PSSX0S67by2tucsd+QGAx269+o/HtXYT+FobG9j1HTbXczKY95+VcHoSD7fzPtQ2uXl/4b0OfFYiOkY7nnOreA4ZriFIZL2e4n5aWGP5FOcEkjOefTH+OjZ+GNG8JxxXd1BdXV7tKAzLtG/jkDtzxXqukXKwxhrQRvbIpRZFI69Mk9Dz69/wABWbqj38mnxRkWq3jO3714t4QEfw5yfXHHTr60/b1Je7Ju3rb9PwOSOKls0ijdx6X4qi+xFJI7wxhoyQMN+7ViQMZGGJXBxnaDyCK8W1nwvr+lXkwubOfYkhIfGQOmP5j8+2a9n0PRmsLZTJru6/aZyjSgIQvKkjn7owTnrx0zxVHxZJqVhok6atfG5scM6OuMqec/XHH1AH0FUq3sny02mn01/A2w9VqSieS6X4d1fxFJDHY2E/2yR133MrbF2kgdeB/EP065r6Ni8PHw94bttOaBZriOAbpmTkvjB57c5H48d8eDReLfELQLNZ3jwwhdnmRnafYHv3/zmu48D+NNceR4NbINnKpX7TKTnJGAR/nmqxEak1ray6df68jXF06srSW39f1c7Py7wabFI7iOOEFpASw6DoQD7DIHQZzkcHC0VtZ1PVZhPJK+mksfKQYyCOeufwHTr0zXXaTarZ6J9nvrnz0blXck5yQeh9v0rKuNG1ax1cTC7WHR3RSxC4EYx/T049qwUkrrS3R/5eZ5keXVNamklnNa2Mz2DbHwQxkO7sPvZznjA59vSooNLWPSv7T1GKO91GHcYlEYQFjj5RjgA4HHTjjnmi+W2tYk043zJNPGJEUEl2HHzDJ/zmudhvruymlvb6+aHQYEZmafcoBxgEkZJO7aoUDkt06kRZz1X/BfkEIWi+hv27atdWoupYJNNdmx5KOGyMgk8g4PbqMdsVHp1paX9peWk19HLfsCxk3cqD0K56Zz9OOO9QaXe6rqUU915KvpSxl1C7S7gcBcZ3Z4IIJ/WsbwNpc1lq660kF1BDKxSSKdSd3YYPUjoR+P1oto9UvTv0RSho5dTrtPsJdP0K2gEgkmhXIeQby3JJUc5yRwD6nkHGDeEdrptxG9xcxrJH95pJstz3OTknrj04qlpcN7Lc6hLKziKX7jsdxx7Hp3PP8ASsnS9AjfVprfUdP862bOJ3Yg9OcDPI+v45zmoupN3f3GLgtXJnSeKtI0/UpYLxhG17BypRhy3XHuOfrj2rCee9Jia/tIluFcbY1cncDkDgE5B9T3AIGQK3rqSO3dFdDFCq4TBJ246Dp+Pp79BWN/b1o9/Jbx7VlC/IC2T09fUn1x39qmO39af11CmpNW3N2CeGSxjlvI0tPnCgPjDHHbnpkkZz+GMCp0ljSVPtKCCBUJLZCxoeMr2+bg44PRs7TgNhLPHrkkchiZktH5DcKx7446dvp39WeJzBrNtA81xJYyRvu2B/pwcHr2/L2FHW236E+y5nZmjpes22p6XfXV1bmKC3Yl2dd3AUktxngA9ucDA7YpXFja2mpFooQskhxhgMFsZIORx0PTnj04rPsNUupA9ppWdgYgMxY9+SOpxgcY7c471e/tGT7R5EcBaZOGcnjHr7DOB6+3Whrdr8/zNY05Qk10INX0+w1NI0lmmhkgYLkdeTjHHf3x1Pfmqb20lvqqeY1td2yKPMMsY3IAM8HjnH9OaLjSb1zJLuaJ94cSAnH/AH0O3t3/ABqvfpHaQtcXVzayx4wzowyOxAxzxnt+oNPR9bmkVK3Kmcj8Tlhs0byZ1ETZGB0zwcf59fcVw9ncIbBcuAcE5VuT0HX/AD1r07U7XRPEenK9ncQXDqCXRD05xj2/z0ridT0x7by7e3tmaJyRweQQfy/rWsHZcr3v1PXwdVRgoMo291HE6pJI+VyNwVsAHrg4wen5j2OLEd1IlzBNDb3LQoRmQZIXnGSPx/Sq2h6Zt1947t181OVgckB/89PxrrbHVAiXUcSwyQx/u1AJ4AHuAcg9ufX1A6Ekttf+CTiasYy5bbmnonjxoIP7O1bT1uYXBVZkyHAwM85BHUjjGOK0rPUba4tZ4riSMRPwqSH5ieobI6E9eMdzx0rg/Eiie132YS2Z/lJU8gbev168Vm6JZXdhpqyW919tkRsvHJ1I9PTA49/5VnyQ5XJOz/rXsjnlhFJJpaM9Ct9T03TNVMM4mkV4sp5GSfbkZzx3J9MnvT9GstH/AH1zDPcwzSK2BuJ2jPYce3vk9+p4Gxa8udQF86iLaeEzlR2A4+n+RXW+Elkm02/W4hSKWSX5JMjAOSMn05Pbn3FDfKmr22vqc2JwqprmOk8N6D9luY7w3skzFcFWfcGGSPr1z78evTSv9LXXblPMVJUQqTGX3AEEEHHtwRx1A9q4mbxDfWf2eNU8+RMqxDZJHv7fTPtVzwrrVtZarLLLdTedOpJhbIA68+3/AOr3qJc0nd62OCVCUVzrcg8T6XFpusLIMtC7bV7KeDkH1/qAawNR8KaLqU4uL/S98hGFaKJl+XJ67XXJ68kE9BnAFdp4ouYNTuUIyrIBxnPH+PT9eK3NO0KG4thKvk4bHDnkcD0/rk105fWq0akZ07OVn8Suvu1NXJcq50ed6JbR3Dy3cNtiYuW3NGWyRgn8/TvjoRzXpPhvTRq01lqV3NJHPCpj8naVGOnzevTvivM5/E9rF5sOmwzTG3cHMW7+Injv/dYDn8s4HRaPr80t4jPL9nDDMqOuAG6bs9R1xxx/TnqcyV1p/wAN/kbVaE6iudnba1aWDNbXO+4uo+qojAHpnqTjnHrgZ69qBWXWPEcMtzblra3UFAFwu7kD8cE9ORmuN129ttN1uVdTvnS5CrI8cXUHrg5AJwe+O3QdK6/wde3t3pRl3TeXJM6xhlwTgkHORzyMDqMc9MUnHlXMuv69uhk6KpxUkWl8OWttcC/sZRCN5aeKRuO/vgDnr06+uQyW0HlTi0dVMg/e7WJbHpkZPX05PSp/EllK8P2e55gkbEpWQ7vqeuO3Ax/Q51tpUOh38clrFLNYEKG/jKZ78deeP8cmkm2ua/8AXqSnpZmGLaM39zar+7aJhtXadv0z09h/9asDxzpUCRpLpwW5uNo3lf5gDr+nBPpg9lq0d/d3khWyd45lIikB5HJ9/wAPwI+uGNE1a7imWOJn8sDlmx34JPck0rpS57npUKzjbU4KzlltAkd0YlRyAw+vHP4HnPqa0rRb++mQ6S7QyR8+dtxtHfn1/wAa07bwndap+6so0kkGS0oIKr+P4j09a6rw/wCHH8P7YZZyzv8AKVwMF+4/I/zq3JRbfU1r4mEo6bl60guNR0iKO8vjJ5QDPKyFd5yeMYGO/wCf41YiOprfzQXIdbRovLi2/KV2gDg/TjOccjjtWYkD2czxW6xqjvvjDcbuSxwABkgYPHTJ/HVfXZ00d7y/txJ5L7BBF85GTj3zzjr/AD4qd3ZWdzy3GVrjj4Xgk0ePT4zLHbwMGJjbYenYn8PX0q//AGc72iRSrugiBK4OCVHUN26//q7F+gauus6Y11YF9gPzCaPbt47859+3Yc9akhZ5pAXbDhQzxFvu45w3rznt3Hvglz6xl0fXv/mY8zuYt5plhqOy3uI3S4I8xGOVVTkc8dO+T7d+a5f4n2s0nhuey+yG38u3zHIGO1iBk9R7dPfOe1drrOpNHq+l2ekxwTWkxY3DA7mQc8Y7e/HH4YrdWxSS3lgvoY5bdyQqsM4XH046H+Yq4zcHFt6b/j/wDSNT2bTsfI9iJUt4o5rhY2zja56EHr/9f/62ew8OWOseINTtNPsS/wBmtSJJZWXCbef8SPxr1rXfhj4bklF9ZWM1ywY4RWwre3t/+rrW1cSJ4XsYVhhi2su0IEUY7DOOvLD9K3qYqM1eEbvXe2n+Z3VcfzRUY/qYc2rR2kcelyQPLJEFbIUcL1wQevfjr+lWfFNyup2Q0tpJVkukBTA+TcOQM8D16/jWV4zstNuLJGmnuLG7EqyM5UK5XpyOvr34x69Mq514ab4wsZLnzp9Ni2rGqAkgknJPb3xxnH41ywTdnDf9V5mHIp3kba3J0rxPDd6ppRdrezWB2HPz8AbRn39P6mt/WtG0/wAV6RHDNFJBG8izKPLDMHUsN2O/3m+h5qtrfi4OjQ28JyvzqWTIYcYIz1GTgf8A1qfDrV++kJKLSN1PyKVJPHbAH+HPFKSk0pWt8zJptX2Kui21noniWGyWH7LaW1kbaCNB+7EYzwePmPUknkszE54rU8Rayi6ZeNBtVgnDEdVyemOT0Pfr6Vz8k2oXrmaTTJrydZAucALj1/8Are/ar1xYMJ4L9tOmDH/WJ8u1AByG4zgFs8YJO3nBxSlFt3nv69vx+bHywTXkcr4T1fXnuLq5S6mmjw2xZ+QzemSRycYBJHJ5xmr1tq+p6zY3aX0kVpM5KKFUrv7k5/qTj2yeNe0Ory3iSabBE+n78tuRVCqRwwwTxjP5HpWR4l0K91W+uJobc27RICmxgoZjkDGDz0yPf9K5oylfT87G/uuTvodDo8TW2jW9tdztN5SkB3YjjPbqCRj8OffPKf8ACKRDxWdVu7iRo5G3pt3ZySDk89ff2p02ifbn0t/EGtfZp7QB1iiPytz0bqB0/wA4robrxBFpuoRre3dqmnvGEX5cuz9uPf6fSleUdYPV3/P8bkcrTajsEPiDR7AXVujybGJQhF7jIIx3+779uowaglSB9JXU7lZPMkGfJPzMpOdwODhvTggcZ54rmrfU7SPUrpUj3iTJVyuQOeOex/rn1zS6hfz6c9kzulxHMAAI253EkbSvOBwOSc5zxxmmoO+iG6Ki9yvbqbbxPaXGnX0kcanfIrZAXg5yOnQ8ZHvXTa/4k0K2gv7a5kkNwsZUmEY3E54DDjHB9OTj2rIvbSBtYNvfW5tEJBjuY8Pk5HB68ZzwR149qwvizplu13HZ20+Li3j8x/7zDAwWzySRzzn8apJScb39f+D/AEzeEIVaijIytT8b3N1pa2FhPJDaKvLufnYn88Hk9a5O6e9ns4LeGQvLkqMnOfYf59KoTCKKxIl8wzOTggjnPX/PNdF4MtkvYWlEi7IEbcp5Y9cYPHfHFdLtSi59E/vPa9hTpxtFa2MgS3Hh28tH89mZzudUOFAzgjJ5J59h25r1S6iS4tLG+t42SxdVRmYZYEZGPw+v0rzC+nE9rJHGBFLkq7oPmZc525Pb6fjnpXoPhLToZfDVmbu52EFnUOcKuOg/PH0/HmcQ7wU5b3sefXhymXrPhrWbzV5NT0W5CywkbDyrOM46/wCfwqnpE+oXUbGU2wlXCXEioBlgPYc/Tn26Yrt7HUFl094LowpeqT8yNtGwdMjvxnk9PXmkstP0QQyT2c7CduCzrw7f/rrH2zjFxkr20Wn9aGUa3N8S1OK8Q2V0IvNtybgKgMgAYg9f8/4Vy+h61LDq1xabDEgQgfL+n6mvS/D0l895K0OJyqhWKnIYg/dx6dyf0rqYvC1rfkytpzQvwCWUZJ4wcY6YBrSNaMYuE43uu45Yr2eidrPseY2tvdzwRtYy7mkPzcYHfJFdEqXmmWcETzbd5HY8HHb6EfX8snpbTw3bXQubfR7phcpyVCbR0z1HGMfl+dUYvAmqm5T7VP5zL82c5yOOMd+Mfr+OXNG9m7GFfFRq/EV4bOWO9i8xcMV5PYjP/wCv16e1Salo1uJBcbYRKmOe24+n0/P9KZrdpfWF+UlePdj5CcDvxkAdscZycgHqM1m+S0rIsp3sz5IBGPz9epxj1pWvaRyxu9U9Czf289rtnkuQzhQMjOOnA/8ArZzxx61etvE17bQJHa3BEYHZlPP+f0x9aW8jgit2WbDD5V+bAznsf1HXsO9ZDWMUTt+7Q78N86KT0HqCe1XhqlKM71bteST/AAehfIpq0kZGt6Pc2EtvBY3aWzTY3gNjc3Ujtnv0HTmrV7P5Gl2eN806/K0yAncQe+M84Hb1/CvRNK8LJqnhyR7mIwu67GcEnK5DYwCMg4B/Wue8LaVZWaPpD5khuNyqJOSTk/1z29ahzUvNxfbf5nTTxUXGzOemf7VEwurArOqB1faMydvx6/54rsPDPiaZtAvLWGUQSKBHHKBkxjB5/HH19utXLKxbRbS/u9QDzRWyjOW3Nt4444PQDHX9K5W7kij8TwR2gVLe+j3Fs9A/bnkc9c+lJrm0ttqu2mo4zhXTR0N9rE+gaVDNpX+nXErM97qF4GbGMcqAf06Zzmk8Ra5Y674eFpY6xgXLKRPGPkYjOeuCRw2R2x6ZpJV2WN/pvnZtrpy0cqxs5Td1Bz7cDH9KzNKWysZU0BtKjm0y1QmO4ZgzbzkMxA6Z3MPocc000/ee61vpt5307WS6HM6SWy/r+rnR6Drk9jZNbiOa7dVVQxOSeAPzPtnt15pLjxKkyCN7S4tw4CyRkbQw5yAT7Ed6z9N8TwWd3cRGxlZvL2iRRwFABIIPb1Ge5FR2PizSdeVoJLWVDG4WR9oXPPTjBPUjrj27U/ZyV5OPZmMoXlsbdprFnpNg4s7KXaiKzPnG846n6nv0544rDu9futQtU+0xhNrliYfvbM5z+RH/AOo4rrft9pb+TBPAktp/z0+9jOMZ9+MfiPXi1qMvh2e3jgtzbwXsy7YxIQckt07+/JB5IJ9azvbVxuTCSTs0eQ+INSsdX1WzXTnnZYU8xtoPzPg9Tu9cc56Y699/QLnW9Glia+0qdrN28piedxOSCc/hXN+JI7rRtcnjWFIhLlUlVl2FhkrlhgemegP61uaH4lu73ULLS9du7vyQ+VeGPJORwGC5wfvDA9B3znZxk4rlV1b5/Kx6U1FU9Njs4tda5aKGwtFt2X5trfKpJHTt6E/gayrfWn1LxAq2eqRLLCjRGEKQHwMEn6/56VRTwxa2eq+Xa3s1ziUuHDZUk5JB7dgfyqxrljpyaZcPdn7NcFvMUwnc4AB5yOueeepO72AzioXsuvl38n/wDmUYLYfpljqWh6lcanHFNJCxI8ktgZyRg9+3GPzJOKzfFGra/dmW6tI72NFGY4k6ZIArpNE8QWaRaZpVmLm7ub5fMWSRtoROQS3vlTx7j6ncEYjmZ4tkbRku21Q5b5SNpGCfTAGDwPU1V5KSlOOv6f0jGVVRlqjibd9an0pBLqD25ijVrlGf5gxz179jnHtgccZdjqkF5e/ZI7+e7gc7GmlPQ5PK+g78d+2a6m6uLY6hJbXNsu2ZsSEchj9c89F59wcnHGRrOm29vqtnPa2ogt9zbE6ZbsWHr09Og680t9H19P69DojOL6FCY3H7zSJ4WuFik86PzTgewABwMkfqPSq15axLbCfV9SFvKoJSJRlugx+mP0+lXIbmWHVwkYMs+whcpwOMYHfH9BVjw14cu18Q/b9YSAx8m2iwcg5BHToRk9SM8kZwaFG27t19fv8A8glV9mrmxpV0jaWs0tj9git8bricENyD1/AD8/XNV28b21za3PkSwwWlo2WlY8uO2Acc9+/48g9bNMsiNBdRRyWoHzB0ODjHHPBHH6fWuS1e88JaTrEGmRaKbq7udoaOIZQAjIy2cdPTjpyM0oRTduV38vve5zQqxfxI6H/hIruTSI76zjykvKAjy2K5Hrjuf1zx34Rru/8A7ZlsZ7y8S4v8FNikhep65/2j0/DvXS6pHLrcU2nW7G2jydrqCAvGc4445/HOBzmpfCd7aaSx0ayma+e1B33jAkbvTPYDpn2HXIoiuVOy/ro77b/ebKShFtFXSNR0jw/H/wAI5e6nc/2oGbCquAM9OgwO3Xk559um8PlHhk3288qp0Zzlug4756Ht6dc8VotJsReNftbQG96NMgA24HA4Bx9cDr7cWLdtUtruf7TPaPaNnaoA346An6YxQ1defX1620Oac4v4THv4RLqV21v4finuPKPleY4BPJwSMdD/AJNcfqvh/WNQjRrzQPKTJOIyflbOSQOMH6+v1x3OozpLqUt1pllu1KKIlZHPCnbyOuMnHX8Dmt7RpdRfRLefUhFHcsm6ZDnaOfTsen0/CnH3bSVvvd/z2L+suklZbnGaNZmyuodPawaXeo8yU8gYHuOo/Ljj0Ob4juNUtnNta+G/tRRlKtGfmQcnJXJwQPp9T26O/wBWs9H1sxG6TypF3MGGdhB/hx9f85xXlPjDxq9zd3v/AAjZktwn7t51y3mAfUdM806UHOV0u3e34NHRRhOq79zvoNQ1Wa5ttmnWNlHITvN3Jll65fHbqT07H8TxdYPqBuLeGxhutUnt/Lkuo5AdmOenb9P514xoXiY6dcpeanLPqDlgSCTwM/XrjpXrFk1rBYahrHh7SQX+ymeBp3VgHOQSC2dvBI9OfmyM1dSg6TSfonsm9N23f/M1qxlRkpLpZnkNx4Z8SMzWB0qeR4jlnIOAP8/nWpp3ha6soVnkaXvhFOFPY5596938L3L3Hhu2uryJo5p1ZpI49h2gsdv+qwN23Gdo9M8gmufbw5pkdzHJGHCWxbajsTnsSeexxkj+dN4lu8WrenV/f91hrMZS+Lp+Rx2g+B557n7WvlknbgcEdeh/z0roItGg1K4fRtQuJIZLZVfcg+8OhHpjn2xu/LYuL+DRhprJHF5N4XABPzox4Bx+PPH9ayr7X9GhaG7uNQjh1CMESeWmMDH156eufx5ENzk7/dboYTrVauyMu1t5Jr+S0ktCLGPcWd1wSMdBmmWGnfb7gWw0yS008fMD13c8cnjvn/POZrupjX4/K0bWCqSNna67D1J6HnjP8z7V0/grTtW0ux1Aa3dLLCkRkiDODtOCcn/Pc/gSjyxbuk+2t/X1/IqcpU43tqy/4KF9pt7c2qWyQRnne4wT9cZ+n49eRjtrvVYdLtHkv512RqXZy6x4HAJLMQqqCQOSByB1IrD8Fak+ueHIru4jXzcvHkDhgPr7Y/ycVZ1LSbfU7V7SeRo45PLcmLAcbGV0YFgRwVzghgeCelYS+NqS16nBOfO7s1dIitbqQX1naiNpY1berowZD3DKSCCOhBI9D1q60DRRvL5ckqrlggXazkZ4wxHU+uB0OQOT5/faRrEGmWtnoF0bS3sVEUUJk3uVAOSzYGSSCc4UHOAABXcwXM6adbrdusl1jBI4z69MdyT7jPXnCcet/wAzGtG2qZS1/RIdTidJBtYnO4EkHnoBnpxnGBzz61wGreHdPtGXbe+bcZIcAg7ec9f6ew4rutbvJo7F2jKhyjHIzn0/oOPb6V5Jq+rtFeRxXU0s1xICVC/iO574+n1FVSTk/dZ04VTa1dka9nBb28rmcu77udxUjGT17Ecc/wCNK8NsXbZcGIZ6dck8/wBcfhWUL5p2SO4BjkMeN2NzdP6dvw68VoQkjeIp9i7j8qSAD/69dOGpqpVtPZ+Tf4JnVNcqPR59KGo6aXttRe287GwCTAU8nbnt+R5Htzwsy6vp+ut9qSMwRz/6Ow6uv94jPt2+vbJr6hMutz2EV1BMlssuVQPgFQecnp2GT2FdxfWSNcwtFG00XklVUZJGBkfTke1ZN+zSUtd/l8zmhenp3KF5rVnqttLpV7FLHuVXdzht/JJB25GPcH/GsrXfD0ltp8mpLcyNKrB0zGdu3HHOf8c5PTJqLQ9YfV0udNbSW+VH3vIBnzAegyBzz9fx6t0SXVNYnsNOvbkpDBuMlue468juckD0/qODg3d2tv8A1522N6V6fw7DvAE9nrXmtrLLBbwZDEnALEEE4x7D3rY1PwSbKe1n0K5WOB5DJPLM/JGOgB4H196wXutOm1iOHR7+ylu5I2RYFXG1skc/gR2B+obA39T8KyajZxy6peTS3C24G2N9se/B5I9/x9aTvGV2+VPo1+jt1HVlrzJmHrNt/Y+tEGWSTzkzGiRcSLjoD2yc9v61Q1G902EWWnsjw67cbCUSLt0BJ6f/AK66yyfVdKtFEzQXrJGG3ImdijgAf/X7+nAFCTW4LVpNTv8AS5bjVJ8W6mNf3iKTgkZHGPbHbpwacIt7K/o9306bd/kHthz2j2aKUXzA0YV/3gBYn0H4DnPX0rh4bHVY9cg1AWsGoTvKf3C4/dqDnPsRn6Ct7QfDlzBr13dfaV+xxqAiTsc9cYI9uP068V2GmaHbyW73WnzgzZIYRsGKcHjJ5655yT78U+dU29b/APB/L+kP2igtjAniN7pIuNSgdgj/ACrwQo5xjnj69h7A1a8D2UJvboF8LOg+TAYoVY85OP7xz24HoKT7eImezhupPtqEb4pMDOfbv3PPXH5QxXj6bqLpHGI75CMIwOD8v3lxjI6Z75BGQQcTy2vFf1/XcUpSnE2L/wAOJYXZFo75lVmO5uGOPXt/9aqfha0azt7jVtaQ3JZjFGiKCQMgZxjqMdPU4461o2utXl1r5tLy1RrPydyu3B6c9epGcEdto+ptzXFpq8MOmWtw9hJ1RVYbyuM9M8j6fpjNEm0rT6/kc8ZTtys1Lp9K023juLsrbvIBGrFRlBjp7enp6nirkflMjtHJG7nacA5zkdf5+mTXPxnUITcR6jbf2lZ2w/0dnIMjtx8uSOOv6dDxWbf2Ov2i3Or2cUatcqpa0jGTt7D346jA/wAFZJ2va/n/AEzHk5t2S+NNCvrqzt/s8cTTMxke5cj5TjGQcj69D19qba+FpY7uF9QuvtE6x5dScjPU5z7DuOh7VqxXMBlEV66yXJVWFr5g3RDjkjPbkk9898VV1sazZa7a3+mx/aLFiEmg3EF8+3Hf6/hzioTdlG66+X9fkXea90XxfBa2lla3cEaq4KruUdunYfkOmcfWqkeuWV1qsdhAgmuBDiQ4wB3OOpz7j169q3datEuLKVZWZFDhih6oMZ/DgmsnQX0a7mZ7SYRRQv5TyuMAnkAZ/Dvjr+FKFuS9np+v9bEXvHXUltLWeSRJGUtbFiQpwMEYAz69M98celUvEFzqFpFZz6NYWs0k0gieZyrOI8fdD9Wzj155+tdJrNyNOskeOZQ1wRHG+RtyeAw7dxXL2Gn6nJP9kvdUie2ebdA68bBgfePcH04/KnZNczt/XoKk2veI9M+2DUZ3uSksUxZni5+U9hnng85544FbWn6ZZJMVtLJY/m8wkHDZPf8AHJI9iMda8v8AGPj9dNl/snSQLq+gcrJds3GO3Az2AHPb3zUvhT4km4ubay1r92ZiALmNlUIffPbp6e+cVsqVRrmS0+752/I7J4Wq487R6uAqxkQh4ty42ghW56cqcA9eQeo74zUN/fqqNZ2E0EOsvGXgSQ8ZOBnPQY5/HtUlxqKR6H580iWMK8hrl1HbOMgkE4ABwSPQ9688f4g+CLLWJb8/aLq+C7POiQYPPbJ56k/pWcYc8tIt+mv3+Xc5qVKpJXSPQLYzRafbyyCF75olE7Rg7C+ecenTqKuiZbm3a3ZNhBDBGPzYHt9B+n4Vy+jfELwzqarDbXhinfG1HUBifQ5784rf1aBxBM0N08d8EPl7Tzu9SO+Md/Wk4yi7SVv6/T8CZwcWlI5LW9ItdT1+7a8s3WWytWELFiVds9PTgjp2wfavJba6j0uwuxDCDcS7klR4+FHtx17/AE9ME17noS6rLpdvJrIddSG4PgcsO2f8P8K4fxToGl6vc3GnW7/2fqkJ3lgo2lcYHOPXA4+uOauDs3TnqtNtVp19D0sHiFF6niUfmFHttgDSsFXccY/+vXsdhG2l+GbWCxuHu7i0VGuo8naR1246Dk449vTFVtI+H+m6He20+o3DancSg+UuBsXrgnr0696abv8A4R/V5Le/Mt28r/u1hUMsY98cdCB+XvXRUqqq1GnrbX1/4CNsRVVX5HQeLfFmoWuhJf6ekdjYrhXWRD5pO7kY7Hrn+nZdU8ZaVpWgQ6hA73j3cIYLgjY2O+enJqaOcR2sk+p2EV0sYB+zzJxjOQQDnn3+mSOteI+JtSfVtWWZFaK1Dn93/CvzZwMensKwpUY1bRtot/Py73MMPRU9Wtv8/wCrnqHgrxZYa8ZbLU0SPUFDNAdvByOOfx/L8K8w8SwXVtr9098N6+awKsBnuOnbvVwjSNPtIpxG6aoHDq27C9emP6e9P8TafqLD7dds09vcoJVGCcZxx7/55NbQjGNRzjopaa9/I7qFNU5OP9fM56KVZr2RmkML/wADJwAccf5/xr3D4V30muaNPZau6SeUwBLEHKkds9+D+APrXlnhzRl1i8QwWrARna21fvH/AD3r3LwRpdvoWnMJSkUspy8jMBtOPX0ycfWnipx5ORrVW+Rz4+UbaPU19JW10VPLt1jitUIAAXAXsfzPr607Up5bbUIlFp5kDqdjoOh5IHXsOvPPtgVee8itoY1YKyNkhlYc59O3btj8xWNqV3qVhqJdXM9g643bR8gPXGfTAwPzrzk23ff9f+CePGN99DUn1ay02Ca4u3QRqVGxBnbk8HjoOfb+VMurr7S0P2c7o5QMAjnPHTj6jGR64GOOThGkCacjzpQSGKsPl3Z6fXn279OzdN8cRNq0a3toUhAAj24Hoe3+euB6NR7a2/yLnhpNXijc1q+Wxe2tvJaUXeQG3AADHUds8/1rzjxRpJtbvzXHzcjPBIUHPpjIz3P19T30ur6ZrXiDS4LKQOUQytkruUDn09RnP06da5T4maBeXMr3lqHkKvsZdoypABAx2yCCPbriiD5XG7tf/gm+EXLPkloZMK216gV3ZZTxxjqB6ev48857ms6Y3qPgbGXAwzIOR+PNc0+qGOzZJIzHcRkfMf4hxz/Wur0TUL6506KUoDu5525/HJFd+Ho1I1LqTj6Xf5HpOKjtZ+puw6rey3jXMOxbSNljXOAcdx1/D2IPtnX0fxS8epeZDvECKHeNgUCjJwxLcAdfmyOmD3zyMlrGZ7O4NxIsiSBTGrfez39zw3v6dDXRapO8tzbxsiW7SABHjHTjIJxyPx9+1cUlF6JdP69fUxnTjZXLtzf2lpfPd6fqsFs9y4ItT8wIAHT6468Z7VqaHfWt5PPf3Ufk3G8RFwcEjvweCOT2P61wcOjQxTtPrC7coPLlJySMcfT6j1/EOvrS6ubwzQ3CpAqeXGHwBn157/WnKMXpfpvb+vxHGhFrQ7Lw80aXt9LqdlYiOJmMcyqPMxgsxIHoPX0xzVO1uNR1Pw2JdCv5L0JdZ2SDaDwrbG7YIZT1HbrxVi0ENtHpcssguIWdUuBzjGQSv0IGM/7XPPXI8FWeq+FLxrS1ntb7SJLkSAR4GGVGXfwBgEBOP9n2q4yjK8uvbo7f15HLVptWsdnc3V/pemwf2fpSSag5Uuj/AHM42kL784596q3WqWy3e14RBqKRglMqFDHOcc856c//AFq02vJJrW+ZW23KL+5JBxkcDr74+vH4ee6E95Drt5fXs0c5Ay5ZRjjj684Gc1Cimm/89b/oRSjzasu6S+oam0zX85ZgzeWyLtGMg+g745/wrEs9cOlPM+iwSRSs4UqrZ8wg9/5f4ZArc1PXtRk1CPTILW28q4TzDNGvRCc7iewwv45rK1zQ38P2a6pA/nbuHiHJGTz7nof161ra7UbJX2S2/A6aTjH4zJi1+a4Cf2p5sd88oL/IFOPbA/H+ldc2qaXPqunXqvI11bufNReMDBHAH0wSB26jNctHo8/iKOG4tHjb7pGT8wGeT35+Xgd+eRkV3dzoFp4V0a3/AHD3M25C8it93nDHI7j881EuS66Pay/rY1rzpxXKtzpokN7dpdS2yBWHCuMqg28c8Y45rjdY8MXF34iGsaVGZLi05CLlc8Z5z175HXt1pupa7p0V/DFZ35mMgwy7jt7/AC4xzz6cdevdun+OYdMsbi1hsZ5rxWyI+gIJyTkfXHf8hSp8yfuLy7aedzz7TiuZbHVWviFjbRrfx4lTLOdvCEg56cn/AOt3zTPDF7A1zeIL2aaeV9kaA7ViXI4AHXtz2x1Hdrw2uo6payxPFtZcmJmG4HBPJ9cfXp7c5PiyW40Ka1u9B0d7q5uZjukVgFQY/wAMnr2ohBTfLHd+aXrv/TJ5oy0NvV9Bs9Oe/wBUhAbWrqDyYi5IO7jBA+vPH+NY0NpdRHRoNcvJpGjbAjjBjwVxkZxyMqOcY6cnisTxPrNhp+o2drqS3c9+gViq5wjMB93t1INbFlZXkmn6vcTXH2qHj+z04DKSMgZ78kD8faqSmoqT+9rfppvpr5GzpuGkmdd4gR/7EaCCFXd2A3lht/Tjtz9VqpeeH7O+0Ka2ljxyvO7OWIwfwx1GeMc1xV/qWo3Nrp+nlpE1Rk8zYPu7cEnnscY4/wDrV2our+18PtLpca6k6qA67uQRwcdOg+vQe1RbkSSevTp+PYxlTlBEH9kWl3HaaX50lxNpcgd2bt2K5+ozn3x6modekvINKubq2RGn8lhHkFQhwM/T6fTrWp4duJr23W6ktPsU8zfPEWzngdOOM+3XrknNVPiNoH9t+FJfskjw3lspniELYWTjv698Crly3UJPr/w/4/gTRlaorny7FJLaXM3nrHLcO2GJPc0lj/pmsWcR/dhpl3MR05HNXDiaJB9nBuBwcdSR/n9K39MsDrFvLdzx/ZCh2cqBllX+fv6GvSdT2cueSt5/lofT1bSpckWeiftF2d2PDWjLZgtpyyBJApyCcDH8v8K8e0rRbeS+S1kkyzEKGDYQHsCf8/hX0J4C1rT/ABH4ZOkaxtElvGEcu42yEEjhskkj5SSf7wPPOPMvFa6T4S102tvHHqaff+VuFyeBkVy0ZunD6v1V/n5nl4ST5nFrU45YW0nxA8luxZ7Y793Xkd/896+kPCOu2+veGLfV5UEO5TFJ5jhRuGR9BwoAB5+vAr568P6He+Jr54NFgkM9w377nCxqT6n/AD9a+jNF8HWGn+DbTQ7xZJliC+Ym48sTk49OSffsaMTy2jzP3l99uul++xjmUo6Ij1Se8/smU2twYrpmBWT/AGQckjrn2+gPsOf8dS262sWYUm1SUJC437ZGXvwBkAEf55Nd9cpBLAqALHGo2Zz93H+FcD4s0m2uNT+3ag0Ntb2xHmz5LEHI2rgjHbpiuWn8S/q/6nHQkr6lPF3c3lxHGYvLt4/LiWLl4m7YOM88/p6VQ1zwzqkNnHcWcillw88rEMyKOuCcY+g/rXVaFpVrpkK2ulGX99iTz3wZGJOQCCB69PfBJ6njprPzk1b+1bx9MspvlRpHIMrZPTrn39qcJWd09rdNX8v68zojLmfulwXst3ZW4slnn+0Ptd8rkAcZyO/XBPXP4V53q3w51ObUpoLSSIWqPkuT9089vTOec9Mc813Nh4ag1HRk1CxvXhEUgjeVWO1lQYOAep6Z+tPsDJfWUk1s8kq71XkADvk/+OnkEZya1jP2Um6bs/T+vkXGo4ppbHJWfhK2TUANYn+0yx7VESsBjnHPr3rtbaEzSzWc9oTHDEAAcgDg8g5565xzn1Iqvd6XFcXE0+7ymcBXYHgHAORxx2wOlR/bvslv5CTq3lqEwpJx049wMj/OMTObmtXr+W3YJSlUdy/Y6lp2nwmGxs/L3n94m37zA459ue4PfpySmv6lZy6JdQoZDcXQATLcpxjIwM47g9ee9cxNdC9uy8jOFJwmxcevPb07Z61JplsJdSW4vC1yqD5QG9v17D1/kIcdeZ37mioJe82dV4J1tJYrbSblWmkjjYefI2SRwAuDycZYZ9/QZrotVjlvITb2332GNznOB2xn2+mPx44vR5V/tq3t5NOVLSbAR/MYEEnCk+nzZAyeo+tdbry3Av7HTLNTtZvPlO4Z2jnHPI79Oee1YzXveuv9f5HNUilO8TjPEUcug21s17Lse4IAjJwRk9DkZz169Misi8+zTRDyzGMsXbDD7zEMxPfJPUk5655rq9ac+I/EU1pc2HlQ26eYqt97IHtwOw7fhWBd22l2E0ljdho74/vBnIBGBxnPHX044/Cova6130sd0JWWu5R0SGPTtXS/t5B54G1Qh7njGO/X6Y/XrX1q9I8iYK0EilF5XHpx+J/w9a5O2sfNkMlqjMJOMHoenb8q6iDw3cXVosUoYSovRRtGRjj9B6d+OtVKV7OTuc9dU27vcn1LS9J1F44pLNQ8mG8wA4yPpx3z+P1rkb65nt7ya3TT7ZY4mKRiRlTC9sA/X8811VvYzafF5guRiJgwXIIwBjnPHfHv75rUjnhvI0knWGORVCneu4kjqc7xnnI554rvyqrOjiFKknN2eiSk18mn+Ry1KjS11/rucDL4WSymDNNIskWSOevPXn1xnrV/Tdemnly8AlKHrgBgduM8cngY/D8a1PDN2dV1C4t762neQAt5gP3GOcHPqMf/AKqltdDjs0cKcBm+VlQllGTzj06Dv+PVeGTvdT1f+Z3uqtpoq6bIjzsNQMhiY7ssehwFwMDGMDPTGSfYDNuY/PnMVvfTujE7Y1QEAdNvX/PQ+ldJJbQRWkzM4kdHVo3UEnJBxjA578+3vVBNPubD7Zd27hbbC+TCifMG6E8A5/D+tJPqv6/AcJxTtsQaa89uJI53E0D4wmQCpHfrnr/KmvrNzFetZqqHcg2spx/CT93Gex5zjJ6VjwjVXnefUIpQrvuRlj2g5PU+o5xn2PNdLG8NraRPc3hRGyrB8nCnLcDjvknPU44ByaHo/eNasUkmt2aOi6tNDEVn3zxEbncn7uMdeee/T8uprL029sdWgvIbWEvESBJkAMcY6+v4dgfUZ07DUdNaR7TT5hJkhpJCoAZB6+p5PH1461Lp2j28WuXl1BNEkUyqRAwCAEchsHByOePU9jmlort6Pp/X/DHI2l0E0bV4bmS4SLTRGUQxMAASq88D16Y7irct7YxTFxHG6RJ88UmMsSM8jJznI7f41y7sbHVpIIDOvmZd7lCVVPQc+2f8gYl8INYzXEguJjeeZkAy8clSOB7jP4H8Kc4pJyW2n9f0yVTT965asNcxumsbVmLOAVjXAHfIABwOgPA7fWunm1+2urZbTVt8jfKcZGCcZ69OOevTH1rmbmw/sm2uZZ7mKC0uJdkbBssc9MfrU0tjImmw28VrM1pbx+cJ8gkMRnrwOoHHB4HtSko2uvv/AK/ImrGMkrHBfEGCy0/XlgWSOCGR90IgU7l56cmoZZ777clxDenEaY39GcAev4Yz/kMkuHnvPJ1d2lKSEROV+6pPI+mec+9XdQ+zWulyKlwjnLbST0f6dP8AP1rdJxSi9/w/IylKbkkixoeq3Wsacs8VnJDeCVhvjJ7D36Hjp0/p23hpdU1pYpY9Wnt7W1Y+cqHJYg9MH6EE5HTvkmuC8D3ep25tIRcQRWyo0kpYjnkkDnqeP/1Zr0P4e3epRaReS3a2kkMkpeBIpMeZ1Gc+p6f04FVU91y5bafPR37inGXLc6TxF4fsdbtlbU3MbK24yoAOx4z6d+eMdTWd9uudT+2WGgpCxgkEbSE7kfrnIx0wMfjyOprb0fXLXWXnsmhuYZrYbZYnTgeuCO2DjP1HYiuFuo9S8KeLLi301lWzvkZkaP8AhxnA68Y47/zBrBRtePVbJ7f8HQKac/dkxPF95c6fqNmswLsBskljUFGJyApPpkdB0z6mt/w+dXt4pRaWcUkL7WR2cAj7n8QJ+YktuTaAuPaslvtmi+HtNjxHLeXdyd7MRgKcgKPUEYHp7CrOgrqNlrWowXVy8rZ3iONSFQHkZI9P68YzVRSUdEtPx17GtZc0LXPQ5428p2A2S45A/wB3vx26/wCcVUnmikjCuiLIhyd3AOeMZIPGCf8AJqm2tW4g8qWR4XYbMMvyj8fx7UstrdJawi3ljl3fMrsw29Oeeccen4dOVJNKz0v/AF/X9X8+OjueJ+MfC15pPiK4vtMshLp4HnPKFyqN0K+3P06VzF9rF5qrCyuVKLCflMeAD2/z3r6V03ypN0V1FGJW3F9vQc8EceuD9ccnGa5Gf4Z6FLJcT6eXt7iUlmJc7DncOBn1I49jWyqxfxrVbM9jD5hyrlmeLWU13o2pFw/zkeWyg5GO/GP1xWdqvmvKZVtmM/Tnvx/n/wDVXqWpfC3XLe6jfRZLZz5vBkzjABb09v6Uy98DeLNVuprm5TT4Jw/liKOXcG9cntnGOcdR9DoppWk2vvt+B3wxlC907HnVsupRwD+yLqeOcLl1hyNvft2/+vxXvfwi1q91bwbnVFkZ7N9glPWQZ6Z56f14745/4a6Hrmh+MJY7rTYpLO5h2zzkYC4x3OPb/IrtZbhLTVry2i1WC30uyBme3WH5SO/zdzk/r0rOtO69no9pJ7+q0X3Hm4+rGvK0UaGo3dxFJBJaWZeORiG3kZQeoxwT+PbnmsC+tRda7ewSXKJbsm6YSDcUBxzkjsfT/Cut02+0/U9It9VsHaS2kztZgc5zk4FcvfPdTLqotljuBKOBGuCi4Pfoe/r1/GsE2rrqv81+R59NfITTdHHlSywa204m4DKu1cjIxj6n/wCvXORaaNZ1t9K8Q6dNcXEe54LiNR5aKckE4OD6c/8A163PCswuIG037PMjQ7mkcjABJ5Gfrnj6fjPr8d5F4du5dOuo2ABGI25UDHAJz1wfzqtYtp79OjXZ6W+7qWpNS5Uyp4d0S70Gw1CzDLLC8jSxqY8bfpxgr1/DP0rNtYIYbKaGBmR2b94Y8DPOOn0Hp/8AXzYtd8RWbWWniObUPtaByzkYgXvyOp5J71QTzLHUYIZY5bi6vZWjK8lSD8vzZGCPqOnsORqbbk9b/jb8jSFO3xMmvhCLXyLm4YQO/wDrfM6dBt9Rjnj1z7VmLcx6bdfZ7XTZGjYjM7puD9eQD7+vp/vZkTwrKb1keKWRZrnzFRmK4ye3Ynr+Z/HZ1nUrjSoooBbmR9yovlKQGbHPfGCScf170t7L3r/I35o2shlyZYNeS9vtPkjsYlC+TDGD5hI4GFBzyeMZ568c1pWdgNRtHeex+zSBgY1GCJFK5B5Ayefbp6irzQ3up6A8F7OlvJIF4VyGQjoBgggjAGcjvXIaxrN54R0qxWC83OJSZ4rg5ZwBgKP7o7856854rFWdorfZb/1+f3DhGdV2W50UmiX12FBjBgH7yM9HT+L6cHnkHnOMcVHfa/qVpdtHHZlLW3jCee/3mPAPOPY/0rhl8WajJM+pSX2HblYmXCjpgcnj7vfpxWpr2rNremWd5uZFOFkVeM8/Tt/nvQ4S0Ul+e5v9XlFrn2NOTWNQlv1vYYkeVlAwBk/73Tg9/wDIFR6ybnxBGgurVY7leCwXqOTzjBHQ/n+TNOVLeyP9ltLdSNjCuCccjPB/zk810em3EOm20SahC0LynLfKAuR2OfoOo+maXKo2aW23czrT5G2lqYkVjc2iWwindAE242jO7GcYPfAH4j6inm/1qP5HfAdBggYLL7j/ADz2Pffub0K6iCMzs+BujyBtLc84689fp6GiNYpbome0eA7fuqSOucjPT1z+o9Ve62ON1NbyRzUWnJ9pkmuL8hmBKo3Kk/5470aXDPHbt9o1FYmZyyoxxhcAD+E56Vt3ltazSGFYfn2ghjycAHHHfHPfj69JILGYIcGKFifnUnPPryM9Mfzrvyyu6WI5+fk03/prf1FOquWxy89veb72xW6a1SVDG0sZBKg+g6Z4OP8A65FaUsd5p3hAWmkXNtNeLGoMjEbmHQn3OeOcYz9M1re50y01mGwKSyMw8zY4LIwYHg457euOnXrVzSvC9vb6pfNYXhu5HUukL9AwHT8cgcf/AK+OT5d+lntudPMnuWbC5jSxsHnELX6p++jDZQMf8+/060XniQaf/amy0ctZLzIj7izHAwBjg9T3qPQrK9vrE3Go6W2lyiciTexzIi5ORkA8/wCe9PsfBMkd9qd7FeeZbXcg/wBFClvr7EDjjv6cUOMYtxl0/wA9rrTuKMoS95v+rGbf6VFd2CeJog0MDx+fMJCMAMOcHbk9vlOAM9T0rm5E1DWILd7lbaCyjlDxY4yPfv2/T8vRo9In1OzvNMvLgQxgmOEAfKQAQOB/njPfngTFcWV3baXJM1wgYI8mD1x37+nf6dsqN7O26/Bf59Dro1E9GzYs7+xtZ1OmxxZVcDzBj69+ee3PY1heJNcSfU4J7hcXQQQiAMecYxj16Dnv+JFTyWsi32Lf5lQ4LEdO3H5H/PTd1e00JxbS3Sozx/KJExyT/Tn8hRFqMk7N6fPYp8kXd/1qVLbUo72wVRBJDHLhJAFyx989MHB/M+gp8dglvbR3DSl4ycxqC2CcdAfy4/8Ar5l0O0SwuX8/ZPbykrBuGQmcDkk+uP8AEVr6vDezaMdOsYlFyZA8bMrZjxz1I4GARkeuM5OKqKfNZM5alSMdEauk6M9/p0Us9oXQHdDHJnHJPzYP1JGah+Ien2X/AAjUP9qapfWqCYExWyMzzYGMY+g/n1rf027MMUcLrJNOV2v5bttDAdj/AJ96zPEWtPYWQa5soZhHl/Ol+ZU9AvvgfT8KiEmpRlL+vvv+RxXlOVomLq9lC8VlDZW8bLJGuBcKEdE28MQW+9yOuP8AHBn8GziyiumW1ngJBD7xs3MQAMk9DnH5cHilk1//AITDUIotqM4x/qwc46EZ9+fzr0XQfDWn2VjLZtaFUmLFolkJxkYJ9cdf1zV2lTST0fp/wV/W5tNukve1PKI/Ckt+t0ts9uzQgMRHIDjp6E+vr3H1E9oy6c8GlW9zFZ6nHiWS4lXKRLjqOgzjP516Zd+GrDS4mbQbO3hIUO6ZJEgB+6eec8jj8xUWr6bp2rPbR3RjEUjKsm4YPA6bh15HrWsZ3dne39etwWJTWqKLTalD4TS8sdQi1KbcUMwjwn0756AZ9cHiuKt5NQiuYJtSvGluy3yoh3bByB6/48+vJ9ButI1LSbNdP8O6hG0JuhK0UqgDYf4eR9PzHeodO8EXj6hLq2pyRJcl+IrcZjC4/wDr9/XqayTiot6W9Nfy0+RcK8I3uZz6xFOLQXUFvK0J3RlZdgP4j6k9OmOeK2F12NXuP9FVGLBWkR95zn254OBgc8+1QSaRYXOqTCSOTzYQCTklcnDkbc47jJwDg8kjo6HwZewawt5pc0ZtriPE0TRnaecdCeDjPt9OlCUba+vX9DKVSnLc2/7VsNT0uaAxRtLJH5ZHXrnnPbv/AJPHF2ularpkf2HStSJSPDB2Yk/Pu4GP0xS6jqVzpXiuO2u1QWsSje2Tuxn7wAzk8k9+N1dPY2cWs3s15YXsSxT20RCPlmBLzcYzjPb15/3aq/IvJ69/66k8qp27MXTNNuLexxql8s0oZgJVOFII+6cfy/nVnWpbvTNGlntrFLlIyD/rMADOd35c8frg1kILl0urd33CNiJWJDMSP4cAnHHGDg8Z45q3pttKi/u9Qkl3HmJk4A5yD+P+eOIcrfFr+X4A6Sb5ugmjeMdOupVt7wXdoQAySujFWJU9Ovrnv6+9WvDSi5sbvUIrQ2UL3BzPLj5x/C6jg8/qc55FTvb8RKNpUSfOpUcEZI6jP/6+3WlLW7WE9ussAVQQbZDjIweg/wAPpxUSqJX5U1fzf9ffdB7NS+EZLcXVz50lvIs2nZxuj+Use+c9s44wO34513pa3ul3ENo6xm6j2GLHHP8ATJ6jmmT6ZJqTNNZXlzZhXB8vIC464HpTvt5gmW1eVQSATk5B5GOeg7d/T2qHNaqL/rz6M15JRty7mRp+nQ6HHaG7lkBs1KRwq2UfuxPHPGeOcVLc3MF7cWkulagtgqyF5iTzIFPIGewGcn39c4u6hDDc2LK9xEVlyiFWDE9cn17dhVe3s4LaW1s7F7S7RVIuCzBnUn1OSDg47d+9ac93zX1/r+v60m6s2zBXxxdX3iQppNzZz2sce91jQ4xhsk5wMLgKQSM5PToV0W5FzHdW0d1AhuJSHEZwUbP/ANb19KcLfTZY5NN0+y+xK8mZpI1xnB4J784H+elP4gwDT/DgtdBtSsq3C5ZRhj7DoTyeh5yenetVGLajFWu1vb72HPFvlsaVpOY2eGUKlrFtO95SSxOCOeeTtH1zWJqeranFqAlhszNvfy7dYgO55Y4+vrzkdOtbVpibRFi1eTbNHGGlULlgxA6Ac575P454pvhqwtIbWS4S5kaCSTaUbOMYHGTzgZ/XtRpq2r+XRkKpZala28TXtn4ks9MlsAsdwm3zlfdsfglR+PHWrl5f3RvB5flsmd2Seg9fw55/lUIRL3xVbvqelyQraq0sEsZO0rnq3bkDHOOPyqF/H2jS2zXlyBBuuWjjUYLbV7jA5Bx168fQUpRWiUemvXvbv0X4FQi5O8Fcz7Wez0HxJd+RZTrqE8bTrM0rFTweBjGBwDkdO1eSm9Ota/fPqMkpeR2MY2n5BycDHSvo3SvEXhvU9UihNzaPczKRGkgGcY5H4814/wCMrO98MeJ7wR2yxq0h8t9mQwPp3xz39PwrSjNyk00+ZxVrvt2uehgqihK0lbU4NLm4glhWF/NjU4KFO2ef89a9g+D93a6za6nbSqo8sjYhzyPb/P8ASvO5dNvLy+WF3S1IjMrlRk47Zx+NegfCXwrqWlj+2b7akEy7UiJ+YgsBu+gB3evGBycVtWUZUm3o+n9eiOjHYiChoz0S2hbTLNpLKGFrh87VL5DAck7scjHfHp61zX9qG91UWmq25RiwBCr8pwe+Bx+XOec456DTrppJZI9g7gI3RSO31PY9PXjreksod6TXMOZwCVGM4HAz37Y4/wBr8K4FaL2+Z89Ku7u5W01LezgYWi7pQD84bftPv6fKP89ahFypmQSbNwXcGDkZ9Rj0wB39R9ZbnfYqJVdIoc5d5Mjbk4xwPf8Al71iaheRbTcRMrLIPkbPIPTv+A57kGle4Km5O4WeuyDUGhvEUYcRoYRgnJ5OQOcHk8Z9KoN8QLG2YjylmST94jFM/KenBBx0zj3/ABJpOnpdidnz50hGGPbOc8H06nkH+uXJ4QiaaVjeJlnOd0G856Hn6g//AKsV3ZcqaxH7xqKt12/Bo1qRpWdy7Z6Nc67HO1vJ9nmWUpubh2UHPvnPr16da62TRrjSbrT7jzGCRgRyiHILt0BOBnH/ANb2wQSTtcypY24eZ0OzjaBkeg59Dx39OM1/Cml6rb3+qaj4luU/tK8ZVSCNsrEoOQMZ9P8AOK5pvRyulbp3v/lvcl1HJJN6C6v4s0Rda0/R7hhNqbnKDGRF6ZPY9fzp1rezQa1o9naarZENcEzJu25XHT04z+efXh142haPcTzzQpPqs6Z2Qpvdj0BzjoB15qTT/DkMmmA3Gno96371ZNw3KT0PbnkD9CafLFJaO22tnffVbaIqMo2G3rL4Y8QT3d5cSsbicsBGeTnjGcj29eg6Y4wPFF/pd1fvLp64uZCGkJ4KE8Y6dccHHt04qre+HzpWrGddZMD7fMitrkkl2GeR+OPXtmo4PD2qQeErzUnFuLlpDMJt2CVyck+mAP6dqXKtG5dl2/q3lc7FyRXNfUiSzltmKuPO8wbDu4DH+oAx6jj24SOGS6d0ALxhssCCcgkkknHPH4k9+1bkcsN7odpHbyLPdhcsYzhDg8nj3x7c9j1yViuLCCX5lA3gna4UnnkZ68ADvUpt69S1O9y7I1is1pDZp/oyElkZCzbuOmOnuPfsa7i0W1bTHusjeY1CDGDtzwp/M4HTuODmvN0vvshmeKD/AFq7iccjHcEc4wQeOtdHBrU0+j2slhZGdozmYu2MDtg9e/5e1DT0Xc5qtNtXRryeKNNtNfstLYhdQuVJCJ0APv1HTP8Ah3Sx0IWljqmnSTPcW10+YzK+dhI5A9Og+me+az00y1bULfVRDG1y8Y2NN823g8Zxzx/OsO2tPEdxfXMNtEG0oSktOTjHOSQM8+uPeiKVmou2ivfvfoSodUzofCvhrS/C9jKto/m3TnzJpQDwuB8vsOeuO3bnHX6dcrfHaoEqbQN4LHd07gYPIrI0G4todLKPdW7R+cIWaQ4O8DoCTnoc/wCcna81bWxkeaQrbwKXLRqQWAGc49eDxz+NObbbcnv/AF/SOWTlKQtzL/odwogbexdRv4Y89ckf0NUkktbaBBeQ723DEoUnB6cnqOQOfp7Gs46tpviu0uItN1gJNBGWeMnay4PXpkYwenf1qtpF7NdwzW+tvHBBBIEM2AfOA7HPtzTs1o9H26+RSpvlNufVLDT4GuHRpVJCqVOTn2P9e1VfEmp3MI0iK3YRJeSbd+wMI+2D6ZBPNUvG0MGqaXaWVjErrqEhXzlYgxcHJGOSe+O+2ua8M+JbnwzbXul3tiHhguNkEk7ndMccEfp09jUwjzrm3fa/yv8Af0/Q1jS0utztbP8Ac38Sy7nYuRKW5B6AH8yfb9a6E3OJWGCHZflbGAQRkDPHvxXMX01tJpVvfWDJucZSNDnLZOBke4x+eCeRWrpF9cXWnW82oWRtZixQxs+7PuPXp+lCTa5n+f8AXzMKkepi+L4dNvLaRYYGudSiz84GduT3PPX/AB4rF8JSQ6frKWjS27XbRRLvGV2EO5Ubfx6D6HsB3tjpnkPNPuVyZN7LtAx09/0+n1rOktdMfUJLiKzCT5wxVADnBxnPpnP4nrV8ys0n/W39I0hVvHlZevNDhkwbaMwI4XewIZioJ4GAMfeJyeefTmrEUFlpqp5ZbdI+GaRCM/5I79qqW1vGkTbrl4w3IweOTnOO/Xj19u23ZpHFZv8AaZ1mkkYsDJzzj/P+cYyadrCcrdSg2nxSWpisrcM5+fgja3TrgHr64J6e+eTj8OtZXF7fai0BLDEDKm87m4UADBJJZRtBBbOB2NdQIr2TUU2Fhbktkj5cjqD17/5JzxDrmlXdxZTwMr7SyTpcRuoeOSOVZUYEgjIdFbkEcYIIOKiTUPdva+5pCbinyszodLNo1wDOG87LpG7ZKckcfr0//Xweo6RHFbyRt5slxK5y6LwuSMkHtwQOv6DFdhqHh+e/1mHUJLi4+VSphU4Q43hcjnj5s9eoxzznVs7ZZLNB5Q+XBQhi2fX0Jx15BNZxk07t3Ov2qgtDlLW20m3gtdMsrZ0jhUFZmk3EyYwSP/1/lRFo8WjO7afOskrMBOrEs+3Iznv3OfXOPWt260eKe3muYWkhkKkZDYXjp+X0Pv61X0xbbSLG5uri2n+1DMn2h1OZCGBCn37Y/wATWsW7PX1MZTUl7pXsWSa1+0adbyxoxZWE0eD6nGOxyfWs3xNptssNhdarcPvim84iLueg6/j+vrV+fxv9r062udNsnlvmPlm37ICcZPGc0utSQy6xpsU+VknOfLwWUfLkjj3I5P8AhWyjKL2tv66f1uctmpXkFlb6Y8091bO0k1025iykhc4GMYwD0Hb/ABpRyaV4V0O4k1S6DxF2bYXBc44wBn69Pr6Zl0ZrXRPEs+kuGP29BIpZiy5HRR2/vcjBOOcYrlvi98PL/wAUXMOqaVcuzWyBHgz2yTu/Lv3qklzqDlaL6/16WHSipStPYxNV8Z33i+LULPwzDLbaTAhWaZgFLZz3+mePrya86aS20iaK33GfYuUXYWBPr0+taGo3/iOXR4fDWl6Zc2NnbSFZTGhDTPx94j8P0rq49Ot9B8HR3+rSq+rTgJFasQSF9SR/Pj1+nTOCoq7Vk3or6vs2/wCrHvYWcadoQ1+WhwGmTSTTtNG0a3MfKOw6YHT6D+lfQ3gK3GreBbJtfVNQuA5ZpJeTkg8g447D8+nb571FrC3v2eBJZpZFy4BIVc9gB/j/AErppfiPe2/hSLS9JtVhVW2SShmLnOOPT/8AXSrQlVglBb99LfqXjcPKra2ljuPEWqeHNO1iW10+yjkvMhZps58sA5wAQcH8P1re/tOO+1SDTbYXDk24k8xQRHgAkAdcDrgHt6147ouo6df2YstTi+xs+5vMjGS5PQf59a9o07ytD0DRbWS6giu7oH7NFO6rLMvLZVTye2cgDkYOMVy1aTjFRd7/ANa+itt0PLxFFUkrs1tIsIbdXch1HGMgggAdBn2Pf+Y4nlvCLj5YsKMhFK5yc4Hp1z261BBcXTeT9qjAU4I+Ytngcknr6e5+taF8kU9vcLKJFgZP9aAFIHc5/Hgf1xnGTtqzz3HVoyvEsdvPB9hNwkbzodpBOFPT8D0rz6dW063hsbuQyvCv7sIucc8/5/yV8WyWlporWtk0z3ke8sQPmGASQD+A6+vTpWX4R1uPU7dYjAyXKhl3OwKtyoymAoxzjGByAPpcISs30X9XOtL2dO5rWmqXtpeQRW8reXLkOGBK4APBA44HGf8A69bMV3ZtJOVmKNv+byriJMnA5YNznGPwxWTrcnk6/FYzREb4c7iOc4AGD6djjI4HXoLFl4VuLi3WaB9RWN/mXys7ce2SP0yPevRy2lTqVo+02afmefia9k7LU9D0/Mn2Z5cWrAHda5Vg3TBOBnIAYAA4wxyCcYrSai8PiVbK9i3wzoWilVcjjOQ34enp25qtBY3Eetz6zqUkSRKRFAGBwgyc/mcHPtxWRrnjebQdfaLU7SCOxCnyY4MNI/bPqvH6e1eelfRK7t/VvQ2hSc37p0WsFNN1aC+TT4pYrjbDPcBTuUngHPX6f5zBZavcyeJ5NJRbNIC24/Od0gI9PpyevQ+9cg/xs8PwTiJ7G6mj35IZVwB7DOM5Ofw+hrsrXxPo1xBFrVlaw/YHQiS5J/eIcE7doGTkH9eO5I4SikpQd2rL+vyNnQqQV5LREmv6To3imNJIJbae7s2aPzlw3lHGSDz7eo6+xqC38NW8Ghpp15LIIJkMW3uxI6+nYH+lX5RYaTos1xY7LZbl8qEXmQkdSv4/SuLjiv7Wy1i81bXS04BEDGP93D2zj3zwcenXggabTSlotr3v+C6f1qZRbehVj8O6n4c8MyWn2GS4xctHb/Zztl8o/wAXQgnuAQenI4xXO32oRTSyMba4sLQYiCTgj5/Tnr/+ruDXp3hiHUHt01G91eS+ljh/dgYVRwecAdeT7/yqLxXpKa1ok9yun+ZewjeiBOQQBnp7EHHb9atyUpu+t3uvPyf5mlLEckkpHK6PdW8nkJPHsdI8jKnJA6d+eP8ADiqkuo3GmSC5sz51vJlnQ5ChfyH9f6VY8LSXur5hbSZ3ui5hNxt2qpwR+PPeug0tLTQkvbDVJLeWR4sCJlIbGCCAPT8vTvmpcHTbUldrodbrQvpqWNF1TT9U8Px3NxcxJJja0fZTzz9cY/LoOans/EFkkLW1rLDcStlRGjgc54zn2z7fnXOWcNtdme1tooIhKnyedkCMnkfTJOfx61lTS6dYRtFLAi3cOVSaLdtLjGCeQSAcdxnB570KEb8upl7PmV0bsksEt3Fp+oxi3t45S6bhlS/PJ9D710GrWEd9ZQ6XdTz3Nqz+Z58AO8dwDjPGCOv49zWNM0V/bR3F3B5NsOc7d2Rjq3oMfT681e0fUbd7DzfD90FnLnmVCSeMEHnPr83TGOOtJydk1/wL+uthWb2K+jaVommQXOnaBdCWa43C5uSwEkR/hGOc8g9vzrV8S6XqJsLSW1kila1kDvGQcOAoyCAcjjI+p7iuG0KeXTvEt3eTWa3Gp3e+MGNtkbEc44zg/KMYBPoD0rqtS8TixijF7dNJGIleZIYuA2Gzgkn5T8uFOdvPJ4q5qTmrav77/wBbLYU4yi1Yn8MT3Sa7dTahEJMjaiMceTnnI/P17Vr6loceq3kAktEuooT5gduAe+Mfl6/liuPudYfV77TV0azuhYrL9ollC7SwAAwPT39RxgHkdCNUfV5prPS5riR4/nkZRgD/AGf/AKxpcjdntp93T5E1FKL5jSt9Ihs5SHgTCudkKH7gz1z6Ywfp6GrFrem6uWRkkj2j5VcY6e5+n8/Y1hzXN3Zq8/lPK8aEEsp/ePt7ZyQexyT6embXhyW4lNqb+BopGPzKMbQ3XnHHJOevX8SJS+0zKcW43ZuS6dcXPiCHUkvW8iKARi1wSH5zu698+h49+ltkgkCPKEBJLERtkD8c9P8AJ44rlmkbTvEzATXMpvdzRqqfu48A9T68dPb8KZoOov5kzXcbySv8zxIh5Jzjv/8AX45xVtNavy8jNU7rRnUm4sNDsDczQSXEZb5mUZYA98dcc/54q681rIsCxXIIcGSFZMcDOcf57c5rjIPEc99JA8FvJJG5KSq6YOOOqnkZ689OgxXWS6ejILqBQbpkyuQSQe3p9OKTk+1v669hyhyW5tyS2nlSMKrL5gBwNxAIx7jqP88VlaPHdXOrS3Oo6g+YjtitlBVCPQ/mfX6+thUvr77TBcW8SlQGWTBUZznoPcZx+fvWsbO5tnktJoXuROC24HheORj8T+Z61hy8t0v6+ZqmrbmhcIEtXjVREjg89zz27enXHT88CyLXc6Jpt9FJbQMv2hM5z82eRtO7IO3kjBweOtWJbprSWf7WhkZATiTrjBO4evfj3PTnFfQL6xuNSmGi29oomU+ZOM7i2T9epzx/jWaXLdtf1/Xb/gFcrtoNll1C11OSSVc2AChVHTO7r9OP1zWxBqVpd22zYpcrjA5wM8f1HI/CnaZexanJdaddpuuYkDF0GNy4OP8AP6Vj21kkEDCCErOXxMz9CB2/Qjnp2FaKKd9P6sRKelnoyndWJtdLv5dPdVDlm2IFPPrk8enXj171zGp+IlsElnUn7Yu2LDJwDn72euR6/wD6607rXYtHuYR9mu3juSoRooiQpB43Zx69Ooz27w+I9O/tCyYywM7OuVZM5A5IBI6dPz9a3S1XMtGY+2s/e1J9Dv8ATb0Wk06Ce6hAAdgdyk+hPXoOnPr2rol1OANGkrbJZP8AVMBwePvA+p/I9u2eH03UYbbTYLRbZQETy1ePk46YJHbr39a3tJvdNvbb7U8vmzxkABmIxxkDj8PyqZJJ+QNOTubHiOO4h0G9l81VlERYOqjd61813skd7dpMXkumyUlkZ8kN69f8+9fQfhvUrzVri+j1C5jnswTGsDxquQcjAPUY6euM+tctc/DPw3perz6lLdS2tiy7miJOFOOuc9P/AK9XT5aXMpb26fl0/wCHPRwWLVBpSPFrLRpZNCvdQL/6NExUyY6k9snvWMjXH2SFbbGXIYhuprvr/wAN6jBfx6MsgOgXzmaCaNTjHv37dP8A9damg+AZZNUNu8SLbRPgyyKegHY4x+P+1+FdnOo3lJ6PVen+d+h67x0OTfXY54WTeIp9JsbW0K3KjEskaEgr78f1/qa9I1v4c2K+OY/F11eX0zrNDLFYvGpRZVA2jzd4bywRnaF54HNdDpej2egW8X2YxxzEAefsyW7E4Prk9+Mk1d/tnT7iwupLq9Pl2658x4yNvHYHnPH+PauN4lqNqey+93Z5OKquvU5rFCLWDZ6raaS1tI8zpummfACjknpx3P8AL1pNb1R3VIbVvNJ4KjBbBIPUe3+T1rn7rVX1TXrSTSpFktWizI0i4kHsevc//XxzUZax02K4niWVn6sFGdzckj2ywP69ay5drr5efn29AlTV79Se1gKzszRq87KQvB4PXIzx1A/pjvkSadPHqr6heyK96wxsU/6vIx1z25P68jFaMWr21zpEN3GkpuJSQoYbWxgDoCdxznpjg+wNUUtPNlMsYz8hJxgBf8OnTPamrqTvoQ05KxOJ7mO6a4uYYn2oUGw5zwcEZ5459Peqtzuubu4uFO0yyM7JJpyXBQk/d37+QOAOBxjiugjsHjsEnkC5KhQNuMnnqT25P8+c8FtHFIjPcRq7E5BS18zj6/nx/wDrr0cs5XXs9te6/I8yvTjJXNO00rU9ZnurWWZVgSVfKjlUYc9QcdRznGOo5rx3xhBrtx48uQZI3ZnZA27hUB5A57env9a9es/GotLTU59eghtbaGby7OPdte4HA/n+lcL8XILyKez1i2jCw30at13bGxyM+u0Y7+1c9GbVRwaWqaW1r6PT9T08HzQkpS0R5Y2nmbWJYIyzSkcr1x+P9f8AJ734W6hceG/F1pod6izQ3zKzwvkBOvPv9en584Gm3VlZQJqNzcGK/lfChBub+v5/T60/TLu9vfFKXKSQ+dETtfHUDp26+3/6q6Jy9opRkvdt+PdadD26tJzjaO7/ACfzPo/Xr7w3danBpepalDBeWreZHbswXf8ALwCO/wBPofSsf4hW1nN4XuQzYhupI1EgxyFOduQeeAfb8yap+H5PD/xG0SWfVdKt2vYl8iWRMb0bnnOM9s1Q+zw+GtHbS9Nhu52jlLIJyGbOc8Z/Dp0z2JBrggmkk2+aLWjtp10f+a+Z83KlaVvX+v8AhiXR2v2uhaXUDW1vGoVHVtvyg9PbGP8AOK6WA61Zabff2O0N1cZDQyTN8pAPccc9se/auV1/xZe2Vnoen2tv5/nuElJQl1GcY46cnH0I712SahcadYRpJIgEaHzZSDnjHPHfBPX3oaulJx0f6afj2FWjK5c8KX+sXOm7PEsNvBeeY+VgXCjHUHBPP0znHrmk1rTLOynXUzbB7t8IAyjC56EnoOvUVgReLLcLYSaYF1O1llKSyQuAYO+SAOoHODj9Km8WeJ5tG1azhm0+W5srkhY25ALH+EH2H69xilyNytGNr3dtvVd16MyUJRlr/X9eRzXimSx1GC70uxmca0nlm42jAGMnGRwev+cDGW2nWltpU1q6Ttcyou2bacB/4snHBHYZ5G49Aa6p9PmGuXoMLWyPjzNgGTwMnPQnjPbvnPQUbhbS21mGBmaSBAQWl4VSBjB6jHuMH+jT920fX8P60O2Mnaxh6Dqlw90mlSxebBgRmQ/LsYkLnJz+f9c56EWVtpKAs4KkcqpwCQB09Rxk9eD+ePfadJI0U+kpJKiTbpUBXJUnkjv/AJPvVMx6dd3G64W4klQHbKzjaRjjIwPXH17UnZvR2XWxvGPNqdNZPNLJKsajbJ3zhlPYHj0P8uBnmxFdWU0TJDArtISr+YvKrySf0P8A3yfQ1s2Z0620iEPLHBbIuJJphgM3QDkf45wfanXPhxZLNStyi27sSSgB3KQeefoOhPGD9EuV7nPKrZjbrRpHtYE0LVfIg/5bgEsQATnA4x3H4e2K1NQuzoWn3WoQRoAqtsKjG8gNkkCsO10yXT9TuLgXk0lm6eVHF12cAZBGPQevX6VNd6jdac7W9rpUd5aCBT5k0gKk56YxwBwfy5FOy0T1X3eur6rb/hjB3k7Iz7hLjVV0jUrvUYFikRn29Mg5IIyfQZ/OtGxZLaItBKLtWBKSBgcEH29M8jnsDnipL2307VEbUrtIpGsrcE2kDhwvB4Ax3weayNN1Wy1W1gktM2dzFz9mR+vA57HPI9Oc44ANLmbjeK2/Dy/4JprLRnY79R1DRrmC02Wt9GQqs+OTxjkcgZ9c+n0rW2hXHmjUJNU8q9EJjnjgP7o9c/LjHOc84IxwcdcDww9yl5e28mqTTvK+7aR/qx7c+4H4V11hEy2+yKMk4IZjyT15yTyP1qmuW6jb7vTv0OWTcNGYmiQpeauJtLvYJYTuE+DlsnPOeD6du/oM10FrDNbXhSJjIQjMVBwQOOSvtjGRjg9D1FW6sZrPSLo+H4rax1GeTAlkXA3E4BOOucD35/Cm6I4aaO+ucvqrR7J5AVA3YBICjPPbH45Pdvl7/wCffp+Apz5tS62qo0kcAgvQwj3mR4iIwd2Ahbu55OACAB8xGVzI+pW5ZAhRi2TjzCp2gc8enqeP6VFqlzai7ikl3su/YQQuCTjgn8Kz7zTEWdXgcw7U/wBSjkIW287h0+8dxbOTtxzmocdOzIjLuWpLyDUZpbaCWKaeNisiKMbeGPI/D/OKydK8P2lnbTuzpHKztKWTHTngY6/TqPyqtY6Fb+VLvLW0THfJKG2vKcckk85x68j8AK07K20O3cwXdwsXmNhFunClyCSee/b9Pek4pP3X+BsqnKrIr6PcTXNrPqWgstwVcxvvwG4z34Pp/j3rOn16UuIdWsniI/eExA5Hyn+725HbGO3aunh02zgnX7KfIjH8MfAJx9f8/oK9/pcMKXFxcSgITmSc8kL68fXOR68dhSSS1/4D/wAvwLVWDbuctpd3eTa5PYgxzWlwA0Lk8YAIwcjr0Hpn8Kt+K7+C10S/ga5tfNeJoX2zDcq7SSVUDlslBjg7TnPABa2i2OosbjRL9JY5FG/kAnI6HOCpwOh6foIb34faVH++84ee5ARXywLdcdfqeTzx602l1dreW4n7Jz5mef8AhTU5YbVVsgERCyOZgMsxPOB+BHHp2rTvLWcsZ9Ma3Wd8/MGw5bjBH4H9RjqcddJ4Rht7FILa0jtxFgAfKoYD27jsMgHnnHbm/EFndWN7BeaVYieIsRK6HCQp1yfcDt7YPUCnKanJ8vW/9O50U5JtcuhiWGra8glMFr5jQMAcgguM5y36dfz6VdPi46ismnXenrcR7RvjZcnI56HOcHn/AAxmqlhq91d61L9hinaKZ9kZUHbx2x3GcnPoK6lvBk1/qcWqLePYMigSRKAc/KBjIOPbj8zmqlaOsly9VvuaylTWkzPj8SazdrI9lp9ube0TbHCDkg9lODxxnqOtQ+H7rxDqMNwNZnjRZ2ACIATGBnIU9Tgg8fX1IrU0zwxqdxr91c5k0u3jDKhVgQ+47iSMA9QO5/kQng3T5ZbzULS5tpUiilx9ql/5bY9Bjpkfn2qbQjF2S6eq/r5sl1Y20ZSQXMFrdXTIz2cK7w/J3cDGPbIxn2656ammaVHe6DHcywNHcuTI0Uq9Rkn5vQEHoe3YYxUd54lurO6e2jhSUPlYoQC+0c8nqT29evfpT/tNzH80xMtzIhQtkcZwe57AY9vftM78uit/X9foQnJtXZy1u9zZ6hf3r2cS+YfLhWH7uPlxwD9Rj8O+Dj/23NYxA6rFMXm4CRpuJU9ckcYPv+HHFeleGINP0pXQqJDLIR+9cZb5iOOemDnnnnBGcity6ht7oq8lvGrBuHCqx2g9OnQ4+uO4NHPTvrqvW233jnipQduU8i1C+1kQb/sqx2rDKxbcMQRjCjj27ev43rLQry8sPPMghjZcsrDJHP45OQPp1rovEenXAKyQSsyZ5Gc5Gfbt7f8A66yLPVv7JaRdUcwQ3KAbJBhkyPw5Hoe4/AkZaXikaSqOcfdOv0uCxGmCMOsyoPvcYHXI5/zx3xVyxhto42/0d3ZmyxHPOAO30FZPhnVIL9biy0+0maGPH7/HBJ49v5810Ed1phXa1/FvQlW/eL1HXqK3w1SVGte9n52/VO33HkVoSd0fM+o642pxC5vo31GWZTglcCNjk4+mWP15/Ds/hdPba3Z3vhrVds/mL5kDdPJbHOTnn7oH0xXAz+Hta0gSNqMYtrNMgSKenPqP6e31p/hy6WC9hXQLO4ursnaJscLyOTjtyOvrXfXw3PCUab9Gtl+SR9JzUvZqS/4P/BLF3ZHwh4tvLPW7SO4diQpYhhzyCD0/z61u/D3QNLvNdklvNTaIglkjQEdBn26Z9fUCvS9Q8JXXivS7ODxOVSaIZDQqA+eeCcc/5/HI0f4RxW+rQ3lxrTeREwAiEPzP1BGfTseuaxlWhVg+aXLJqztdp+mnX+mYxxyhBQetv6/AX4X6TdafpPihtEAjmafbHJKMgDpuGOp69u4pNVuJoPFFpZPFc3t00ZlluFUbduOnHb8+/wBa9Lj+yWMRt7d0W3X5WJGAfr6/j61PbwCXzS5O2QFQuB/P6n+XXtyzq80pVJLV/fslv172PO9vb0PPLk31x4ysLeC1SFQqzAswIUZ7c89T1757Vu39zcXESJPBE6JIoLxpkMT6Ak8Z/njOel6HSrrSpdUu4lWdSu+He+47scD+X8x1xVPwtrd5qlrfPqgt7KRW/dkYw2OM98ewGaiVkvdSskvX/Mbm52kYNsNJsr660vS4PLmjAa6VflTORxnkZ47cZwcV6DBiK1t1v3SQ8eUFUHDYAGCOo6cjHWuDs7G3lgn037YpunlL3BQZkbkY49BjpjtXUadpdrGLcpPJ8n3mckgc84+hPXj044oqWbs3/Vt7+fQmpayOYgv/ABHot7dPe2x1G6eYuojbPlxHHp7H07j8d7V7fT7fTZ3msirFiT0y5yQpG0nIOcj0B5wcio9YtrPUtZuZ9H1YRXrRrDdPbtu3Lz0PAI+nofes1tN1HRdQ0y3tMT2iFi5kPJ5OS3HXv7e+M02r6rR/Nf15FpxkkXtL0S0jjjaFWsYrwZlBJyVBHqcDg/yPvVq+0Wyd/J0qaJXZstK2TjPUZ9+npVaPxHFc67JptwrPcM+2GIKdp6cA+uBntxj61LeytprvcR2YVAxIXbuIHXjkerf4cAVMm9Obd7BHnTKV3DeJFJFcva3VpFgOjghW4OBk9+OvPQYzxVzwzeabNoEltB50ao25lYlhHnB2qfTJ/A5B6GsmfT7/AFydbgzrBphyHZG+bn37dfbr3xUGin/hGjeQajCzxykuvGMkccH/APVzmmnZNJ/Jf1Y1nGM46bnbXbpJGFjl3ys3ysTjB7n/APV1zWAdQivbJYZLiOTYxilkVCvPOf0z/wDW4qUX9lcae13ZQqTAD8kjYIAzzkfTqT6++cnw6LN45rW0jSRpJGmkVwc5xng9eoAxyOT3JqFJW1IhSaTfYr3WnnSNX/srws1xbWLRidpG+cM/cE88dB9QK0m0O3Orw6lYxML5TiWNV2o5PXnPvjr3qfXNVvJJBZQxmGErsMgDZYY5OMZ7nHpgc88YekpcWP2lLW8muPMGTI4AP0B/EdPr6Gnzt+9fW33+rNVGTjrodHpmmNNr11epHFlWH3RnHHvyPT/61djpsplt2aQCOZT83GM89RjjHoPfNcr8Oku2jv5bkNsnnIj3EjIJzkDn+Z4rrxbeVA0hZS0gwDwRtGOjHmtHe/oedW3cWytqRGoWktnAQjSKVeRuABjbjpgg+vNWvD9vDZ2siQIwkD4lkYYMhxnPv16+xqlcJHCW80klAWbnHXH17Z57fQ8SWlxJIXaFXJPzZ9BjkjPHYdPf3xPNpuZSWlkaF4IJIWif5UHIAbBH+fTvxjtXH63LdStZ22mWhZnk/eySHChcgHjqfTj+eK3muJwM3MStuUFWVjgk55BPzeuCe+MdOKiOHk3g5QDox7fzxz/L2o5re8TTTFusJE6qu1GALZ5B78/jjt+FYuoWGk332Nry3jDR48ny8qBjIxgdAOnTj2xV3WW1NbXbo8cUt3IQQ0jfKqk9Rnrx9OtQ3vhVtaRGuLxrW5j2lmg4yeSe3Trxx07cYUbqzbsbJJO5pQyN5f7oxyQ8ghl6nHfJ9+ffPuadb67b3Vu73ctv5Qk2/K4xkkAcgcn1xVhbCK1jaGEkxkDeTyzdsevr/KuNm0Hw5da/DYxsxuEh+3/ZQWC7C5RXwQFZSysO+MDIGRRFKT1f62EnGzudUo0jTrWOC28myhcjYchc9s/p9Kp6vp1nfi1S7ZWgt5VmVk7sOVPXnp6elZXiXSrLWJonvbeQQWBMm8McEDuQOSTg8frwK0fC2q22p6DDPb+YYwPLaSSPZ5wHBYDPQkdBwCPaldpKave+v/DhZLYbq+h22oag+rJNI8+wRxjf8ucHoM885I9ycVz/AIY07WrbTtRTU1iRFlZbYrtYlSMHr0HTngcdq6+zs5pJLiQFFhkIZeMEcHIPGcdeD71BLY3NmszmcyKVYAM24dT7cHA9+/XGSOTScW/6RpCpZKJy86z2+nw/ZIoPNVyFUEfMwPPTqenPr+FQWfjMkCO7t189j96PJyc8c57c4PvnnNYtn4e1zVtea/W4jmtUkxEnuCQTjt9cDk49zR8T6HqXhy5fVrsIlskoYEZbLkngjGM/y49qtQ5nyp7/AH37HXalblm9T0fwzrMuo6e7avtW5SYhFKgEr2zgdMgenT3FampX+nwy2VrLKkcl4cQKVzj5c5z9O/4Z7VxFlrzDUoYdaSGD7WA8AKFnf+6CPcHv6DrimaZ/a3iLWbo3XlhoF22b42oCOAe/OQx7DjHXmo5G7u1l+Hy077mEoRvduw7Udc0zRPEh0v7E1yUI+eNc8sBjHPTp09KvR20OupL5UxgNuSCoBGCemfXHp07+ldLHotrZ2No195ct9DGu9wcZPY89s45781YhsraCKTYoiWU73wOSe317fn+FRO3z2v8A15DVaNrwOXsfCWmG2sLvUXdZYB8q7zg/e7n09/xzmpNUtJtTs5bTTZz5kxy02SCg/HPYfoOnZfFN1ssMIouEfaI0jYDOefy44P8A9erOk6nBomlw/wBoN5dzcAlVjIZkzjpgDjkemD69ad3L33r2X9fiEuZe8tzP0jR77w5YmGW7W/u0OCwGRGTg4/MDj6VneJbU+IHS3mtSr/8APVwVQjBH0z3/AC6V0vhoWcFg4s5Gfz5GkkJb5vTGR6YPr7VP4jdHsvOKBvKBIQHB3Y7+lFRtTu9++xMKj5jzGwub+EPpnh8RpDCHLGFADzkt24JP55461HPp8lvIUfUfszd0LoT6ZySPT6Uug3Z0Z5ZpoRGzuxfbkjBOMfLz6fj9TkuLpL66muGSKRnbJLW+7BwMjk8fT8e9evlDjDF7O1nqkm2/m0vxNcZGcoe6egebo/ivw/JBMqR21wSgQlc9Cdwzx2/X64raDpfhTwxdLYafNYi6BEm0OCVI+v4/99fQ1naD4d1EQPZ67MrTyNuZoFIEYxlV9znPHc9+ObVx4X0g3SNcw/voXJWaRiW6EYHTGfm6Y5z6nPmtKKcOZ8vls/PXf7jO8b6M6xr2JrEvDexxldpJZlAI7jHTp1xWcl1byXTCS6R7Y5Y8orNyMZGN+4HOSeD75GOcvx4e0mO2i1OK83uq5MUZxyxAJI5HfI5wO/rrf2ELe6T+zixt5ovmmmOdvGO2O3Ht+BFTflV+nTT9Rxoxb95kI8VWgbyLbTWSJHwWyFJ6+nbn9e1Z934mu5bw2zwFLHII8ssCueRzwOCCP8ina1afYle7mKz7TsVYlzu7kH8R7dvasOyvf7U1mKyitrmEmLc5EZcIuDxgcsQAOMdxwaFG6cktDq9nTUbnQyXZtYkEs0rw4CqVYYzn0J/IfWn32nwX0MYtdSQbgOVbLMM+noScZwOvY4FZ+oFI7WWTzPOFsD5e/KZXOSMH1564/Pg5dhrcc2soZtLO9QN8oPytt46jjgZpJStzLp/XUSpqS0Op03T9NnvrbV8oL+ziYEhuoxgE/QD0/DtWudfitdLabVibOCQ7ImKnqeB26duORnp1J4e5vbG21Z7yxuJHuHABk27ljGPrzgAfl+fSjVLiy8PF7hX1SF5lEZK7eCfl7cDgfj+VVZya6rT1t5aWMKlLkWpee1h0uaaW2tlEr7XadCczEnkkkZPGBz1qzZ3ZvbtTNAAmMMyuQB7j8D/4778pfGDTY11DX7k/ZAVSOEKMITkDOO2PUcZ5wTgX9ftrfUNLKW6EvIFO8NxxwMjPbn8zU2TScnv1+453K2yMS5ibSWub268mGEtiNpFy+CDwp4xzg/Qe/GP4S0SeGZNYt9ZvbqJ0ZzazDIYnuQc9Mdh+Nb99Dp2rm2gumeaGy+QkMQPMGBx69KuLpMipOIb14JdhEYPIUFQB9e5655A+rb0a2b306fn5mkKqSscTFrF8l9JbypPcW0zszRIfuDsQVIAHfqMZ6nrW/qemX2r6hpDWUsJsmDBpcDrjGOnoD+ArRtvDqvpDWLysjXBJuJlYFn5+7zng+vTp24rooraOyjisraFYbaFQsZAIPAA5P4fpVrlutO//AA/9fMmpiLP3NzhNT8I6jpOl3cz+VeiYnESqF2H8B244x/D+df4eeGoZ7iS51aIRXAO6JAB+7yCOfQ8MOK9ASK8Yt5a/MyFVYjgHP6dR/P2qDQdFvbHTnGoGJ70szuyAgMdvHpg9P8mp5nytN2b/AK+4PrUnGzZgalp1rbxyxtOGvAfvMRuTPzDj/J69OtYenW811dT3Vyl1Fa2gAUFDsnx6DGDzjn+ldLrHgzTtV1201O5muoZYwBJFyA3blf4SfqP61V8ZS6ra2qpokKz3M5EcSueIgT9456n/ABPShWdmnq++lvn/AFoJYjTlRb8OatpziXTYmxcoolZCCNpIPX3IGcfiO1Xr/V30+K2j0+1a+VnVSwIGFP8AEO34e4wK5S81Ox8PC1/tm0l1DVbtDHLdWqAhOvB/P69/St/TriUQRGPKxMCFweTnPBzz0z/nrT0962n4P9fyMOZNm/fKpZ9+WRlwEUDOTyMe/H+eoz7iyN1p1zZhHhiuAAWU8gdD69ufTA9axbqwup9Qs57KQiS3kDM7/MrA4469Tzn3NdTYEPCxbHUlju4BP6dvXjj1NJ6P+v6/MG0ldMWGFLHSRalpGihUgk4Zm4+n17dvbNc5rtgmr2ktja6hHZ3NzgRhyOQSPxPccevriti01SK61SexSdGlRcNFnJAOMn27flWbbeGbH7U95fzTXt1lvLaTogz0APbJOPbpxUxk4vne++w1ZXTNnTLJNM060tT87JEFaQkfMQOTnPPQj8frSyNsVkLrvwDv4yPU/wCf/wBedp+vNd3t7bXFrNaeWfkl5KyLnHH/AOs9qmkjtfK8xgrH7yEngDjJ/EZ9O3pUtWer1E076oksx58jSbmIGAQR3x06/wCeO9LdXawH9zjzBn2+UkD8B/h+dG1mNrdZCF0J5XcMHkk/Xr/OmC5t5Jre6eQxefjyxKhjbnnBU8g/7JAPHbmlcfJqWZLndKkE0HmRzDkEYB9+nSsHxTfvoyWgsbB5UlxHFbwrgK3XPQ4+70x2PvW1cCaCR5WjBRByvA44Pf8AD/8AXRG9t9tS6n8ppeURnQblVsZCsfug4XPPOPpgVk02tCldbGcGuXtlkf8AcXLplIQScKCATgjtuGeB94d8VbtIZBAI7yTMrncuSSccenPU9v8A61ac+Tau0rKrNhW2jgnkdM/h/OomS3eDMnykLnoflHf9fbP5cl0o+RLbZR07T7fSYpks4VQSt5rk4xng9B35/Ie4zja+i3emyWl3GZVjO4iUA7sHGPrgY7da0rDxDY6mLmK0iuXa1baHlTaC/Oce+M8dfz4y7pryaCQmICNFIUZweAMD3Ht+AJ7apNO8t13MZRkjldT1SH7VbrdwRPPDHgCTBVemD0z0B9uox0FOuPEcVppr3UH7+7GNsSuMFuODgfL656deua5XXGEt6zYeGUtyG/hBPOfrjP8AjXLz6hNbzANE/wBmTBd9+SBx2H+eK2VJSsrf12/4YFOUXc9tg8Qz2uhWd3qcMtxdzMAbeAE/gc88e/ueeK3tB1m21TbBePBbX8mdtrvy4HuOv6dQa8d8MeKkjkt1ikIiBzvchccc49egHv0yTXpng9dNs9Tu70Wg+13GMzO4bpnnI45BHGemenIrknCKvzXT8vyt0+5s7FUstvmTzaZezapJIYJUhB+WQHgAgdPf/PNX5Le3vUZ3fmMtFtBCtzghg2eDg5HI4YHvitXU75DYOwlU5YKSGyRn/I/r0NcnFqcRvlia7RZol3pBnOcZJPBxnqcdevNC126FOUpq7JdJuIG1m/061t5EEGC07cAsfTjHHPHuOgABx9X1e1nvo9IR545kwGZeVVfTg/5H5HprW8wJnnLCMc5jXJJxjAxknjHT071Vv7vQ7JoZ723jjmmwI3PJ7AHI7e9J2vd3/wCCEZ2eiOO8Q6ZcRtI1tFLcSKBgBcljjggdT/M/SsXVb9dDa1srrT7aGRIEOzYGwOR/eGOnT+mK9MK74i0OJYyxZcrndjOQB6YyORzkdeh5HVfAsjahPJPf3U0sjb2aOF3GTz1HH4V6mTpyxKjHez6N/gmRXxX7vU78XMrkpc3AUKrZKABsZ574HTg57dgTWD4hv7a7uEisFkZo1aTKtt3nlcEA/MMHoeAQD1ApNM8Ealb6OrJq3/E0YbGcngLnt+h/Dn3z77wRrttPBGLiDa7A+cg57cfQc/qOBwfP5NbKSuVSdFO7ZnaXrOtX5a1v4oIISqtGzMBlc8fNnJ49eDgVZuGtry8Ml3LdR3cQEf7tV24ClBhj8wG3OExjOecZrd1P4eQ29h/aZ1Oa6vrXEjRyy7Ub7pJJHtg9Op78VR8NT+HdQ0HVdQ8R2cNytvIV8tYt6ngYAyOTnHT0+mXyp+9BaXWiXV+v/AOl4iDTaK1zqlvYXttAuURcuUBY4fDDDEdRgng5GcdwMXbK8udTvfsa/Z4UdsSBWxIQORn0565yDznvmn4/8OTxWem3PhbSJFtZlRl8tAdgIGFI6AYFaHgyI+HtRmS801vt08RZbjnaRgEr0J9fc49+V7LRSWr/AMvn/mVVrU5U9NyK31Ky8qa0OnSrcLJ5JS6R0EzNjcRu9GIGe5xiuWvdF15NVmsrLTp1jUlyh4RQenPc8889vz9rhtYb63tp721XcGWRBtGUbqD09f1+lRTzyDVHEDbY1TO48cdlHUY6/T2GKd+VPlX366nJSxbi9EeefCvQrS60+4uL5QZY5jH6AHqecZ7fp712Pid0l8Oz2topgg3LDKyR7ii8c9P/AK/FZng668R/2heWl7aILJZSUlhXajDngdMZwMk/41DqniTUtN8Qw6T/AGI5+0A+XMso+f1bGCO5/lWk4S9o7K/XdbfO2xk6jqTu2Rafot7NBN4a1yO5vLYMk8N4uwh0H8DAjA/iXpnGSCCARr3GmQ6Y63aXrBYkCtGZm2D0y2eAB+Hv66kr3EttCvnT2uHUbwyk4BDFe4IP3TgZweCDgjnp9Wj1HxlDpjqRDFHvkztYSY9QR0OeCSByPXIL8+my6/dr9/lsyHOT1L0PhW5S1ZUcHfci52RzSRHI5w21hnjgqcqeM8kEatwrw2dp5siGRQu9tyqSMEZ7DsDjjvjmtC5u0tbea5dj5UQJOc/KAOgz9K5/w7qUfiW0nuYfOjtUkZVklXG7jkjt2+vTNS25Lna26+v/AAxlHXW5ctry1XUorFpYYZpFLxopPzFRhjj0znA9q2Ef94wyuV4fBzj2/kf/ANWaz7e1jtZY7hkR7pFKK5HIHY57dfXPXPepHvRC0m6Msx6AY59Pp6c+v5K/YUveZeOXIJwTgnt26Hn65P8AjUxdlGVG7a205Y4H9AOnTpWdb3UdzuCARMCFBP8AFn09ODx9auBiXyFJyc8NnPA/znn1HXFSmtxNNOxXv2SCFnZcDKqodjhc8Ang45IHuSPpXParo5GuQat588TrCUWHd8oyAeQPcj/62MV0c0twZfJjBUjA3t245xjjPP0JIpbizeW3aF2xwPnjUZVwchgGBBIODyCpxyCCRSTa1vb+v6/plLQ871DUbSyjuPtDvFbrMYUITO7GCTj+EAlhzjoOgIq/ocmnamQ9teM0cSkBHLDjscHr37dgCehHX/YIfs8VtLFHPGuSxdF78lmwAMknJwOpNUo9MtzkfZoorYqR5KquBnk8ev5jjrVNrdLX5f5Di1azEjniupVgguYGUKHZVOQRznPHA6c859u96VQRGqAeWPvYPXtzzz27/rVKx07RtKupRa2226bcw5+ZufmC5PUdce3tVqW4VVilONp5A2jB7c/menuKV0tIjabY5ba0imM8UEKtnDSKu0kD8vyP8qWF4xtVQSCcAbWbp13ce3fucc5GcW78RLYaharf2rfYbnconC58tuwI6/5FVrDxbp1/bT3FjG5eJzGFdRubBzwR9KUk7Xa0K5HuVt2pWkGuvqWVgiGbd8ZyM9fr7ew9eIvD5ZFSG7uPODRrNG5PYkjGe/655rea9e7hB2D5l3NGCDz9O46fn17UwATyMZVaOUKArY6cn5Tntx/jTUlZ6bmrlfcw9ZsJINSGpSakIbaKMR4I43ZB7cZwAOfUjgVmR+DX128ZtYvJZ7NNkkLq+3dkD8vw9sc9Owu9FtL+1xqEZniRg4XHTH88k/TJ9KZrGr6foFtFd3nmx2rfIqKf4xnjGep9M46dOcvnatyb9P8AgDVR25UR679ot7TZpzLMoUIQX5+uexOSR39Kz7OK11vS2gvxIs0TK7gPyCOePXjv9aZ4Z0t78yapqE80ZucvHDJhWQDPvxnJ6evajS/C8VjrM10l/LMCwJT0Oc8/5/8ArQo8r5U9V+f9fiU3BJ3LF7qsGmxw2sEfmAnyUUE9gRyeoHajXNVt9IZpJ7SdrSON5ri4A3bECsx+XnPCnjp9OlabvaC9G+AmbdgRlN+D6AdSeOP/AK1cX461pddspPC+hst7fagDFIYbhXCAtzGCMqW2hg7E4RCRySTVwSbSaduvzMnJJX6nXaNeWGt+H4rzQASodlUSLtw4+9kd+GX8/auZvtP1S906S01S8jilLbonh68ZJPT/AHvw/Ta8L2cfhbw5Z6NbsLmO3yXnUjbIzsSSueo3MqrnrtBx8wrSuD5iCUxO0jAH5nAIGR36Y/p+FTzcl7feCl0PNrixLQhITHPjcpuGzjhiCD+IOeh6jnpXHXHhWWGW8uS32jzW/wBUfmwMdl45yRx7/l6naXdtrq3dtZTOxhZN9xGmwNx2PcAce46djXL63FrNvLaw2Udrdo4/eEkHABGc9fXHpx+NaKpJNrb8NNxxoc6scKNCEtnD5kDpC2ExEwYk7RkAk887u/THqK7fw3FIq29taKGt1UOpzznnj+Y59PYkZmiTXUfii6tNTvDcBoyRFIA0Z4GDjBHJ6fWuh1PTtZeztLnQ7xbVBJskUryRyAcY6Y9MduOOJqyeib39bamtOg4vlOhTdOjrKIyyFSEWXJXBPXHuPTnvxxT49Jt47mTULiGMaksJjWT5twXg7RtUkHGRwCcEYzXLaH4cntp5LtluG1BHbed7bX9x0z+OODyPTYv/ABLBZRtcalYfuox13nHI7Z7dcnrx3zWdpKTUXf8Ar16jnD7MTcQxmySOGOKKXafMbGNxBPOeCTgAEnBIUZyMYwZo7HxAwhaSOZFJVmTKYbjI4HPpj61Z07X9MvNOS8kie2inBjWJvvPnPI/PHH06k1kaxp2kvoiadYX32LdIH3quGJyc5Ax2P4YFNaS1unf+v6RCg0rWDWbCe51Gw04TpaWYAKyB9zdQQCvcHrkH2715n8VtRmt/F0scE7iERqEMqIxYAkZBZl4yCOBjj617P9o025vFtbWRLq9swruAMbxtK85Gf4geMHIHPZvLPinf3Nr4gtzb2J/e2wkcfZmkwfMdeuRjhRxXpZTTnXxEY00r2fxWt3vZp/kYYqp7Km3Ndv60sez6Dr9trAn+yxXq/ZpNkm9Npzz93369fatCczraWyrO1zcxhcySAAsQBlsDAGTk8DHXjg48+8FfELUNZ1S202W0SUq+xpYR19C3ocDp0PtXp+1whVlKgnIkVsEZOMjOBuB6e+Pw8+acKlmrfO/+QVKbp79SaByU8q6i+aRcvGUKkgk9c468/Xn1qO3060igEVvbwi05DQKo2k5GM8ZyNpHX684xT0iyj02CSxSfzh8kpwmxfu4+4CSM7Mk55Pbrm/Z3sE6sqPl04OTye36+/X3xmjRbGMbvcv7m2FFkwCewx/X6H8KzP7KY6os9yY5FCbPn5PfjJ7cn6/zuPImOHTcRzzjr/k/5zhY1aQqjKCCASOTn69Scgf55pKNl6jlNkgJdiVBHI2leTzgYGDn0/L0rz4+L9LvvGt54ft5blb0D94JTG0ZOCSNysGRuOcqcH9e9PMjHYpUD5cdD6k/njHP+DJTE6LHM4YsMAySFnAJ5AYnI57A446dq1ja92r/1/XQhO3UZZSKtipiLKh4JPY8E81DfwW8l/BdvZia9hVkjmPVFPYZ+vp69OTT98FvatJO8cUEWcu7cYzzkn6fr7VR1/Vbmx0+C6sIorm34EkoGSF5yQPToRzzk9Mcxa8rLf+uoRb3OZ8V6rNZXltZxzBrqZgRCMnOQcknHQjI5x+tT+Fm1GKa4jvYAmxcCYk9B2PT5epAPHB5552LaebV74Xv2KCHTxF5kM5Pzn1z6c5Gfb3rO1fXLfTniuLlntoZTgZLbyx7kHtgZ9qtRvaCWr/q3/AOj2nu2Ogjdb1JTPEGgY7SrEEMCBnI79xx61aaNVtkSFEiWP7ihBx747c5rLj1L90gtYxLuO5iff/8AV/nFX43eeNCwCHA5U88Dv0x3HHWs7XaMXdblhHEbBZhuGd2xTgEZz+eOPrn8Me+vtPsDEurX/lAuXjeTeoXCMST8u0HHYkdOvQG7LKZF8sNudvmwD2z9en9KoXum6drDxyXixSSRkqjRyyK69sZjdeQRwTkj9KuPutN7Gbba93cs7be9VbzT50ntWdlDJIGVyMA4YcHkj05GD0rZMiJln27Fz8pkHJAz+PUccd6yY4diiBHZtoEmWkJOPUkk44HH445JNaqM5T7rDdxwxGAf6Z/qalW/r+v+HK5m9xTcx7lGDvXOPmGc/qPx9/zUTLOhwFR8gKx+bJ6de/TkA571GiIMMhGSBjzF5BPPQ/h+ZpSojAUKgHXO72HB7/56mhbWY+t0LM3mschgAcgEcH69u49+DTY3eQ5JLFhgkZJBPTPp/n8YpZyIy4TIUfvCCPl+vpz7dfbpkeJLFtct7Y2t9cW8kTF4vKBAc84J9c9fSi13YqFr6nO+KtXsrC8af7U0d1pu2SUOuNwBDJgnsG3jIyQNo54AtaD4l07W7aS606ZnjjO7yJUCuBzgAhju+9jt+FZ+p6Fqd5HBDqup+ffJJ5ikEx/J1+8vzA9cY+ntU/i7RtV1m3X7BcQLNbESx7TgtxjB5wTjvz2x600ls3r36Lby2f4d+/RaFjqI7m3uoRGzQyMoDeUrDj09uv8AIe1UG0u3lhZcBYzztXIGc9xkk4556cVjeFoNStNXujqMMUcMcIUOAdzuQN2T7HHqe55ropFSP72NqksCwOM8NnnuCMjuMcd8ZuKTXciTs7LYyPEMLWugzNp0TTTswDI/3TyOD0BBGQeR+QwbtnHOiB5gpbyl3cgZOAD0J/Dn060arp0Or2M1jfF0t3I4jO1ieSQR24z9fasfxLptlqWlJppuZrdQ4Ikhbng4P8x0z146DLSTsnpr2Gp3Rr2l1cQy5cjMhBCFR9DwSe3+ecDQ1SztLqHbJGjhMBSy52fgOnXOKx4vJt5LeC2u2uvJON8zc4/L/Z5+n56N0zW9g0zzGLHAeRto552gjJzjPTceR1zStd3W5LlYV4bjzWQyqsXOcL8w5OCPU/TqTniq0aT2txMsUaBd3XOC3b064/T9Lkd0oEU0jgf3n2twcjP3gDn2Iz/SjHdtc30m+PEccmEGfmz3UjsRjntz9DS8ik2/QmUh4preco0siMHwANu4YJ56cduKx9B8KaRYrefZUiFzMrLK8qKGZTklcEYVDjBUD5sksWHyjRKrbTiQYjaTlmJxnt17jp36fWsHQ9HjtdautSu7wzXcxbG5sBF4zjPpn/PFVG6Tsymk0a4trq1kkml1GSXe5YAt6546++COM9+tNaaRleOTc4IKOpJ3Mc5GT+Y6cnPIyaisbSC6vYeXGDvILH5ucenTGfy9625Y7eDDvmKIYyRnO0c9Ppkf54GtNSHLWyMnSbKWyt1SSG1S2Ehby4kC9enPrjr7jtXDeKtYkh1421i13FEQqMLdB8mep5BAbGCNw4wOCOD1yWdtPqGnapqRYT2sQV1iciIMRhiCeoJyRn2znitpUTULpWeIrhtoHTLHt2PQZ78/Q1UUlLmav+Gv43NIVuTU5+z0+FIorlYJ7iRY9rTzYeRiBycgAA5AJx1PYd8i7bT9d1SKyKXdv9lYs0eSFkPqT0+ma9DW6+z+VBJ99uAoOTn3GPUf/rqrBJpl3qMlughkvYsb9n6AHHPb696xT5X7vRfd/wAA3p1tLyRg6fqvnXM1t9lZYkGDIwIBP04Pfv8AlxU16kSQFbgRm3gLSvI4GFIPUe+DgZ/DIq/qWnXcCg2uxFMik7uBjPIGO5HHH54rG8Yy2kektFqF35VtcfKXQFicdh27Ec46Gi6k0l19WN2lLQyr60m1G0s7u2iaOAAtCGOCVwM4GDk4z+me9ee+dc6p4muPIs5xGreTvILFiO/fK9TxXZ2FmdTsNKbTdRMcdoxSN5E5cZ7++O/9a0NNbXLbU47UXdj/AGQwDrLGAGOR147nP0wR16VvG0L3tfXe6tr+LL9q4qyOV1fQ9cs7ue+028ihmJWIIwwT6knsvBOfbn25zxRqt3aXdtFf6k73X2dWkNreCEZLNww7sOmfTA7V6vqOmQ3CyxRXLCIglmJYuzEqQd2eBgHIIJPGCMHPjnxN0PQdA1qzt5pJJWltFm3Km7rI464PdT+lezw7ClicZGnVnGKs9ZKNtF/eTX4HDmlXmwzbTvdbHveg+F7DSfFN1qFhDEkDRldqDAUn155PXkADGPcnqUzgRnB45K8kH3+uaw7XUo7RmkYF4JpCFYIegIXnJ6ZGc4wRggYwS/xTrmn6RpElzLfJHK3CIib3fODtxjqcd/YemfFblKS6t2Xcws5mzE2QOdqnA+bA5P5jPT36Y93n7HaJI9y0UEK/eeVwi46ZLHp2rgR8QVe2iNvpOqXjPjbJFGBv7DbjI56Ae+PWptD+J+iXVgLm5tr7SlD4kSWFiCSNzHIAwRyCMHkjBPNNQqbuL/r8TR4eSWh28MnnlJYmLxFQyDGMZz+OPu//AF+z5GWKN2kOEC9+gHPPrnj6Vz2meL9F1WEro94ty+VGI1OcE7ckY5A5J9AMk+uvBdwzWDxYYSKvK4x0Bxxjg8/oeuKSXLK0lZ+en4MzlCSWpbeUS9GIyB1zyDnv0J46dsg455gvp47dFZpoopXIMayybSeeePwyf8iqsd0BDtCFmTodu7I9vzxkZzj3xXEfFG0v9Wu4PsGn3Pl2lv5wnVAcvwVCnPUfj0/CtoQcpcr0/r5ERUW9Trte0hdajtor27nhhiYNJGuP3nPf2+vb0qzbrFawJBaBfJiXbsHzDPTH1wO+ePfimaZcSjTbJrpna5MSFyQchvcexp4EZkyFILt827+Ljp+vTB/rWd5NJPZf1cluzJo5QFVWC/INy8YBz/Pnn0pZLCxvZI5r2zjnMPyxmUDgnj0z2PJ/WhuZvlIPIJ3KT34+p/l1rmfFWmeJG1B9QsbhJtMi2f6EuQ0n1wPm7cdffjDVCLk7J29Rx8zpdQ0xZtOumtnMV26nyyRnY2OCPXp796paJBdwafBZatL50yxZMwIVXLbgVGDuBAwckD7y4JIbbHYXsqfY4riK4jkmBMqSYZgfcgYz14H8q0bj7K0ah40mEiBQ6kEOCPUdsY7kYNDb5eWQeRVu7sWlmXUxmUtyqkkYz1P0BrlrS98vxK0VxOqzYAWLaQMEj168nkD0Xjit26jt1mVn87cxPUE456Aeo/oeD2zLvR7C8vILuOB4riBtx2q2DgcbhwDyMZP9ar2abu79QTj1Orz5Jww3ELz149D9f8893xXZWMsQF7/MMDpzyP8AI/ly8Md0NUMhkkKhhvyecFssAScYJIyOuOmeBWm90EZYwGxkl9wxyM4Pv+PNZ8rSE5K5uLcbxIR8pGQSpyOef8/TpUcdy28Q84P3m9Cegz+P15rFi1BYpBF8iRlSSpbaVAHbjB7ccYA78U574QJ5jOCyc57n6HJ4xx+P1qCkzbu2g+Q3Cp8x/duQSVPKk9OOMj9Kp3Nza28W8uo3EERcLjJz9eDx2rCS6+0F51ld8t0BA47gfl69h14rQWysL2RTJar9pjyyHgBSPb8sH3461drWKil1G/aftM3KR78YyuQQfcn/AHvwx275Ud9cWOuhpIy1tLlQV+baeOT6ZB/P9dW8e3jke2toWMhHmP5inacEYHQjPP1OM461HZrEu2V2iMi5YEgEK3Y/XGOmOv5qKRblpsWim66eQJj5QMEEHGOmM9vf361XaZYcEI4R8tvU5UZ5688D1I9+aumWOUDyAX2kYDcsM+3sMfpntiWKZkdHOW4/iY4XPJz36j6/XpSSvoRezuzPS7UmaPqV78gryP8AP+QKyntPMmlcSqERhlQBwSAQvHTAI9eoNdHD5YJLp8wO75h+eBj/AB/OqVzZW0l3vK/vMDAGcKM5P5kdM4+vSqitLjcrOyMpmjkLOT5QjPAVcZHHXvkHHXvVbUZzqMMMEhLxxsfliPzFSME4PIOMc9Ru4xyasa3HdBd1p5MqRctDjpnORnBxnnnB9hyKzdSGrX+mXjaB5MF6TlZZCGKqBg+uD16+/uaXKr7/ANeZrG0lZ9TUuS0irHbxrDCqkiOAkc85+9k5PqSeD61ZE4eJVZYoS5wpbqwAB/Dv+XTpXnOiPqvibTIC2sf2fcQSlbow7wWwRtOT0PHB/H2HZQK0cS77nzERcKGPJAPUjOck8/j70Shyu0n37/8ADalystjXNvdP85ZEw2N5HUAjPXOM9vTPaqXhnUbPXIpZtORhGsxjLueCQOvBz36f5NHWdbGnaNNc6vEstjOpt3iKDLh8q6kE8gjOR6Vfe+s9JsoY9JWCG3c71BI6nklieme5P40lpG7X+Wm/6eRDu0l3NlFjjkyq7CwG4hlBH1x9Pek1S0L2hbAO0jk9ux/DPb8sniufsrm4uFS484mYyHG3BCjgDJGcdR74xnHSt+O2SXTY4rqZnVlG5VJA56Dr36evQdKOV2epLtFq5mafNBIA5uIZkV8EJJuKt0A49M9DzyB2qHWPFFto1pA88bzs52mKNck5xnI9Og47n61Yh8O6Ro8stxZWs0kly6lhuOMfjx+foO4FWrWBRJEiSW6OoJSIpycDgjn+7u7Hr7cv3ebrb7v8zRctr2MvTZrm/uraeK3eMsm/ZIu0jHQEDoen489s1XtZ7a68Q6jDp1u8dyRmedRwuCM89M89we9baBzqabpgqopOxQcseOevfLZ9ffBzpwxwo8slpCiSuDubZtLEcZJxnjH61lKSS1XTTXzLUraI52+1BlhhhFrqMqz7gzkjbFgA4bnPzZIGA3I5wCKqXgRzDJdaeHjB6MMlMnpyPbHX8+tTX2t2tvczxM800i/e2Dbuxnnr+Y/xzWfc+LYX3eTp2oXMkXABXgngY464OOP/ANdKOvwxf32NvZzWoyC1djEskyWlqTtFvEgC4J569en1/pbl0S3cOlrI0pcBmctknPGRk8//AF/oK5K/8T69PIM2Ulukrjy/3eAozwDxye/bqO3BLO9urRty2xaVhlnaPb1yD27DPcnP41q1NeQ/ZyetzohoCJhZNS8rYSz4DDnqByQDwfX8eDjw/wCOlpbaf4l0xV1OZRLp4l3NH5m/M8w3ZJ46YwPTPUmvWLjW9P8ALNtNBG87DcSWyDjoc4HqvGfbnbkeT/GnVZ/7c0gBApGnDKxx+YF/fzEZII7YPToRXs8PRqVsaoxdm0/L8mn+Jy4ynUVJt/1+D/I//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <em>",
"     Haemophilus",
"    </em>",
"    spp. under high power magnification (1000x) in sputum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23157=[""].join("\n");
var outline_f22_39_23157=null;
var title_f22_39_23158="Latanoprost and timolol: Drug information";
var content_f22_39_23158=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Latanoprost and timolol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?28/22/29028?source=see_link\">",
"    see \"Latanoprost and timolol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9662409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xalacom&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9662413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Beta-Blocker, Nonselective;",
"     </li>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma;",
"     </li>",
"     <li>",
"      Prostaglandin, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9662491\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Control of intraocular pressure:",
"     </b>",
"     Ophthalmic: Instill 1 drop into affected eye(s) once daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9662492\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F9662497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Xalacom&trade;: Latanoprost (0.005%) and timolol maleate 0.5% (as base) (2.5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11234035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9662493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Wash hands prior to use. Remove contact lenses prior to administration; wait 15 minutes before reinserting if using products containing benzalkonium chloride. Separate administration of other ophthalmic agents by 5 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9662426\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers, prostaglandin analogues, or other IOP-reducing agents and in whom combination therapy is appropriate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9662405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Xalacom&trade; may be confused with Xalatan&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9662464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Percentages as reported with combination product. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Eyelash alterations (including darkening, lengthening, thickening) (&le;37%), iris pigmentation increased (&le;20%), eye irritation (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (&le;4%), chest pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Depression (2%), headache (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin disorder (2%), rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Endocrine &amp; metabolic: Hypercholesterolemia (2%), diabetes mellitus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Arthritis (2%), back pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Hyperemia (7%), vision abnormal (7%), visual field defect (5%), blepharitis (3%), cataract (3%), conjunctivitis (3%), corneal disorder (3%), eye pain (2%), photophobia (2%), refraction errors (2%), skin disorder (2%), conjunctival disorder (1%), keratitis (1%), meibomianitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (6%), sinusitis (2%), bronchitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu-like symptoms (3%), infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Bradycardia, cardiac failure, corneal ulceration, cough, cystitis, cystoid macular edema, dizziness, dyspepsia, dyspnea, epiphora, eyelid edema, glycosuria, hyperglycemia, insomnia, intraocular pressure increased, optic atrophy, pneumonia, retinal disorder, seborrhea, skin discoloration, tachycardia, urinary tract infection, uveitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9662431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to latanoprost, timolol, benzalkonium chloride, or any component of the formulation; reactive airway disease including severe chronic obstructive pulmonary disease (COPD) and presence or history of bronchial asthma; sinus bradycardia, second-/third-degree atrioventricular block, overt cardiac failure, cardiogenic shock",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9662432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactic reactions: Use caution with history of severe anaphylaxis to allergens; patients taking beta-blockers may become more sensitive to repeated challenges. Treatment of anaphylaxis (eg, epinephrine) in patients taking beta-blockers may be ineffective or promote undesirable effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bacterial keratitis: Inadvertent contamination of multiple-dose ophthalmic solutions has caused bacterial keratitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Ocular effects: Use of agents that reduce/suppress aqueous humor production has been associated with choroidal detachment after filtration procedures. Discontinue use in patients with chronic or recurrent choroidal detachment. Macular edema, mainly in aphakic or pseudophakic patients with a torn posterior lens capsule, has been associated with use of prostaglandin analogues such as latanoprost. May permanently change/increase brown pigmentation of the iris, the eyelid skin, and eyelashes. In addition, may increase the length and/or number of eyelashes (may vary between eyes); changes occur slowly and may not be noticeable for months or years. Long-term consequences and potential injury to eye are not known.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bronchospastic disease: In general, patients with bronchospastic disease should not receive beta-blockers; if used at all, should be used cautiously with close monitoring.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Conduction abnormalities: Consider pre-existing conditions such as sick sinus syndrome before initiating.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may potentiate hypoglycemia and/or mask signs and symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with compensated heart failure (HF) and monitor for a worsening of the condition. Adequately control HF prior to initiating therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Safety and efficacy have not been established in patients with hepatic impairment; use with caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iritis/uveitis: Use caution in patients with active intraocular inflammation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; may worsen disease or other myasthenic symptoms (diplopia, ptosis).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Orthostatic hypotension: Use with caution in patients with orthostatic hypotension; signs and symptoms of hypotension may be enhanced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peripheral vascular disease (PVD) and Raynaud's disease: Can precipitate or aggravate symptoms of arterial insufficiency in patients with PVD and Raynaud's disease. Use with caution and monitor for progression of arterial obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Safety and efficacy have not been established in patients with renal impairment; use caution.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: May mask signs of hyperthyroidism (eg, tachycardia). If thyrotoxicosis is suspected, carefully manage and monitor; abrupt withdrawal may exacerbate symptoms of hyperthyroidism or precipitate thyroid storm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beta-blockers: Concomitant use with other topical beta-blockers should be avoided; monitor for increased effects (systemic or intraocular) with concomitant use of a systemic beta-blocker.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiac glycosides: Use with caution in patients receiving digoxin; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Calcium channel blockers: Use with caution in patients on concurrent verapamil or diltiazem; bradycardia or heart block can occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Inhaled anesthetic agents: Use with caution in patients receiving inhaled anesthetic agents known to depress myocardial contractility.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostaglandins: Concomitant use with other local prostaglandins should be avoided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thimerosal: Precipitation may occur if mixed with benzalkonium chloride-containing products; allow at least 5 minutes between the application of latanoprost/timolol and ophthalmic preparations containing thimerosal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact lens wearers: Product contains benzalkonium chloride which may be absorbed by soft contact lenses; remove lens prior to administration and wait 15 minutes before reinserting.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Absorption: Systemic absorption of timolol and adverse effects may occur with ophthalmic use, including bradycardia and/or hypotension. Beta-blocker therapy should not be withdrawn abruptly in order to avoid acute tachycardia, hypertension, and/or ischemia.  Patients undergoing major surgery should be gradually tapered off therapy prior to procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Safety and efficacy not established in treatment of chronic angle-closure, congenital, inflammatory, neovascular, or pigmentary glaucoma or in pseudophakic patients with open angle glaucoma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Initial therapy: Combination product (Xalacom&trade;) should not be used for initial therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9922603\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists (Direct-Acting): Beta-Blockers may enhance the vasopressor effect of Alpha-/Beta-Agonists (Direct-Acting). Epinephrine used as a local anesthetic for dental procedures will not likely cause clinically relevant problems.  Management: Cardioselective beta-blockers and lower doses of epinephrine may confer a more limited risk. Patients who may require acute subcutaneous epinephrine (e.g., bee sting kits) should probably avoid beta blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dipivefrin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: Beta-Blockers may enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha2-Agonists: May enhance the AV-blocking effect of Beta-Blockers. Sinus node dysfunction may also be enhanced. Beta-Blockers may enhance the rebound hypertensive effect of Alpha2-Agonists. This effect can occur when the alpha",
"     <sub>",
"      2",
"     </sub>",
"     -agonist is abruptly withdrawn. Management: Closely monitor heart rate during treatment with a beta blocker and clonidine. Withdraw beta blockers several days before clonidine withdrawal when possible, and monitor blood pressure closely. Recommendations for other alpha2-agonists are unavailable.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Apraclonidine; Brimonidine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoquinolines (Antimalarial): May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May enhance the bradycardic effect of Beta-Blockers. Possibly to the point of cardiac arrest. Amiodarone may increase the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Beta-Blockers. Anilidopiperidine Opioids may enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotic Agents (Phenothiazines): May enhance the hypotensive effect of Beta-Blockers. Beta-Blockers may decrease the metabolism of Antipsychotic Agents (Phenothiazines). Antipsychotic Agents (Phenothiazines) may decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bimatoprost: The concomitant use of Latanoprost and Bimatoprost may result in increased intraocular pressure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bupivacaine: Beta-Blockers may increase the serum concentration of Bupivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Beta-Blockers may enhance the bradycardic effect of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction.  Management: Administer these agents in combination with caution, and monitor for conduction disturbances.  Avoid methacholine with any beta blocker due to the potential for additive bronchoconstriction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: May enhance the bradycardic effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Beta-Blockers may enhance the vasoconstricting effect of Ergot Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Beta-Blockers may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Floctafenine: May enhance the adverse/toxic effect of Beta-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: Beta-Blockers may enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Systemic): Beta-Blockers may increase the serum concentration of Lidocaine (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lidocaine (Topical): Beta-Blockers may increase the serum concentration of Lidocaine (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mepivacaine: Beta-Blockers may increase the serum concentration of Mepivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methacholine: Beta-Blockers may enhance the adverse/toxic effect of Methacholine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Beta-Blockers may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the antihypertensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Ophthalmic): May diminish the therapeutic effect of Latanoprost.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of Beta-Blockers. Propafenone possesses some independent beta blocking activity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May decrease the metabolism of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Reserpine: May enhance the hypotensive effect of Beta-Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Rifabutin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Citalopram; Escitalopram; FluvoxaMINE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sulfonylureas: Beta-Blockers may enhance the hypoglycemic effect of Sulfonylureas. Cardioselective beta-blockers (eg, acebutolol, atenolol, metoprolol, and penbutolol) may be safer than nonselective beta-blockers. All beta-blockers appear to mask tachycardia as an initial symptom of hypoglycemia. Ophthalmic beta-blockers are probably associated with lower risk than systemic agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Beta-Blockers (Nonselective) may diminish the bronchodilatory effect of Theophylline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9662427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproductive studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9662429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk (timolol)/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9662430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Timolol has been detected in human breast milk following ophthalmic administration.  Latanoprost may enter human breast milk. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9662495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     IOP, iris color changes, eyelash changes; systemic effects of beta blockade",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9662486\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Latanoprost: A prostaglandin F",
"     <sub>",
"      2",
"     </sub>",
"     -alpha analog believed to reduce intraocular pressure by increasing the outflow of the aqueous humor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timolol: Blocks both beta",
"     <sub>",
"      1",
"     </sub>",
"     - and beta",
"     <sub>",
"      2",
"     </sub>",
"     -adrenergic receptors, reduces intraocular pressure by reducing aqueous humor production or possibly outflow; reduces blood pressure by blocking adrenergic receptors and decreasing sympathetic outflow, produces a negative chronotropic and inotropic activity through an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9662488\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Higginbotham EJ, Feldman R, Stiles M, et al, &ldquo;Latanoprost and Timolol Combination Therapy vs Monotherapy: One-Year Randomized Trial,&rdquo;",
"      <i>",
"       Arch Ophthalmol",
"      </i>",
"      , 2002, 120(7):915-22.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/39/23158/abstract-text/12096962/pubmed\" id=\"12096962\" target=\"_blank\">",
"        12096962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lang DM, &ldquo;Anaphylactoid and Anaphylactic Reactions. Hazards of Beta-Blockers,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 1995, 12(5):299-304",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/39/23158/abstract-text/7669259/pubmed\" id=\"7669259\" target=\"_blank\">",
"        7669259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Odeh M, Oliven A, and Bassan H, &ldquo;Timolol Eyedrop-Induced Fatal Bronchospasm in an Asthmatic Patient,&rdquo;",
"      <i>",
"       J Fam Pract",
"      </i>",
"      , 1991, 32(1):97-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?22/39/23158/abstract-text/1985142/pubmed\" id=\"1985142\" target=\"_blank\">",
"        1985142",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9516 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-B2407C6BAC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23158=[""].join("\n");
var outline_f22_39_23158=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662409\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662413\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662491\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662492\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662497\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234035\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662493\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662426\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662405\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662464\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662431\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662432\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299579\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9922603\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662427\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662429\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662430\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662495\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662486\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9662488\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9516\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9516|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?28/22/29028?source=related_link\">",
"      Latanoprost and timolol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_39_23159="Clindamycin: An overview";
var content_f22_39_23159=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clindamycin: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23159/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23159/contributors\">",
"     Melissa Johnson, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23159/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23159/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23159/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23159/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/39/23159/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is a lincosamide antibiotic that has been approved by the US Food and Drug Administration (FDA) for the treatment of anaerobic, streptococcal, and staphylococcal infections. Its major disadvantage is its propensity to cause antibiotic-associated diarrhea, including Clostridium difficile colitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There has been increased interest in the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    because it achieves high intracellular levels in phagocytic cells, high levels in bone, and appears to have an antitoxin effect against toxin elaborating strains of streptococci and staphylococci. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The spectrum of activity, pharmacology, and adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    will be reviewed here. The clinical use of clindamycin is discussed separately in the appropriate topic reviews on specific infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    works primarily by binding to the 50s ribosomal subunit of bacteria. This agent disrupts protein synthesis by interfering with the transpeptidation reaction, which thereby inhibits early chain elongation.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     Chloramphenicol",
"    </a>",
"    and macrolides such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/43/33456?source=see_link\">",
"     azithromycin",
"    </a>",
"    also act at the 50s ribosomal subunit and may compete for binding at this site. Clindamycin and the related drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/24/43396?source=see_link\">",
"     lincomycin",
"    </a>",
"    are often discussed along with the macrolides, but are not chemically related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link\">",
"     \"Azithromycin, clarithromycin, and telithromycin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    may potentiate the opsonization and phagocytosis of bacteria even at subinhibitory concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. By disrupting bacterial protein synthesis, clindamycin causes changes in the cell wall surface which decreases adherence of bacteria to host cells and increases intracellular killing of organisms. The drug also exerts an extended postantibiotic effect against some strains of bacteria, which may be attributed to persistence of the drug at the ribosomal binding site.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is considered a bacteriostatic antibiotic, but is bactericidal against some strains of staphylococci, streptococci, and anaerobes such as Bacteroides fragilis. However, killing activity may vary with drug concentration, bacterial species, and inoculum. Bactericidal activity against B. fragilis is inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/3\">",
"     3",
"    </a>",
"    ]. Penicillins are more rapidly bactericidal versus Staphylococcus aureus than is clindamycin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/4\">",
"     4",
"    </a>",
"    ]. However, clindamycin does inhibit production of staphylococcal toxin associated with the toxic shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/5\">",
"     5",
"    </a>",
"    ]. Clindamycin has also been shown to almost completely inhibit alpha toxin expression in S. aureus in contrast to beta-lactams, which strongly induce, and fluoroquinolones, which partially induce expression [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1249199640\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    generally has in vitro activity against staphylococci, viridans group streptococci, Streptococcus pyogenes, and S. pneumoniae. It also demonstrates potent activity against anaerobes such as Bacteroides fragilis, Clostridium perfringens, Fusobacterium spp, Prevotella melaninogenicus, and Peptostreptococcus spp. However, increasing rates of resistance among B. fragilis have limited its utility against these organisms. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is not typically active against Haemophilus influenzae, enterococci, or Neisseria meningitidis. Mycoplasma pneumoniae and aerobic gram-negative bacilli are usually resistant.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is active in vitro against Toxoplasma gondii, Actinomyces israelii, Nocardia asteroides, and Babesia spp. Clindamycin also has some activity against Plasmodium falciparum and P. vivax (both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/54/25447?source=see_link\">",
"     chloroquine",
"    </a>",
"    -sensitive and -resistant strains). Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    or chloroquine has been tried [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/7\">",
"     7",
"    </a>",
"    ]; clindamycin should",
"    <strong>",
"     not",
"    </strong>",
"    be used alone for the treatment or prevention of malaria. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=see_link\">",
"     \"Prevention of malaria infection in travelers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several mechanisms of bacterial resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , including modification of the target, inactivation of the drug, or efflux of the drug. Resistance has been conferred by both plasmid- and chromosomally-mediated mechanisms, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasmid-mediated resistance in Staphylococcus aureus and Bacteroides fragilis, conferred by methylation of adenine in the 23s ribosomal RNA of the 50s ribosomal subunit [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/8\">",
"       8",
"      </a>",
"      ]. In gram-positive cocci, this mechanism also confers resistance to macrolides. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=see_link&amp;anchor=H3#H3\">",
"       \"Azithromycin, clarithromycin, and telithromycin\", section on 'Resistance'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Alteration of a single 50s ribosomal protein of the receptor site, which also confers resistance to macrolides.",
"     </li>",
"     <li>",
"      Adenylation conferred by a plasmid-mediated 3-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/24/43396?source=see_link\">",
"       lincomycin",
"      </a>",
"      4-",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      0-nucleotidyltransferase that catalyzes the nucleotidylation of the hydroxyl group of position 4 of clindamycin [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/9\">",
"       9",
"      </a>",
"      ]. This mechanism of resistance is most frequently found in staphylococcal isolates, including S. aureus, and impairs bactericidal activity and reduces activity at high inoculum levels. Although adenylation confers high level resistance to lincomycin, clindamycin resistance may not be detected by routine testing methods. This type of resistance is uncommon and probably not of great clinical importance.",
"     </li>",
"     <li>",
"      Gram-negative organisms such as Pseudomonas spp, Enterobacteriaceae, and Acinetobacter spp are intrinsically resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      due to poor permeability of the cellular outer envelope to the drug [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cross-resistance of S. aureus to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/24/43396?source=see_link\">",
"     lincomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is complete. In addition, bacteria that are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    -resistant may quickly develop resistance when exposed to clindamycin. Strains of S. aureus have also developed resistance to clindamycin during treatment. Other bacteria such as Streptococcus pneumoniae, group A streptococcus, Corynebacterium diphtheriae, B. fragilis, Peptostreptococcus spp, and Propionibacterium acnes have also developed resistance to clindamycin. Increasing resistance among group B streptococci has also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/11-13\">",
"     11-13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A resistance phenotype identified in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    -susceptible,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    -resistant strains of Streptococcus agalactiae had high MICs to clindamycin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/24/43396?source=see_link\">",
"     lincomycin",
"    </a>",
"    plus high MICs to dalfopristin, a streptogramin-A antibacterial agent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/14\">",
"     14",
"    </a>",
"    ]. By contrast, the strains were susceptible to macrolides and quinupristin, a streptogramin B-type antibiotic.",
"   </p>",
"   <p>",
"    Rates of resistance of the B. fragilis group to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    have increased over time in the United States and Europe. In the United States, the frequency of clindamycin resistance in B. fragilis increased from 3 percent in 1987 to 26 percent from 1997 to 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Some centers have reported clindamycin resistance rates of B. fragilis to be as high as 44 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/17\">",
"     17",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=see_link&amp;anchor=H18#H18\">",
"     \"Anaerobic bacterial infections\", section on 'Antibiotic resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since rates of antibiotic resistance within Bacteroides may vary with geographic area and local antibiotic use, local susceptibility patterns should be considered in the selection of empiric therapy. Susceptibility testing for anaerobic bacteria is not routinely performed in the clinical laboratory setting, since the techniques are cumbersome and not well-standardized. However, testing may be indicated in certain clinical situations, including brain abscess, endocarditis, osteomyelitis, arthritis, prosthetic device or vascular graft infection, and refractory or recurrent bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/18\">",
"     18",
"    </a>",
"    ]. Testing may be particularly useful in the setting of serious infection, persistent infections, potentially resistant pathogens that will be treated medically rather than surgically, or when prolonged therapy is anticipated.",
"   </p>",
"   <p>",
"    The primary benefit of susceptibility testing is not documentation of susceptibility but rather demonstration of unexpected resistance to an antimicrobial that is normally useful. The clinical relevance of documented bacterial resistance in the setting of mixed anaerobic infections remains unclear. An alternative approach to requesting susceptibility testing upon isolation of a Bacteroides spp is to reserve such testing for a clinical treatment failure or recurrent infection and to send an isolate to a reference laboratory at that time.",
"   </p>",
"   <p>",
"    Clostridium difficile is often resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    but susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    . C. perfringens is usually uniformly susceptible, but other clostridial species may be resistant in 15 to 30 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is well-absorbed after oral administration and is approximately 90 percent bioavailable. The drug generally distributes well into body tissues but does not achieve significant levels in the cerebrospinal fluid (CSF), even during episodes of meningitis. It does penetrate well into bone. Since the drug is actively transported into polymorphonuclear leukocytes and macrophages, it may also achieve excellent penetration into abscesses.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is metabolized in the liver to active and inactive metabolites. One active metabolite, N-demethyl-clindamycin, is more active than the parent compound. Clindamycin is excreted in urine and, to a lesser extent, in the bile as metabolites. The half-life in patients with normal renal function is 2.4 hours, but this is extended to approximately six hours in those with renal insufficiency. The half-life of the drug is also extended in patients with hepatic failure. The drug is not appreciably removed by peritoneal dialysis or hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    are diarrhea and allergic reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea has been reported in 2 to 20 percent of those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Typically, the diarrhea is mild and self-limited in nature, and resolves upon discontinuation of the drug. Clindamycin has been frequently implicated in antibiotic-associated diarrhea due to Clostridium difficile [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Pseudomembranous colitis caused by overgrowth of C. difficile has been reported in 0.1 to 10 percent of patients receiving clindamycin, and can be severe or life-threatening. Although this condition has been documented with almost all antibiotics, clindamycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    , and the cephalosporins are most frequently implicated, the latter three based upon the frequency of use. In a comparison of clindamycin and ampicillin, pseudomembranes were documented by endoscopy in 2 percent of patients receiving clindamycin and 0.3 percent of patients receiving ampicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=see_link\">",
"     \"Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antibiotic-associated diarrhea can occur during antibiotic therapy or even several weeks after the cessation of therapy. Topical and vaginal preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    have also been implicated in causing this disease, which may be attributable to systemic absorption of the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. Clindamycin may be used with caution among patients with inflammatory bowel disease, since antibiotic-associated diarrhea in this patient population may be particularly intolerable.",
"   </p>",
"   <p>",
"    Other gastrointestinal side effects have been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . These include nausea, vomiting, flatulence, metallic taste, anorexia, and esophagitis. Following administration of clindamycin it advisable to sit upright for 30 minutes to minimize risk of gastrointestinal discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maculopapular skin rash has been noted in up to 10 percent of patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Other reactions such as drug fever, eosinophilia, erythema multiforme, drug rash with eosinophilia and systemic symptoms (DRESS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/23\">",
"     23",
"    </a>",
"    ], Sweet syndrome, and urticaria have also been reported. Some cases have resembled Stevens-Johnson syndrome. &nbsp;Although rare, cardiopulmonary arrest and hypotension have been reported with rapid intravenous infusions of clindamycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Local reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injection-site pain and swelling have been reported with the use of intravenous and intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . Thrombophlebitis may occur with infusions of intravenous clindamycin. Induration and sterile abscess have been reported with intramuscular administration of the drug. Contact dermatitis may be associated with topical forms of clindamycin. In addition, symptomatic vaginitis and vulvar irritation have been reported with intravaginal clindamycin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common adverse reactions reported with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    include elevation of liver transaminases, jaundice, and polyarthritis. Hematopoietic effects such as neutropenia, leukopenia, agranulocytosis, and thrombocytopenic purpura have also been reported. Renal dysfunction associated with the use of clindamycin is rare, but may be characterized by oliguria, azotemia, and proteinuria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    has neuromuscular blocking properties, it should be used with caution in patients receiving neuromuscular blocking agents. Since clindamycin, macrolides, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    target the same ribosomal site, these drugs should not be used in combination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DOSING AND ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is available for oral, parenteral, and topical administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Formulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is available in a number of formulations including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Oral capsules (75, 150, and 300 mg as hydrochloride) and oral suspension (75",
"      <span class=\"nowrap\">",
"       mg/5",
"      </span>",
"      mL, 100 mL)",
"     </li>",
"     <li>",
"      Intravenous infusion bags (300, 600, and 900 mg, in D5W) and",
"      <span class=\"nowrap\">",
"       intravenous/intramuscular",
"      </span>",
"      injection (150",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      in 2, 4, 6, and 60 mL)",
"     </li>",
"     <li>",
"      Topical preparations including 2 percent vaginal cream (40 g), 1 percent topical gel (10",
"      <span class=\"nowrap\">",
"       mg/g,",
"      </span>",
"      30 g, 60 g), 1 percent topical solution (10",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      30, 60, and 480 mL), and 1 percent topical lotion (10",
"      <span class=\"nowrap\">",
"       mg/mL,",
"      </span>",
"      60 mL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    dosing depends upon the route of administration, the age of the patient, and the indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children over the age of one month usually receive oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    as clindamycin hydrochloride 8 to 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into three or four equal doses. It may also be dosed as clindamycin palmitate hydrochloride 8 to 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into three or four equal doses. In children weighing less than 10 kg, the minimum dose of clindamycin palmitate hydrochloride is 37.5 mg three times daily.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    is usually administered as 20 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three or four equal doses. Alternatively, dosing may be based upon body surface area, with 350 to 450",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day administered in three or four equal doses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    in adults is 150 to 300 mg every six hours, but 450 to 600 mg every six hours can be given for more severe infections. Intravenous clindamycin is usually dosed as 600 to 900 mg every eight hours. For more severe infections, these doses may need to be increased. As much as 4800 mg daily has been administered to adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/24\">",
"     24",
"    </a>",
"    ]. Clindamycin dosing can be modified in the treatment of specific infections (",
"    <a class=\"graphic graphic_table graphicRef78758 \" href=\"UTD.htm?11/41/11932\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No reports linking",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    with congenital defects have been published to date, and animal studies have failed to demonstrate fetal risk with clindamycin therapy. However, a lack of controlled studies in pregnant women warrants an FDA pregnancy risk category of B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 2",
"    </a>",
"    ). Clindamycin does cross the placenta with levels approximating 50 percent of maternal serum levels.",
"   </p>",
"   <p>",
"    A study evaluating pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    in pregnant women reported lower clindamycin concentrations in umbilical cord blood than maternal blood, and suggested that maternal concentrations may not exceed the",
"    <span class=\"nowrap\">",
"     AUC/MIC",
"    </span>",
"    target for effective group B streptococcus prevention for neonates during delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/25\">",
"     25",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In a study of pregnant women with bacterial vaginosis at 15.6 weeks gestation (mean), use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (300 mg PO twice daily for five days) was associated with fewer miscarriages or pre-term deliveries when compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23159/abstract/26\">",
"     26",
"    </a>",
"    ]. In contrast, since intravaginal clindamycin has been associated with an increased risk of preterm birth, clindamycin intravaginal cream should",
"    <strong>",
"     not",
"    </strong>",
"    be used in pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Nursing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    is excreted in the breast milk, but the American Academy of Pediatrics considers clindamycin administration compatible with breastfeeding. However, some practitioners may still elect to avoid clindamycin therapy in women who are nursing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    should generally be avoided in neonates since each milliliter of intravenous clindamycin contains 9.45 mg of benzyl alcohol. Organ system functions should be carefully monitored in infants receiving clindamycin intravenously.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     Clindamycin",
"    </a>",
"    does not appear to be significantly removed by hemodialysis or peritoneal dialysis. Thus, no dosing adjustments are necessary in patients undergoing dialysis. Patients undergoing hemofiltration also do not appear to require clindamycin dose adjustments.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Renal and hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific dose adjustments are recommended for patients with renal or hepatic dysfunction receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    . However, as noted above, the half-life of the drug is prolonged in such patients, which could increase the potential for adverse events. Such patients should be monitored closely, and dose adjustments should be considered if toxicity is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MONITORING DURING THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    should be monitored for hepatic or renal dysfunction and for the occurrence of potential side effects. If diarrhea occurs, the drug should be stopped. Patients experiencing diarrhea during or after receiving antibiotic therapy should be evaluated for the presence of Clostridium difficile and treated accordingly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1249195076\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      is a lincosamide antibiotic that has been approved by the US Food and Drug Administration (FDA) for the treatment of anaerobic, streptococcal, and staphylococcal infections. Its major disadvantage is its propensity to cause antibiotic-associated diarrhea. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      works primarily by binding to the 50s ribosomal subunit of bacteria. This agent disrupts protein synthesis by interfering with the transpeptidation reaction, which thereby inhibits early chain elongation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      is considered a bacteriostatic antibiotic, but is bactericidal against some strains of staphylococci, streptococci, and anaerobes such as Bacteroides fragilis. However, killing activity may vary with drug concentration, bacterial species, and inoculum. Bactericidal activity against B. fragilis is inconsistent. Penicillins are more rapidly bactericidal versus Staphylococcus aureus than is clindamycin. However, clindamycin does inhibit production of staphylococcal toxin associated with the toxic shock syndrome. Clindamycin has also been shown to almost completely inhibit alpha toxin expression in S. aureus. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      generally has in vitro activity against staphylococci, viridans group streptococci, Streptococcus pyogenes, and S. pneumoniae. It also demonstrates potent activity against anaerobes such as Bacteroides fragilis, Clostridium perfringens, Fusobacterium spp, Prevotella melaninogenicus, and Peptostreptococcus spp. (See",
"      <a class=\"local\" href=\"#H1249199640\">",
"       'Spectrum of activity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are several mechanisms of bacterial resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , including modification of the target, inactivation of the drug, or efflux of the drug. Resistance has been conferred by both plasmid- and chromosomally-mediated mechanisms. Rates of resistance of the Bacteroides fragilis group to clindamycin have increased over time in the United States and Europe. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      is well-absorbed after oral administration and is approximately 90 percent bioavailable. The drug generally distributes well into body tissues but does not achieve significant levels in the cerebrospinal fluid (CSF), even during episodes of meningitis. It does penetrate well into bone. Since the drug is actively transported into polymorphonuclear leukocytes and macrophages, it may also achieve excellent penetration into abscesses. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      has neuromuscular blocking properties, it should be used with caution in patients receiving neuromuscular blocking agents. Since clindamycin, macrolides, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"       chloramphenicol",
"      </a>",
"      target the same ribosomal site, these drugs should not be used in combination. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       Clindamycin",
"      </a>",
"      is available for oral, parenteral, and topical administration. Clindamycin dosing depends upon the route of administration, the age of the patient, and the indication. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Dosing and administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common adverse effects associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      are diarrhea, including Clostridium difficile colitis, and allergic reactions. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Toxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No specific dose adjustments are recommended for patients with renal or hepatic dysfunction receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      . However, the half-life of the drug is prolonged in such patients, which could increase the potential for adverse events. Such patients should be monitored closely, and dose adjustments should be considered if toxicity is suspected. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Renal and hepatic dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/1\">",
"      Veringa EM, Lambe DW Jr, Ferguson DA Jr, Verhoef J. Enhancement of opsonophagocytosis of Bacteroides spp. by clindamycin in subinhibitory concentrations. J Antimicrob Chemother 1989; 23:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/2\">",
"      Veringa EM, Verhoef J. Influence of subinhibitory concentrations of clindamycin on opsonophagocytosis of Staphylococcus aureus, a protein-A-dependent process. Antimicrob Agents Chemother 1986; 30:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/3\">",
"      Nastro LJ, Finegold SM. Bactericidal activity of five antimicrobial agents against Bacteroides fragilis. J Infect Dis 1972; 126:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/4\">",
"      Sande MA, Johnson ML. Antimicrobial therapy of experimental endocarditis caused by Staphylococcus aureus. J Infect Dis 1975; 131:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/5\">",
"      Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production. J Infect Dis 1984; 149:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/6\">",
"      Ohlsen K, Ziebuhr W, Koller KP, et al. Effects of subinhibitory concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother 1998; 42:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/7\">",
"      Kremsner PG, Radloff P, Metzger W, et al. Quinine plus clindamycin improves chemotherapy of severe malaria in children. Antimicrob Agents Chemother 1995; 39:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/8\">",
"      Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification. Antimicrob Agents Chemother 1991; 35:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/9\">",
"      Brisson-No&euml;l A, Delrieu P, Samain D, Courvalin P. Inactivation of lincosaminide antibiotics in Staphylococcus. Identification of lincosaminide O-nucleotidyltransferases and comparison of the corresponding resistance genes. J Biol Chem 1988; 263:15880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/10\">",
"      Leclercq R, Courvalin P. Intrinsic and unusual resistance to macrolide, lincosamide, and streptogramin antibiotics in bacteria. Antimicrob Agents Chemother 1991; 35:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/11\">",
"      Castor ML, Whitney CG, Como-Sabetti K, et al. Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 2008; 2008:727505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/12\">",
"      DiPersio LP, DiPersio JR. High rates of erythromycin and clindamycin resistance among OBGYN isolates of group B Streptococcus. Diagn Microbiol Infect Dis 2006; 54:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/13\">",
"      Phares CR, Lynfield R, Farley MM, et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008; 299:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/14\">",
"      Malbruny B, Werno AM, Anderson TP, et al. A new phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus agalactiae in New Zealand. J Antimicrob Chemother 2004; 54:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/15\">",
"      Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007; 51:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/16\">",
"      Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides Fragilis Group: report and analysis of trends for 1997-2000. Clin Infect Dis 2002; 35:S126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/17\">",
"      Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome developments. Clin Infect Dis 2004; 39:92.",
"     </a>",
"    </li>",
"    <li>",
"     NCCLS. Methods for antimicrobial susceptibility testing of anaerobic bacteria; approved standard- fourth edition. NCCLS document M11-A4. NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA, 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/19\">",
"      Gurwith MJ, Rabin HR, Love K. Diarrhea associated with clindamycin and ampicillin therapy: preliminary results of a cooperative study. J Infect Dis 1977; 135 Suppl:S104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/20\">",
"      Tedesco FJ, Barton RW, Alpers DH. Clindamycin-associated colitis. A prospective study. Ann Intern Med 1974; 81:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/21\">",
"      Parry MF, Rha CK. Pseudomembranous colitis caused by topical clindamycin phosphate. Arch Dermatol 1986; 122:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/22\">",
"      Meadowcroft AM, Diaz PR, Latham GS. Clostridium difficile toxin-induced colitis after use of clindamycin phosphate vaginal cream. Ann Pharmacother 1998; 32:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/23\">",
"      Tian D, Mohan RJ, Stallings G. Drug rash with eosinophilia and systemic symptoms syndrome associated with clindamycin. Am J Med 2010; 123:e7.",
"     </a>",
"    </li>",
"    <li>",
"     Pharmacia &amp; Upjohn Company Cleocin Phosphate (Clindamycin Phosphate) package insert. Kalamazoo, MI; April 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/25\">",
"      Muller AE, Mouton JW, Oostvogel PM, et al. Pharmacokinetics of clindamycin in pregnant women in the peripartum period. Antimicrob Agents Chemother 2010; 54:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23159/abstract/26\">",
"      Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361:983.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 485 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-210.101.131.232-895BD5A23F-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23159=[""].join("\n");
var outline_f22_39_23159=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1249195076\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1249199640\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Local reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DOSING AND ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Formulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Nursing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Renal and hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MONITORING DURING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1249195076\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/485\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/485|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/41/11932\" title=\"table 1\">",
"      Clindamycin dosing for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 2\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1514?source=related_link\">",
"      Azithromycin, clarithromycin, and telithromycin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/18/36137?source=related_link\">",
"      Clostridium difficile in adults: Epidemiology, microbiology, and pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/29/6616?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of streptococcal toxic shock syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/3/13370?source=related_link\">",
"      Prevention of malaria infection in travelers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_39_23160="Stepwise asthma Rx 0 to 4 yrs";
var content_f22_39_23160=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76669%7EPULM%2F67459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76669%7EPULM%2F67459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 636px\">",
"   <div class=\"ttl\">",
"    Stepwise approach for managing asthma in children 0-4 years of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 616px; height: 543px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. If clear benefit is not observed within 4-6 weeks and patient/family medication technique and adherence are satisfactory, consider adjusting therapy or alternative diagnosis. Studies on children 0-4 years of age are limited. Step 2 preferred therapy is based on Evidence A. All other recommendations are based on expert opinion and extrapolation from studies in older children.",
"    <br/>",
"    <strong>",
"     Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.",
"    </strong>",
"    <div class=\"footnotes\">",
"     ICS: inhaled corticosteroid; LABA: inhaled long-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist; SABA: inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 634px\">",
"   <div class=\"ttl\">",
"    Stepwise approach for managing asthma in children 5-11 years of age",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 614px; height: 559px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The stepwise approach is meant to assist, not replace, the clinical decision-making required to meet individual patient needs. If alternative treatment is used and response is inadequate, discontinue it and use the preferred treatment before stepping up. Theophylline is a less desirable alternative due to the need to monitor serum concentration levels. Step 1 and step 2 medications are based on Evidence A. Step 3 ICS + adjunctive therapy and ICS are based on Evidence B for efficacy of each treatment and extrapolation from comparator trials in older children and adults - comparator trials are not available for this age group; steps 4-6 are based on expert opinion and extrapolation from studies in older children and adults. Immunotherapy for steps 2-4 is based on Evidence B for house-dust mites, animal danders, and pollens; evidence is weak or lacking for molds and cockroaches. Evidence is strongest for immunotherapy with single allergens. The role of allergy in asthma is greater in children than in adults. Clinicians who administer immunotherapy should be prepared and equipped to identify and treat anaphylaxis that may occur.",
"    <br/>",
"    <strong>",
"     Alphabetical order is used when more than one treatment option is listed within either preferred or alternative therapy.",
"    </strong>",
"    <div class=\"footnotes\">",
"     EIB: exercise-induced bronchospasm; ICS: inhaled corticosteroid; LABA: long-acting inhaled beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist; LTRA: leukotriene receptor antagonist; SABA: inhaled short-acting beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonist.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Heart, Blood, and Lung Institute Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma. NIH Publication no. 08-4051, 2007.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23160=[""].join("\n");
var outline_f22_39_23160=null;
var title_f22_39_23161="Cystitis in patients with cancer";
var content_f22_39_23161=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cystitis in patients with cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Beverly Moy, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23161/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/39/23161/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystitis is common in patients with cancer. The most serious form, hemorrhagic cystitis (HC), occurs in 10 to 40 percent of patients receiving high dose chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/1\">",
"     1",
"    </a>",
"    ]; autologous hematopoietic cell transplantation (HCT) recipients are particularly at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Severe HC is less frequent even in HCT recipients, accounting for 10 percent or less in several series; however, it can be fatal.",
"   </p>",
"   <p>",
"    Cystitis in patients with cancer can be separated into three broad categories.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cystitis can result from primary bladder cancer or adjacent cancers that encroach upon the bladder from the prostate, uterus, cervix, or rectum. These neoplasms can lead to tumor necrosis with ulceration.",
"     </li>",
"     <li>",
"      Infectious cystitis can develop since cancer patients are immunocompromised.",
"     </li>",
"     <li>",
"      HC can result directly from antineoplastic treatment. Radiation cystitis may result when the bladder is within the radiation treatment volume during treatment for pelvic neoplasms such as prostate or cervical cancer. Chemotherapy-induced cystitis can arise from agents directly instilled into the bladder as part of a treatment program for superficial cancer of the bladder or from toxic metabolites of renally excreted anti-neoplastic agents which come in contact with the bladder.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The etiologies, manifestations, and treatment of cystitis secondary to cancer treatment will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystitis is inflammation of the mucosal surface of the bladder",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ureters. Patients may experience urgency, frequent urination of small volumes, and a painful burning sensation with urination. Suprapubic pain is common; however, flank or back pain should raise the possibility of upper urinary tract disease. In men, bladder spasms often produce severe referred pain in the glans penis. Pain or lesions in the external genitalia can also be associated with herpetic disease or mucosal candidal infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with infectious cystitis, examination of the urine often demonstrates white blood cells (WBC) and a few red blood cells (RBC). However, the absence of WBC in a patient who is neutropenic following chemotherapy does not exclude a urinary tract infection. In the immunocompetent host, bacterial colony counts of greater than 100,000 in the urine are considered diagnostic of a urinary tract infection. It is not yet resolved whether this threshold should be lowered in neutropenic patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=see_link\">",
"     \"Urine sampling and culture in the diagnosis of urinary tract infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Along with routine urinalysis and bacterial culture, viral cultures, cytology and special molecular techniques may be required to demonstrate unusual pathogens in the severely immunocompromised patient (eg, after HCT). If lesions are present on the external genitalia, a smear and culture can be performed for direct fluorescence antibody detection and growth of HSV.",
"   </p>",
"   <p>",
"    Bleeding can be the most prominent manifestation in patients with HC. Severe HC can be life threatening, and assessment of hemodynamic stability is imperative. A complete blood count to assess for neutropenia, anemia, or thrombocytopenia should be performed at presentation. Serum creatinine should be measured to assess renal function. If hemorrhage is prominent, coagulation parameters such as prothrombin and activated partial thromboplastin times should be checked.",
"   </p>",
"   <p>",
"    An exhaustive history of past and present medications is important since some chemotherapeutic agents may produce cystitis years after exposure (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ). The patient should be asked about use of over the counter and non-traditional medications or preparations. Cystoscopy can confirm the diagnosis of hemorrhagic cystitis. In cases of substantial blood loss, cystoscopy also can serve to localize a bleeding source that may be amenable to fulguration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=see_link\">",
"     \"Diagnostic cystourethroscopy for gynecologic conditions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The differential diagnosis of HC includes tumor involvement of the bladder. This could be due to direct tumor invasion from adjacent structures, a local recurrence of primary bladder cancer, or a second primary arising in the bladder. Diagnostic evaluation should include appropriate radiological imaging, urine cytology, and bladder biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INFECTIOUS CYSTITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infectious agents responsible for cystitis in the cancer patient include both bacteria, which commonly cause infection in immunocompetent patients, and more unusual pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Common urinary pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typical urinary pathogens include Escherichia coli, Proteus sp., Klebsiella sp., and Staphylococcus saprophyticus. Coagulase negative staphylococci can occasionally produce cystitis in patients with indwelling bladder catheters or urinary tract pathology but are also frequent contaminants in a poorly collected specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other organisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracellular pathogens such as Mycoplasma and Ureaplasma are rare causes of cystitis in the cancer patient. HSV can cause urethritis but rarely cystitis. Candida albicans and C. glabrata have been reported to cause cystitis that is often hemorrhagic in severely immunocompromised hosts. In the United States, parasitic pathogens are distinctly uncommon. However, Schistosoma haematobium infection should be considered in patients from endemic regions such as Egypt.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer patients are treated in the same fashion for routine bacterial cystitis as other patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=see_link\">",
"     \"Acute uncomplicated cystitis and pyelonephritis in women\"",
"    </a>",
"    .) However, if fever occurs during the neutropenic period, intravenous antibiotics are warranted. Patients without symptoms referable to the urinary tract should have a thorough search for other sites of infection before ascribing the fever to cystitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=see_link\">",
"     \"Approach to the adult with asymptomatic bacteriuria\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Care should be taken to make sure antibiotic choices are compatible with the antineoplastic regimen. As an example, there are some data to suggest that the full therapeutic strength of trimethoprim-containing antibiotics may increase the myelosuppressive effects of methotrexate-containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/44/39622?source=see_link\">",
"     valacyclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/23/37238?source=see_link\">",
"     famciclovir",
"    </a>",
"    can be used in patients with genital HSV lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=see_link\">",
"     \"Treatment of genital herpes simplex virus infection\"",
"    </a>",
"    .) Cases of thrombotic thrombocytopenic purpura have been reported in HCT patients receiving valacyclovir. External mucosal candidiasis can be treated with any of the imidazole topical agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=see_link&amp;anchor=H2#H2\">",
"     \"Pharmacology of azoles\", section on 'Overview of clinical use'",
"    </a>",
"    .) Severe cases may require oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    . However, some Candida sp. are resistant or less reliably susceptible to fluconazole, such as C. krusei and C. glabrata.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HEMORRHAGIC CYSTITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most serious form of cystitis in cancer patients is HC. This is characterized by diffuse bladder mucosal inflammation with hemorrhage involving the entire bladder. The bleeding can range from minimal (5 to 50 RBC per high powered field on microscopic examination of the urine), to massive, requiring transfusion to maintain hemoglobin levels. Among patients who develop severe HC despite vigorous preventive measures, a 2 to 4 percent mortality rate has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. Disorders in hemostasis due to systemic manifestations of the cancer or its treatment (eg, thrombocytopenia or disseminated intravascular coagulation) can exacerbate bleeding in susceptible patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HC can be caused by radiation, chemotherapy, and infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Radiation cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite improved techniques in delivering ionizing radiation for the treatment of pelvic neoplasms, HC is a debilitating and potentially life-threatening complication of radiation therapy (RT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/7\">",
"     7",
"    </a>",
"    ]. Although HC has been reported to occur in up to 9 percent of patients who have received full dose RT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/8\">",
"     8",
"    </a>",
"    ], it is severe in less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/9\">",
"     9",
"    </a>",
"    ]. After the administration of pelvic radiation, the bladder mucosa is initially edematous and friable. Later, there is a progressive endarteritis which leads to tissue hypoxia, ischemia, and necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chemotherapy-induced cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various chemotherapeutic agents, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9545?source=see_link\">",
"     fludarabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/47/31478?source=see_link\">",
"     cabazitaxel",
"    </a>",
"    , can cause either non-hemorrhagic or hemorrhagic cystitis (",
"    <a class=\"graphic graphic_table graphicRef66805 \" href=\"UTD.htm?35/1/35867\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Of all the chemotherapeutic agents, the oxazaphosphorine alkylating agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    , most frequently cause HC. This complication was described shortly after the introduction of cyclophosphamide to clinical use in 1958 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/11\">",
"     11",
"    </a>",
"    ]. HC is caused by urinary excretion of acrolein, a hepatic metabolite of both cyclophosphamide and ifosfamide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/5,12\">",
"     5,12",
"    </a>",
"    ]. The incidence of HC is increased with higher individual doses, larger cumulative doses, and the use of ifosfamide as opposed to cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/13\">",
"     13",
"    </a>",
"    ]. Progressive mucosal changes can be identified in the bladder mucosa of patients receiving high cumulative doses of cyclophosphamide or prolonged treatment for longer than 36 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    During treatment, patients may develop irritative bladder symptoms or hematuria. Long term",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    use has been associated with the development of aggressive forms of transitional cell carcinoma of the urothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Both the cumulative dose of the drug and the occurrence of HC appear to increase the risk for this tumor. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder\", section on 'Chemical carcinogenesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no reports on the association of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    with bladder cancer in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;HC is commonly seen in the setting of allogeneic HCT. Early post-transplant HC (defined as occurring within 72 hours of the preparative regimen) is frequently associated with the use of high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , while later HC frequently results from viral infections, such as BK virus and adenovirus type 11 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. It is hypothesized that virally mediated HC represents reactivation of a latent form of the virus in the post-transplant period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=see_link\">",
"     \"Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=see_link\">",
"     \"Epidemiology and clinical manifestations of adenovirus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Viral HC can be dramatic in presentation but usually resolves spontaneously within less than two weeks with supportive care, including hydration and pain control. Virus culture is rarely used to detect JC and BK virus infection outside of a research setting. Cytologic examination can be used to detect urinary shedding of polyomaviruses. The most characteristic abnormality of polyomavirus-infected cells is an enlarged nucleus with a single large basophilic intranuclear inclusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Grading the severity of hemorrhagic cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several investigators and groups have used various grading schemes based upon the level of intervention required for therapy (",
"    <a class=\"graphic graphic_table graphicRef53812 \" href=\"UTD.htm?4/46/4844\">",
"     table 2",
"    </a>",
"    ). Mild HC involves only outpatient management with hydration, is transient, and does not require transfusion or clot extraction. Moderate HC requires extraction and prevention of clots with continuous bladder irrigation, cystoscopy, and instillation of astringents such as alum or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    . Severe HC requires transfusions and more intensive interventions such as formalin instillation, embolization, urinary diversion and cystectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prevention of hemorrhagic cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best treatment for HC is prevention. Effective prophylactic regimens include continuous bladder irrigation, suprahydration, and parenteral or oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    (2-mercaptoethane sodium sulfonate, a sulfhydryl compound). However, once HC is established, the optimal treatment depends upon the degree or grade of hematuria (",
"    <a class=\"graphic graphic_table graphicRef81902 \" href=\"UTD.htm?5/13/5340\">",
"     table 3",
"    </a>",
"    )&nbsp;(see",
"    <a class=\"local\" href=\"#H20\">",
"     'Treatment of hemorrhagic cystitis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Careful attention to the earliest symptoms of cystitis is important to prevent progression to more severe HC. Irritative symptoms associated with low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy should be treated promptly. Patients receiving high dose cyclophosphamide or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    should be instructed to drink at least two liters of fluid a day and to void at first sensation. Oral fluids should be ingested prior to sleep and patients should awaken once during the night to empty the bladder. Irritative symptoms alone are not a contraindication to continued cyclophosphamide therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Suprahydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effectiveness of suprahydration (intravenous normal saline at 250",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    sufficient to maintain urinary output &gt;150",
"    <span class=\"nowrap\">",
"     mL/hour)",
"    </span>",
"    was evaluated in a series of 100 consecutive patients undergoing allogeneic or autologous HCT with high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/23\">",
"     23",
"    </a>",
"    ]. In this series, HC developed in 7 percent of patients, and it was clinically significant in only two. The cost was significantly less ($20 per course) than the cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    (estimated $1500 per course).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Mesna",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     Mesna",
"    </a>",
"    has been shown to be an effective uroprotective agent in patients who receive oxazaphosphorine therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/24\">",
"     24",
"    </a>",
"    ]. Within minutes of intravenous administration, mesna is oxidized to a stable inactive disulfide in the serum but is reactivated in the kidney. In the urine, it binds to acrolein, creating an inert thioether that is excreted [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/25\">",
"     25",
"    </a>",
"    ]. The serum half-life of mesna is 90 minutes, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    have half-lives of six and seven hours, respectively. Mesna",
"    <strong>",
"     must",
"    </strong>",
"    be present in the bladder at the time of chemotherapy administration in order to be effective.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     Mesna",
"    </a>",
"    can be administered intravenously (either continuous or bolus), subcutaneously (continuous) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/26\">",
"     26",
"    </a>",
"    ], or orally.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous bolus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      typically uses a dose equal to 60 percent of the total daily dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      or high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , divided into three aliquots and administered prior to and four and eight hours following chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/27\">",
"       27",
"      </a>",
"      ]. However, administration of mesna at 100 percent of the total dose of ifosfamide and divided into two aliquots, administered prior to and four hours following treatment, was as effective and more convenient than three bolus injections of the same dose, administered four hours apart [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      With continuous infusion regimens of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      may be administered as a single bolus dose equal to 20 percent of the total ifosfamide dose, followed by continuous infusion of mesna equivalent to 40 percent of the ifosfamide dose, continuing for 12 to 24 hours after ifosfamide completion [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/29\">",
"       29",
"      </a>",
"      ]. Continuous IV administration may enhance the nephroprotective effect of mesna with ifosfamide (thought secondary to the metabolite chloroacetaldehyde) while maintaining its uroprotective effect [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral formulations of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      show sustained urinary excretion and the urinary bioavailability approaching that of IV mesna [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/31\">",
"       31",
"      </a>",
"      ]. The rate and amount of mesna excretion appears to be less variable over time and more prolonged among patients after oral than after IV administration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/32-34\">",
"       32-34",
"      </a>",
"      ]. The protective effect of combined oral and intravenous mesna appears to be equivalent to intravenous mesna alone [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/32,35\">",
"       32,35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93784309\">",
"    <span class=\"h4\">",
"     ASCO guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines are available from an expert panel of the American Society of Clinical Oncology (ASCO) regarding the use, dosing and schedule of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (originally defined as doses of 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    or 2",
"    <span class=\"nowrap\">",
"     gm/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    as administered in the setting of hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/29,36\">",
"     29,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       IV",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      &ndash; The daily dose of IV mesna is calculated to equal 60 percent of the total daily dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      , administered as three bolus doses given 15 minutes before, and four and eight hours after administration of each ifosfamide dose when the ifosfamide dose is less than 2.5",
"      <span class=\"nowrap\">",
"       G/m2",
"      </span>",
"      daily and administered as a short infusion.",
"      <br/>",
"      <br/>",
"      For regimens that employ continuous infusion ifosfamide, mesna can be administered as an initial bolus dose equal to 20 percent of the ifosfamide dose, followed by a continuous infusion of mesna equal to 40 percent of the ifosfamide dose, continuing for 12 to 24 hours after the completion of the ifosfamide infusion.",
"      <br/>",
"      <br/>",
"      The panel concluded that there was insufficient evidence to base a recommendation for the use of mesna with high dose ifosfamide (&gt;2.5",
"      <span class=\"nowrap\">",
"       G/m2",
"      </span>",
"      daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/29\">",
"       29",
"      </a>",
"      ]. However, given the longer half-life of ifosfamide with higher-dose therapy, more frequent and prolonged mesna dosage regimens may be needed.",
"     </li>",
"     <li>",
"      <strong>",
"       Oral",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"       mesna",
"      </a>",
"      &mdash; If the oral route is chosen, oral mesna is not recommended for the initial dose. Patients should receive an initial IV bolus injection of mesna equal to 20 percent of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"       ifosfamide",
"      </a>",
"      dosage at the time of ifosfamide administration, followed by oral mesna tablets at 40 percent of the daily ifosfamide dose, administered at two and six hours following each dose of ifosfamide. Thus, the total daily mesna dose is 100 percent of the ifosfamide dose when the oral route is used. This same dosing schedule is repeated on each day that ifosfamide is administered. If patients vomit within two hours of taking a dose of mesna, they should repeat the dose or receive an IV dose of mesna.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mesna versus hyperhydration or continuous bladder irrigation",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     Mesna",
"    </a>",
"    has been compared to both suprahydration and continuous bladder irrigation (CBI) for uroprotection in patients receiving high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    regimens. In a randomized trial conducted in 100 patients undergoing HCT, Mesna and forced saline diuresis were similarly effective in preventing the incidence of cyclophosphamide-induced hemorrhagic cystitis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A second prospective study compared the use of intravenous hydration plus either CBI or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    in 200 patients undergoing HCT [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/38\">",
"     38",
"    </a>",
"    ]. Patients randomized to CBI received 200",
"    <span class=\"nowrap\">",
"     mL/hr",
"    </span>",
"    of normal saline and those randomized to mesna received it by continuous intravenous infusion at 100 percent of the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    dose. The overall incidence of hematuria of any grade was significantly higher in the CBI group (76 percent) compared with the mesna group (53 percent) (p = 0.007). However, the incidence of grade 3 and 4 hematuria was the same in both groups (18 percent).",
"   </p>",
"   <p>",
"    Moderate or severe discomfort or bladder spasms were more frequent in patients receiving CBI than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    (84 versus 2 percent, p&lt;0.0001). Urinary tract infections were also more common in patients receiving CBI (27 versus 14 percent, p = 0.03). The authors concluded that CBI and mesna were equally effective in preventing severe HC but that mesna was associated with significantly less discomfort and a lower incidence of urinary tract infections.",
"   </p>",
"   <p>",
"    The 2008 ASCO expert panel on chemotherapy and radiotherapy protectants recommended that patients receiving high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in the setting of hematopoietic cell transplantation receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    in conjunction with saline diuresis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Amifostine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    is an aminothiol that is cytoprotective in several tissues, including hematopoietic progenitor cells, renal cells, myocardium, intestinal epithelium, neuronal cells, and bladder urothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. The proposed mechanism of action involves the production of an active thiol metabolite, which acts as an intracellular scavenger of free radicals.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/42/678?source=see_link\">",
"     Amifostine",
"    </a>",
"    has shown potential value for the prevention of both gastrointestinal and acute bladder toxicity from radiation. As an example, in one randomized trial, 205 patients undergoing radiation therapy for advanced pelvic malignancies were randomly assigned to daily IV amifostine (340",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    over three to five minutes daily, 15 to 30 minutes before radiation) or no amifostine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/43\">",
"     43",
"    </a>",
"    ]. The rates of &gt;grade 2 acute bladder toxicity were significantly less in the amifostine group by week 4 (14 versus 5 percent), and this difference was even more pronounced at week 7 (33 versus 0 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Superoxide dismutase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Superoxide dismutase (SOD) has been studied, with the hypothesis that intramuscular administration could permit scavenging of the singlet oxygen radicals and the superoxide ions in the extracellular space, thus preventing tissue injury. In one trial, 448 patients receiving radiotherapy to the bladder were randomized to receive orgotein (bovine SOD) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/44\">",
"     44",
"    </a>",
"    ]. The group receiving the SOD demonstrated a highly significant decrease in both acute and delayed radiation toxicity. Importantly however, there was no mention of the impact on radiation treatment efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Surveillance of patients receiving mesna",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ASCO expert panel concluded that there were insufficient data to make a recommendation regarding specific monitoring for hemorrhagic cystitis in patients receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     ifosfamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    beyond obtaining a baseline pretreatment urinalysis and monitoring for the development of hematuria and for urine output (reiterated from the 1999 guidelines) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Treatment of hemorrhagic cystitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If HC develops despite the use of preventive measures, several treatments have been applied (",
"    <a class=\"graphic graphic_table graphicRef81902 \" href=\"UTD.htm?5/13/5340\">",
"     table 3",
"    </a>",
"    ). There is no consensus as to which treatments are superior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hyperbaric oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rationale for the use of hyperbaric oxygen is that it may promote healing of hypoxic tissues and aid in angiogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of hyperbaric oxygen was initially described in patients with radiation-induced HC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/47\">",
"     47",
"    </a>",
"    ]. Most of these patients had severe inflammation requiring transfusion of RBC, but they were hemodynamically stable enough to be confined to a hyperbaric chamber under the supervision of a registered nurse without the direct presence of a clinician. All but one patient had failed prior therapy. The oxygen tension was raised slowly to two atmospheres. Each session was two hours, and 60 sessions were planned with a cystoscopic examination after 30 treatments. Twelve of 13 patients experienced durable cessation of HC. The single failure demonstrated full-thickness bladder necrosis at the time of cystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar favorable results were reported in three more contemporary series in which complete resolution or marked improvement of HC was seen in 65, 80, and 81 percent of patients, respectively, with a regimen of 100 percent oxygen at 2 to 2.5 atmospheres for 90 to 120 minutes during 20 to 40 sessions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two of the studies, outcomes appeared better when patients were treated earlier in the course of disease (ie, within six months of hematuria onset). Cystoscopies done at resolution of HC demonstrated resolution of the underlying pathology and return to normal bladder mucosa and function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. There were no side effects of hyperbaric oxygen in these reports.",
"   </p>",
"   <p>",
"    In the third report, the most common side effect of hyperbaric oxygen therapy was otalgia, seen in 33 percent of the patients, which resolved after placement of tympanostomy tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hyperbaric oxygen therapy appears to be effective but is limited to stable patients and those with access to a hyperbaric chamber.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Alum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alum is an astringent which induces hemostasis by precipitating protein over the bleeding surface. Since it has low cell permeability, its action is limited to the cell surface and interstitial spaces. In one report, continuous intravesical irrigation with 1 percent alum solution was administered to nine patients with HC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/51\">",
"     51",
"    </a>",
"    ]. Bleeding was controlled in six of nine patients without significant morbidity and without the need for an anesthetic. Posttreatment biopsy of the bladder revealed normal appearing bladder without evidence of epithelial damage.",
"   </p>",
"   <p>",
"    Alum does not produce irritative bladder symptoms and can be used safely in the presence of ureterovesical reflux. Unlike formalin instillation, systemic absorption and toxicity are less problematic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/52\">",
"     52",
"    </a>",
"    ]. However, there are six reported cases in the literature of acute aluminum toxicity in patients with renal insufficiency receiving intravesical alum irrigation for HC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/53-55\">",
"     53-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostaglandins, most notably PGE2, have a variety of effects on vascular epithelium and may encourage platelet aggregation and induce vasoconstriction. The proposed mechanism of action of PGE2 in controlling HC is that it may cause smooth muscle contractions in mucosal and submucosal blood vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The therapeutic benefit of intravesical prostaglandins was illustrated in a report of ten patients who developed HC after allogeneic HCT, thought to be associated with polyomavirus BK [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/57\">",
"     57",
"    </a>",
"    ]. PGE2 (0.75 mg in 200 mL of normal saline) was instilled into the bladder and left in situ for four hours. Treatment was repeated daily for four days or until macroscopic hematuria resolved. Elimination of gross hematuria was seen in all patients, with four of 10 cases clearing within 24 hours of initial treatment. PGE2 administration had to be stopped in one patient due to pain. Bladder spasms occurred in all patients but were controllable with antispasmodic and opioid analgesics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Formalin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formalin is a 37 percent aqueous solution of formaldehyde. Intravesical instillation of formalin has been used for many years in the treatment of intractable HC. It acts by hydrolyzing proteins and coagulating the tissue on a superficial level, controlling hemorrhage in the mucosa and submucosa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there are important drawbacks to formalin therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Instillation into the bladder is painful and requires general or regional anesthesia.",
"     </li>",
"     <li>",
"      Vesicoureteral reflux must be identified prior to treatment and ureteral reflux prevented [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/59,60\">",
"       59,60",
"      </a>",
"      ]. Reflux of formalin into the ureters can cause fibrosis, obstruction, hydronephrosis, and papillary necrosis.",
"     </li>",
"     <li>",
"      The genitalia and perineum must be protected, for example with petroleum jelly, to prevent irritation from the formalin.",
"     </li>",
"     <li>",
"      Formalin fixes the bladder, resulting in a small contracted bladder. Various schemas of treatment with low concentrations of formalin with short dwell periods have been tried to control HC without total bladder fixation. Gradual titration of concentration and dwell time may reduce bladder scarring.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Intravesical GM-CSF",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a small series of six patients with HC following high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and allogeneic HCT, the intravesical instillation of granulocyte-macrophage colony-stimulating factor (GM-CSF, 400",
"    <span class=\"nowrap\">",
"     microg/day",
"    </span>",
"    for three consecutive days) controlled hematuria completely in three and partially in three [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Conjugated estrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies suggest that conjugated estrogens are a simple and effective treatment option for HC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/62-64\">",
"     62-64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the initial series, five patients with HC who received oral conjugated estrogens remained free of hematuria at 12 to 22 months of follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a second report, five of seven patients with severe HC who received oral conjugated estrogen had complete resolution of HC during estrogen therapy and one patient had a sufficient response to preclude further transfusion [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a third retrospective review of patients undergoing high dose therapy and HCT, seven of 10 treated patients had resolution of hematuria, but treatment was stopped due to hepatotoxicity in one patient and two did not respond [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism of action of conjugated estrogens for the treatment of HC is unclear. Based upon the appearance of bladder mucosa between the time of the initial episode and remission after treatment, estrogens may have an effect on the capillary wall resulting in decreased vascular fragility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Pentosan polysulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"     Pentosan polysulfate",
"    </a>",
"    is a low-molecular weight heparin-like compound with anticoagulant and fibrinolytic effects, which has been approved for the treatment of interstitial cystitis. In multiple series, oral pentosan has been effective in controlling hematuria in both radiation and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    -induced HC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/65-67\">",
"     65-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 14 patients with HC following radiotherapy, treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"       pentosan polysulfate",
"      </a>",
"      resulted in complete control of hematuria in 10 patients, while three had partial control [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"       pentosan polysulfate",
"      </a>",
"      (100 mg three times a day) was used as the primary management for 60 patients with HC associated with pelvic radiotherapy or systemic chemotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/66\">",
"       66",
"      </a>",
"      ]. In 31 of 51 evaluable patients, pentosan polysulfate was eventually discontinued or the dose reduced without recurrence of hematuria.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Local interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;When other interventions fail, vascular embolization or surgical intervention may be necessary. Most patients who reach this stage are hemodynamically unstable with life-threatening hemorrhage.",
"   </p>",
"   <p>",
"    Successful management of severe hemorrhagic cystitis using selective embolization of the vesical or internal iliac arteries has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. Rarely, surgical procedures are needed to divert the urinary stream and control hemorrhage. The available options include an ileal conduit, cystectomy, ileo-cystoplasty, placement of percutaneous nephrostomy tubes, ligation of the hypogastric arteries, cutaneous ureterostomy, and ureterosigmoidostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/70-73\">",
"     70-73",
"    </a>",
"    ]. Others have described the successful use of fibrin glue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23161/abstract/74,75\">",
"     74,75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     BCG IMMUNOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravesical Bacillus Calmette-Guerin (BCG) is widely used in the management of superficial transitional cell carcinoma of the bladder. The most common side effect of intravesical BCG is cystitis, which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31096?source=see_link&amp;anchor=H5#H5\">",
"     \"Complications of intravesical BCG immunotherapy\", section on 'Localized disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cystitis in the cancer patient can result from infections or as a complication of chemotherapy or radiation. The most serious form of cystitis, HC, can be life threatening. After stabilization of hemodynamic parameters and an appropriate diagnostic evaluation, there are several treatment options to consider.",
"   </p>",
"   <p>",
"    The best treatment for HC is prevention, utilizing suprahydration or prophylactic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/0/41989?source=see_link\">",
"     mesna",
"    </a>",
"    therapy. However, once hemorrhagic cystitis is established, the mode of treatment depends upon the severity of hematuria (",
"    <a class=\"graphic graphic_table graphicRef81902 \" href=\"UTD.htm?5/13/5340\">",
"     table 3",
"    </a>",
"    ). Each therapeutic option has limitations, and the choice should be individualized for each patient.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/1\">",
"      Watson NA, Notley RG. Urological complications of cyclophosphamide. Br J Urol 1973; 45:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/2\">",
"      Ilhan O, Ko&ccedil; H, Akan H, et al. Hemorrhagic cystitis as a complication of bone marrow transplantation. J Chemother 1997; 9:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/3\">",
"      Efros MD, Ahmed T, Coombe N, Choudhury MS. Urologic complications of high-dose chemotherapy and bone marrow transplantation. Urology 1994; 43:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/4\">",
"      Steuer A, Gumpel JM. Methotrexate and trimethoprim: a fatal interaction. Br J Rheumatol 1998; 37:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/5\">",
"      PHILIPS FS, STERNBERG SS, CRONIN AP, VIDAL PM. Cyclophosphamide and urinary bladder toxicity. Cancer Res 1961; 21:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/6\">",
"      Russo P. Urologic emergencies in the cancer patient. Semin Oncol 2000; 27:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/7\">",
"      Crook J, Esche B, Futter N. Effect of pelvic radiotherapy for prostate cancer on bowel, bladder, and sexual function: the patient's perspective. Urology 1996; 47:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/8\">",
"      deVries CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol 1990; 143:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/9\">",
"      Eifel PJ, Levenback C, Wharton JT, Oswald MJ. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1995; 32:1289.",
"     </a>",
"    </li>",
"    <li>",
"     Williams JA, Clarke D. Pelvic radiation necrosis and radiation cystitis. In: Hyperbaric Medicine Practice, Kindwall EP (Ed), Best Publishing, Arizona 1994. p.505.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/11\">",
"      Arnold H, Bourseaux F, Brock N. Neuartige Krebs-Chemotherapeutika aus der Gruppe der zyklischen N-Lost-Phosphamidester. Naturwissen-Schaften 1958; 45:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/12\">",
"      Cox PJ. Cyclophosphamide cystitis and bladder cancer. A hypothesis. Eur J Cancer 1979; 15:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/13\">",
"      Brade WP, Herdrich K, Varini M. Ifosfamide--pharmacology, safety and therapeutic potential. Cancer Treat Rev 1985; 12:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/14\">",
"      Kimura M, Tomita Y, Morishita H, Takahashi K. Presence of mucosal change in the urinary bladder in nonhematuric patients with long-term exposure and/or accumulating high-dose cyclophosphamide. Possible significance of follow-up cystoscopy on preventing development of cyclophosphamide-induced hemorrhagic cystitis. Urol Int 1998; 61:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/15\">",
"      Fernandes ET, Manivel JC, Reddy PK, Ercole CJ. Cyclophosphamide associated bladder cancer--a highly aggressive disease: analysis of 12 cases. J Urol 1996; 156:1931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/16\">",
"      Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 1996; 124:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/17\">",
"      Travis LB, Curtis RE, Glimelius B, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995; 87:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/18\">",
"      Rice SJ, Bishop JA, Apperley J, Gardner SD. BK virus as cause of haemorrhagic cystitis after bone marrow transplantation. Lancet 1985; 2:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/19\">",
"      Miyamura K, Takeyama K, Kojima S, et al. Hemorrhagic cystitis associated with urinary excretion of adenovirus type 11 following allogeneic bone marrow transplantation. Bone Marrow Transplant 1989; 4:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/20\">",
"      Ambinder RF, Burns W, Forman M, et al. Hemorrhagic cystitis associated with adenovirus infection in bone marrow transplantation. Arch Intern Med 1986; 146:1400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/21\">",
"      Traystman MD, Gupta PK, Shah KV, et al. Identification of viruses in the urine of renal transplant recipients by cytomorphology. Acta Cytol 1980; 24:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/22\">",
"      Kahan AV, Coleman DV, Koss LG. Activation of human polyomavirus infection-detection by cytologic technics. Am J Clin Pathol 1980; 74:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/23\">",
"      Ballen KK, Becker P, Levebvre K, et al. Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients. Oncology 1999; 57:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/24\">",
"      Andriole GL, Sandlund JT, Miser JS, et al. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. J Clin Oncol 1987; 5:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/25\">",
"      Brock N, Pohl J. The development of mesna for regional detoxification. Cancer Treat Rev 1983; 10 Suppl A:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/26\">",
"      Markman M, Kennedy A, Webster K, et al. Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis. Semin Oncol 1996; 23:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/27\">",
"      Siu LL, Moore MJ. Use of mesna to prevent ifosfamide-induced urotoxicity. Support Care Cancer 1998; 6:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/28\">",
"      Katz A, Epelman S, Anelli A, et al. A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 1995; 121:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/29\">",
"      Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/30\">",
"      Hilgard P, Burkert H. Sodium-2-mercaptoethanesulfonate (MESNA) and ifosfamide nephrotoxicity. Eur J Cancer Clin Oncol 1984; 20:1451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/31\">",
"      Goren MP, Houle JM, Bush DA, et al. Similar bioavailability of single-dose oral and intravenous mesna in the blood and urine of healthy human subjects. Clin Cancer Res 1998; 4:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/32\">",
"      Goren MP, Anthony LB, Hande KR, et al. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide. J Clin Oncol 1998; 16:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/33\">",
"      Goren MP, McKenna LM, Goodman TL. Combined intravenous and oral mesna in outpatients treated with ifosfamide. Cancer Chemother Pharmacol 1997; 40:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/34\">",
"      Stofer-Vogel B, Cerny T, Borner M, Lauterburg BH. Oral bioavailability of mesna tablets. Cancer Chemother Pharmacol 1993; 32:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/35\">",
"      Mace JR, Keohan ML, Bernardy H, et al. Crossover randomized comparison of intravenous versus intravenous/oral mesna in soft tissue sarcoma treated with high-dose ifosfamide. Clin Cancer Res 2003; 9:5829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/36\">",
"      Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants. J Clin Oncol 1999; 17:3333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/37\">",
"      Shepherd JD, Pringle LE, Barnett MJ, et al. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 1991; 9:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/38\">",
"      Vose JM, Reed EC, Pippert GC, et al. Mesna compared with continuous bladder irrigation as uroprotection during high-dose chemotherapy and transplantation: a randomized trial. J Clin Oncol 1993; 11:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/39\">",
"      Capizzi RL. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences. Semin Oncol 1994; 21:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/40\">",
"      Foster-Nora JA, Siden R. Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm 1997; 54:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/41\">",
"      Dorr RT. Cytoprotective agents for anthracyclines. Semin Oncol 1996; 23:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/42\">",
"      Srivastava A, Nair SC, Srivastava VM, et al. Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis. Bone Marrow Transplant 1999; 23:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/43\">",
"      Athanassiou H, Antonadou D, Coliarakis N, et al. Protective effect of amifostine during fractionated radiotherapy in patients with pelvic carcinomas: results of a randomized trial. Int J Radiat Oncol Biol Phys 2003; 56:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/44\">",
"      Sanchiz F, Mill&aacute; A, Artola N, et al. Prevention of radioinduced cystitis by orgotein: a randomized study. Anticancer Res 1996; 16:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/45\">",
"      Neovius EB, Lind MG, Lind FG. Hyperbaric oxygen therapy for wound complications after surgery in the irradiated head and neck: a review of the literature and a report of 15 consecutive patients. Head Neck 1997; 19:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/46\">",
"      Cianci P, Sato R. Adjunctive hyperbaric oxygen therapy in the treatment of thermal burns: a review. Burns 1994; 20:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/47\">",
"      Weiss JP, Boland FP, Mori H, et al. Treatment of radiation-induced cystitis with hyperbaric oxygen. J Urol 1985; 134:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/48\">",
"      Mathews R, Rajan N, Josefson L, et al. Hyperbaric oxygen therapy for radiation induced hemorrhagic cystitis. J Urol 1999; 161:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/49\">",
"      Chong KT, Hampson NB, Corman JM. Early hyperbaric oxygen therapy improves outcome for radiation-induced hemorrhagic cystitis. Urology 2005; 65:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/50\">",
"      Oliai C, Fisher B, Jani A, et al. Hyperbaric oxygen therapy for radiation-induced cystitis and proctitis. Int J Radiat Oncol Biol Phys 2012; 84:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/51\">",
"      Goel AK, Rao MS, Bhagwat AG, et al. Intravesical irrigation with alum for the control of massive bladder hemorrhage. J Urol 1985; 133:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/52\">",
"      Ostroff EB, Chenault OW Jr. Alum irrigation for the control of massive bladder hemorrhage. J Urol 1982; 128:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/53\">",
"      Perazella M, Brown E. Acute aluminum toxicity and alum bladder irrigation in patients with renal failure. Am J Kidney Dis 1993; 21:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/54\">",
"      Murphy CP, Cox RL, Harden EA, et al. Encephalopathy and seizures induced by intravesical alum irrigations. Bone Marrow Transplant 1992; 10:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/55\">",
"      Seear MD, Dimmick JE, Rogers PC. Acute aluminum toxicity after continuous intravesical alum irrigation for hemorrhagic cystitis. Urology 1990; 36:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/56\">",
"      Levine LA, Kranc DM. Evaluation of carboprost tromethamine in the treatment of cyclophosphamide-induced hemorrhagic cystitis. Cancer 1990; 66:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/57\">",
"      Laszlo D, Bosi A, Guidi S, et al. Prostaglandin E2 bladder instillation for the treatment of hemorrhagic cystitis after allogeneic bone marrow transplantation. Haematologica 1995; 80:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/58\">",
"      Shrom SH, Donaldson MH, Duckett JW, Wein AJ. Formalin treatment for intractable hemorrhagic cystitis: a review of the literature with 16 additional cases. Cancer 1976; 38:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/59\">",
"      Fair WR. Formalin in the treatment of massive bladder hemorrhage. Techniques, results, and complications. Urology 1974; 3:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/60\">",
"      Gottesman J, Ehrlich RM. Preventing vesicoureteral reflux during intravesical formalin instillation. Urology 1974; 3:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/61\">",
"      Vela-Ojeda J, Tripp-Villanueva F, Sanchez-Cort&eacute;s E, et al. Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant. Bone Marrow Transplant 1999; 24:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/62\">",
"      Liu YK, Harty JI, Steinbock GS, et al. Treatment of radiation or cyclophosphamide induced hemorrhagic cystitis using conjugated estrogen. J Urol 1990; 144:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/63\">",
"      Miller J, Burfield GD, Moretti KL. Oral conjugated estrogen therapy for treatment of hemorrhagic cystitis. J Urol 1994; 151:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/64\">",
"      Ordemann R, Naumann R, Geissler G, et al. Encouraging results in the treatment of haemorrhagic cystitis with estrogen - report of 10 cases and review of the literature. Bone Marrow Transplant 2000; 25:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/65\">",
"      Hampson SJ, Woodhouse CR. Sodium pentosanpolysulphate in the management of haemorrhagic cystitis: experience with 14 patients. Eur Urol 1994; 25:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/66\">",
"      Sandhu SS, Goldstraw M, Woodhouse CR. The management of haemorrhagic cystitis with sodium pentosan polysulphate. BJU Int 2004; 94:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/67\">",
"      Toren PJ, Norman RW. Cyclophosphamide induced hemorrhagic cystitis successfully treated with pentosanpolysulphate. J Urol 2005; 173:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/68\">",
"      Han Y, Wu D, Sun A, et al. Selective embolization of the internal iliac arteries for the treatment of severe hemorrhagic cystitis following hematopoietic SCT. Bone Marrow Transplant 2008; 41:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/69\">",
"      Gin&eacute; E, Rovira M, Real I, et al. Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant 2003; 31:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/70\">",
"      Noe HN, McSwain HM. Management of severe reflux in the patient with cyclophosphamide cystitis. J Urol 1983; 130:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/71\">",
"      Marsh FP, Vince FP, Pollock DJ, Blandy JP. Cyclophosphamide necrosis of bladder causing calcification, contracture and reflux; treated by colocystoplasty. Br J Urol 1971; 43:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/72\">",
"      Pomer S, Karcher G, Simon W. Cutaneous ureterostomy as last resort treatment of intractable haemorrhagic cystitis following radiation. Br J Urol 1983; 55:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/73\">",
"      Golin AL, Benson RC Jr. Cyclophosphamide hemorrhagic cystitis requiring urinary diversion. J Urol 1977; 118:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/74\">",
"      Tirindelli MC, Flammia G, Sergi F, et al. Fibrin glue for refractory hemorrhagic cystitis after unrelated marrow, cord blood, and haploidentical hematopoietic stem cell transplantation. Transfusion 2009; 49:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23161/abstract/75\">",
"      Ouwenga MK, Langston MD, Campbell SC. Use of fibrin sealant in recalcitrant hemorrhagic cystitis. J Urol 2004; 172:1348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2829 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23161=[""].join("\n");
var outline_f22_39_23161=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INFECTIOUS CYSTITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Common urinary pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other organisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HEMORRHAGIC CYSTITIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Radiation cystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chemotherapy-induced cystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Grading the severity of hemorrhagic cystitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prevention of hemorrhagic cystitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Suprahydration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Mesna",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93784309\">",
"      ASCO guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mesna versus hyperhydration or continuous bladder irrigation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Amifostine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Superoxide dismutase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Surveillance of patients receiving mesna",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Treatment of hemorrhagic cystitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hyperbaric oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Alum",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Formalin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Intravesical GM-CSF",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Conjugated estrogens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Pentosan polysulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Local interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      BCG IMMUNOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2829\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2829|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/1/35867\" title=\"table 1\">",
"      Hemorrhagic cystitis drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/46/4844\" title=\"table 2\">",
"      RTOG LENT criteria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/13/5340\" title=\"table 3\">",
"      Hemorrhagic cystitis treatment",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/15/13561?source=related_link\">",
"      Acute uncomplicated cystitis and pyelonephritis in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/19/42295?source=related_link\">",
"      Approach to the adult with asymptomatic bacteriuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/7/44151?source=related_link\">",
"      Clinical manifestations and diagnosis of JC, BK, and other polyomavirus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31096?source=related_link\">",
"      Complications of intravesical BCG immunotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29592?source=related_link\">",
"      Diagnostic cystourethroscopy for gynecologic conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/21/39257?source=related_link\">",
"      Epidemiology and clinical manifestations of adenovirus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26586?source=related_link\">",
"      Epidemiology and etiology of urothelial (transitional cell) carcinoma of the bladder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/4/36938?source=related_link\">",
"      Pharmacology of azoles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/32/7690?source=related_link\">",
"      Treatment of genital herpes simplex virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/41/24214?source=related_link\">",
"      Urine sampling and culture in the diagnosis of urinary tract infection in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_39_23162="Endothelial dysfunction";
var content_f22_39_23162=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endothelial dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23162/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23162/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23162/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23162/contributors\">",
"     Juan Carlos Kaski, MD, DM, DSc, FRCP, FESC, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/39/23162/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/39/23162/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/39/23162/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endothelium has been considered an inert barrier to elements contained in the blood. However, evidence indicates that the endothelium is an active biologic interface between the blood and all other tissues. The single layer of continuous endothelium lining arteries and veins forms a unique thromboresistant layer between blood and potentially thrombogenic subendothelial tissues. The endothelium also modulates tone, growth, hemostasis, and inflammation throughout the circulatory system. Importantly, an excessive inflammatory and fibroproliferative response to the number of insults to the vascular endothelium is important in the development of atherosclerosis.",
"   </p>",
"   <p>",
"    Endothelial dysfunction is seen in a variety of pathological conditions in addition to atherosclerosis, including hypercholesterolemia, diabetes, hypertension, heart failure, cigarette smoking, and aging. What follows is a discussion of normal endothelial physiology, the association between endothelial dysfunction and atherosclerosis, the evaluation of endothelial function with brachial ultrasound, clinical implications of endothelial dysfunction, and possible therapies for improving endothelial function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDOTHELIAL PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Under basal conditions, the endothelium functions to maintain the vessel in a relatively dilated state. However, the endothelium has the capacity to respond to various physical stimuli, such as shear stress. Blood vessels dilate in response to shear stress, a process called flow-mediated vasodilation (FMD); measurement of FMD is a clinical method for evaluating endothelial function. This endothelial-dependent response is principally regulated by release of nitric oxide (NO) from the endothelium. NO is synthesized from the amino acid L-arginine by endothelial nitric oxide synthase (eNOS) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The FMD response in a variety of arterial vessels is abolished with an eNOS inhibitor. For example, plasma asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, impairs the ability of NO to dilate vessels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. There is, however, redundancy in effectors of the endothelial-dependent vasodilatory response, as genetically engineered mice that lack the eNOS enzyme (eNOS knockout mice) still respond to shear stress by dilating [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/5\">",
"     5",
"    </a>",
"    ]. In these eNOS knockout mice, dilation is thought to be facilitated by prostanoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ASSOCIATION WITH ATHEROSCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The endothelial dysfunction induced by dyslipidemia is an initial step in atherosclerosis (",
"    <a class=\"graphic graphic_table graphicRef56643 \" href=\"UTD.htm?0/50/812\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/6\">",
"     6",
"    </a>",
"    ]. Among patients with normal or minimally diseased coronary vessels, a positive family history of coronary artery disease is an important predictor of impaired coronary artery blood flow regulation, which represents coronary endothelial dysfunction in the microcirculation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=see_link\">",
"     \"The coronary microcirculation in disease states\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The association with family history is independent of other well established risk factors; however, a positive family history aggravates the endothelial dysfunction associated with hypercholesterolemia and age, suggesting additive effects of genetic and environmental risk factors. One study of young patients with coronary disease found that endothelial dysfunction is also present in a peripheral vessel, suggesting that it is a diffuse process that is not only confined to an atherosclerotic vessel [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial dysfunction and impaired vascular reactivity, perhaps representing early large vessel disease, have also been documented in the following groups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Asymptomatic young adults with a family history of premature coronary disease but no other risk factors [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In those with mild to moderate hypertriglyceridemia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In smokers with or without hypercholesterolemia.",
"     </li>",
"     <li>",
"      In overweight (body mass index 25 to 30) and obese subjects (body mass index &gt;30) with normal or mildly diseased coronary arteries [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hyperinsulinemia and insulin resistant states [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/12,13\">",
"       12,13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normal first degree relatives of patients with type 2 diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/14\">",
"       14",
"      </a>",
"      ], and in patients who have insulin dependent diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. The degree of impairment is related to the duration of diabetes and poor hyperglycemic control and it can be improved with insulin treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/17\">",
"       17",
"      </a>",
"      ]. Autonomic dysfunction and altered neurotransmission may be an important determinant of vascular reactivity [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with angina pectoris with normal coronary arteries (syndrome X) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=see_link\">",
"       \"Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Advancing age is also associated with progressive impairment of endothelium-dependent vasodilation of coronary vessels; the age-related endothelial dysfunction may contribute to the increased risk of atherosclerosis with aging [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/20,21\">",
"       20,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A brief period of mental stress, similar to that occurring in everyday life, can cause transient endothelial dysfunction in young healthy individuals without evidence of vascular disease or risk factors for cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. The endothelial dysfunction appears to be mediated by endothelin, since it can be prevented by a selective endothelin-A receptor antagonist [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/23\">",
"       23",
"      </a>",
"      ], and lasts for as long as one to four hours [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/22,23\">",
"       22,23",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25528?source=see_link\">",
"       \"Psychosocial factors in coronary and cerebral vascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction is associated with high oxidative stress and fueled by oxidized low density lipoproteins (LDL), which influences monocyte adhesion and migration into the subendothelial space, modification into macrophages, and the ensuing formation of foam cells. It has been observed that there is a close association between endothelial dysfunction and plasma levels of adhesion molecules [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Abnormal nitric oxide metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced synthesis and release of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/25,26\">",
"     25,26",
"    </a>",
"    ], which is associated with less inhibition of platelet aggregation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/27\">",
"     27",
"    </a>",
"    ], may be an important contributor to endothelial dysfunction. The following mechanisms have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The reduction in NO may result from decreased availability of tetrahydrobiopterin, an essential cofactor for the synthesis of NO; the administration of sepiapterin, a substrate for tetrahydrobiopterin, can improve endothelial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Elevated levels of asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of NO synthase, also may contribute [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Oxidized LDL increases the elaboration of ADMA by endothelial cells and decreases its degradation by the enzyme dimethylarginine dimethylaminohydrolase [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/4,29\">",
"       4,29",
"      </a>",
"      ]. Elevated ADMA is a risk factor for coronary events in patients with and without a prior history of coronary heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/4,30\">",
"       4,30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1269197#H1269197\">",
"       \"Overview of the possible risk factors for cardiovascular disease\", section on 'Asymmetrical dimethylarginine'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      High levels of cholesterol increase endothelial production of oxygen free radicals, which may bind to and inactivate NO [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/31\">",
"       31",
"      </a>",
"      ]. The overproduction of oxygen free radicals may be due to impaired NO synthase, which is induced by a decreased uptake of L-arginine that is caused by native and oxidized LDL [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/32\">",
"       32",
"      </a>",
"      ]. Another mechanism for the increase in free radicals in patients with coronary heart disease is a reduction in the activity of extracellular superoxide dismutase, the major antioxidant enzyme system of the vessel wall [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among patients with heart failure, the reduction in the synthesis of NO may result from marked depression of L-arginine transported by endothelial cells, resulting in depletion in the intracellular substrate for NO synthase [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Impaired availability of nitric oxide (NO) may directly facilitate the development of coronary ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/25\">",
"     25",
"    </a>",
"    ]. It could also contribute to the abnormal coronary vascular reactivity that has been induced in humans undergoing coronary angiography by exposure to cold, mental arithmetic, and recall of anger [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Coronary arteriograms show abnormal vasoconstriction with acetylcholine (an endothelium-dependent vasodilator) followed by the restoration of vasodilation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    (an endothelium-independent vasodilator) in patients with coronary disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef52009 graphicRef63805 graphicRef77577 \" href=\"UTD.htm?12/56/13191\">",
"     image 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Patients with atherosclerosis and endothelial dysfunction also may have a reduced endothelial response to exogenous sources of NO, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , indicating concomitant endothelium-independent smooth muscle dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Role of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection and the resulting inflammatory response can produce endothelial dysfunction. The following observations support this relationship:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an animal model, repeated infections with Chlamydia pneumoniae infection resulted in endothelial dysfunction via impaired NO availability [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/38\">",
"       38",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25160?source=see_link\">",
"       \"Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      An acute inflammatory response in normal subjects, as produced by Salmonella typhi vaccine, can produce transient but profound endothelial dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/39\">",
"       39",
"      </a>",
"      ]. In patients with coronary heart disease, an elevated serum level of C-reactive protein, a marker of chronic inflammation, is an independent predictor of endothelial dysfunction (",
"      <a class=\"graphic graphic_algorithm graphicRef67335 \" href=\"UTD.htm?20/17/20767\">",
"       algorithm 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/40\">",
"       40",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"       \"Acute phase reactants\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=see_link\">",
"       \"C-reactive protein in cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of 31 Helicobacter pylori positive patients with dyspepsia, severe endothelial dysfunction, as assessed by vascular measurements (ankle brachial index and flow-mediated diameter percent change), was present before triple antibiotic treatment and improved significantly after [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/41\">",
"       41",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=see_link\">",
"       \"Association between Helicobacter pylori infection and duodenal ulcer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;External radiation therapy, commonly used as a primary and adjunctive therapy in patients with cancer, can cause endothelial dysfunction in arteries exposed to radiation. Irradiation results in endothelial cell death and reduces the availability of nitric oxide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anthracycline chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/15/43254?source=see_link\">",
"     daunorubicin",
"    </a>",
"    in children impairs endothelial reactivity, as assessed by brachial artery ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/43\">",
"     43",
"    </a>",
"    ]. The mechanism of endothelial dysfunction due to chemotherapy is not clear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Microparticles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shed membrane apoptotic microparticles are produced in considerable amounts within human atherosclerotic plaques; they carry almost all tissue factor activity of the lipid core, largely determining plaque thrombogenicity. High levels of these procoagulant endothelial microparticles are found in the circulating blood of patients presenting with an unstable coronary syndrome. In one preliminary report, microparticles from patients with a myocardial infarction (MI), but not from nonischemic controls, selectively impaired the production of NO, resulting in severe endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/44\">",
"     44",
"    </a>",
"    ]. However, this is an area that is still undergoing investigation and the clinical significance of this observation is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36009?source=see_link&amp;anchor=H1854880#H1854880\">",
"     \"The endothelium: A primer\", section on 'Microparticles'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Endothelial progenitor cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that bone marrow-derived circulating endothelial progenitor cells (EPCs) have a role in endothelial repair, and that impaired mobilization or depletion of these cells can lead to cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. Consistent with this hypothesis is the observation in 45 middle-aged men with no history of cardiovascular disease of an inverse relation between the number of circulating EPCs and the degree of endothelial dysfunction and the Framingham risk factor score [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=see_link&amp;anchor=H1269190#H1269190\">",
"     \"Overview of the possible risk factors for cardiovascular disease\", section on 'Endothelial progenitor cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The definition of EPCs is somewhat controversial, as these progenitor cells have varying cell surface markers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following have been shown to increase mobilization of EPCs from the marrow into the circulation: statins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/48\">",
"     48",
"    </a>",
"    ], erythropoietin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/49\">",
"     49",
"    </a>",
"    ] and erythropoietin analogues and exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/50\">",
"     50",
"    </a>",
"    ]. The release of these EPCs is controlled by circadian clock genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16028800\">",
"    <span class=\"h2\">",
"     Genetics of endothelial function",
"    </span>",
"    &nbsp;&mdash;&nbsp;One gene that regulates endothelial function is the circadian clock gene Period2 (Per2). Mutation of the Per2 gene in mice is associated with aortic endothelial dysfunction, in the context of decreased production of nitric oxide and vasodilatory prostaglandins along with increased release of cyclooxygenase-1-derived vasoconstrictors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     BRACHIAL ARTERY ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Brachial artery ultrasound imaging during reactive hyperemia is a tool for quantifying endothelium-dependent vasomotion and establishing the presence of endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Impaired vasomotion (endothelial dysfunction) has a potential role as a screening tool, particularly to exclude coronary heart disease.",
"   </p>",
"   <p>",
"    There is some evidence that endothelial dysfunction on brachial artery ultrasound imaging may correlate with endothelial dysfunction noted on coronary angiography after acetylcholine injection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/55\">",
"     55",
"    </a>",
"    ]. Why this might occur is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pretest issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several possible confounding factors that can affect flow-mediated vasodilation, including sympathetic stimuli, food, drugs, and temperature; the phase of a woman's menstrual cycle may also affect FMD. In order to control for these factors, patients are asked to fast for at least eight hours before the study, which is conducted in a quiet, temperature-controlled room. Most protocols involve withholding vasoactive medications at least four half-lives before the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Ultrasound machine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available ultrasound machines can be used to image the brachial artery. A high-frequency vascular transducer (7 MHz) is typically used to acquire images with sufficient resolution for analysis. The diameter of the brachial artery oscillates with the cardiac cycle and thus, simultaneous ECG recording is obtained in order to analyze images with respect to the QRS complex.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Ultrasound protocol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects are in a supine position, with the arm outstretched; the brachial artery is imaged above the antecubital fossa in the longitudinal plane. The technician records a baseline 2D gray scale image, usually on super VHS videotape, although digital acquisition software can also be used. Pulse wave Doppler blood flow velocity is then calculated from a mid artery sample volume. Thereafter, a blood pressure cuff is inflated to at least 50 mm above systolic pressure to occlude arterial inflow, typically for five minutes. The blood pressure cuff is then deflated, resulting in reactive hyperemia, which causes an increase in sheer stress and dilation of the brachial artery. A pulse Doppler signal in the mid artery is again obtained, no later than 15 seconds after cuff deflation, to assess the hyperemic response. The maximum dilation of the vessel usually occurs within one to two minutes after cuff release (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50270 \" href=\"UTD.htm?17/2/17443\">",
"     image 2",
"    </a>",
"    ). The ultrasound image is recorded for approximately five minutes after cuff deflation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     Nitroglycerin",
"    </a>",
"    is often given after the hyperemic phase in order to evaluate endothelium-independent vasodilation. Nitroglycerin, given either sublingually (0.4 mg) or with a spray, is typically administered after at least 10 minutes of rest following reactive hyperemia. The maximum vasodilation due to nitroglycerin occurs three to four minutes after administration and images are usually recorded during this time frame. This technique is relatively difficult to master for the technician and potential pit falls should be considered as outlined in a technique report from the American College of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16028819\">",
"    <span class=\"h2\">",
"     Peripheral artery tonometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral artery tonometry (PAT) is a method to evaluate vascular response in a digital (finger). Poorer responses have been noted in relation to the presence of selected cardiovascular risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/56\">",
"     56",
"    </a>",
"    ]. When compared to findings with brachial artery ultrasound, there was no significant correlation, indicating PAT provides distinct information [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CLINICAL USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fact that endothelial dysfunction is seen in the early phases of atherosclerosis has a number of important clinical implications. Its presence or absence is useful for establishing the diagnosis and prognosis of coronary heart disease, for predicting the development of transplant vasculopathy, and for risk stratification prior to vascular surgery. However, evaluation of endothelial function is not currently used in clinical practice as it is a technically challenging study and more data are needed regarding clinical utility in the evaluation and modification of cardiovascular risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Low to intermediate risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;As indicated above, endothelial dysfunction is seen in patients with conditions that are associated with the development of peripheral atherosclerosis and coronary artery disease, such as lipid disorders, hypertension, diabetes, cigarette smoking, family history of premature coronary disease, and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/9-18,20,21,59\">",
"     9-18,20,21,59",
"    </a>",
"    ]. This suggests that the presence of endothelial dysfunction may be predictive of the either the presence or development of subclinical atherosclerotic cardiovascular disease in at-risk patients. The following are two examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 94 patients with risk factors for coronary heart disease in whom brachial artery ultrasound and exercise radionuclide myocardial perfusion imaging were performed, the presence of endothelial dysfunction had a high sensitivity (91 percent) for coronary heart disease, while its absence had a high negative predictive value (95 percent) (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50270 \" href=\"UTD.htm?17/2/17443\">",
"       image 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 213 nonsmoking, middle-aged, low to intermediate cardiovascular risk (no clinical cardiovascular disease or diabetes), asymptomatic individuals, risk factors, carotid intima-media thickness (cIMT), and brachial artery flow mediated dilatation (FMD) were measured at baseline [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/61\">",
"       61",
"      </a>",
"      ]. After 6.2 years, worse baseline FMD, even after taking into account underlying risk factors, was associated with a significantly greater average annual progression of cIMT.",
"     </li>",
"     <li>",
"      In a nested case-cohort study of individuals free of cardiovascular disease at baseline in the Multi-Ethnic Study of Atherosclerosis (2843 participants and 182 cases), abnormal baseline brachial artery FMD was significantly and inversely predictive of incident cardiovascular events at five years [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/62\">",
"       62",
"      </a>",
"      ]. While this finding was independent of other major cardiovascular risk factors, FMD did not provide incremental discrimination to the Framingham risk score.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Higher-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of small studies in which there were a small number of cardiovascular events have suggested a correlation between coronary endothelial dysfunction (as usually tested by intracoronary acetylcholine) and cardiovascular events in patients with [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/63-65\">",
"     63-65",
"    </a>",
"    ] and without coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/65\">",
"     65",
"    </a>",
"    ]. One report, for example, evaluated 157 patients with mild nonobstructive coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/63\">",
"     63",
"    </a>",
"    ]. The 83 patients with severe coronary endothelial dysfunction had an increased incidence of cardiac events, including cardiac death, MI, or revascularization (14 versus 0 percent for those with no or mild endothelial dysfunction).",
"   </p>",
"   <p>",
"    In a second series of 147 patients, 57 percent of whom had angiographic evidence of coronary heart disease, impaired endothelium-dependent and endothelium-independent coronary vasoreactivity were associated, at a median follow-up of 7.7 years, with a significantly higher incidence of cardiovascular events, including death, unstable angina, MI, or revascularization (",
"    <a class=\"graphic graphic_figure graphicRef74218 \" href=\"UTD.htm?15/10/15535\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/64\">",
"     64",
"    </a>",
"    ]. The predictive value of impaired endothelium-independent vasodilation was not confirmed in a third study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial function was evaluated in 819 subjects with metabolic syndrome. The subjects with both metabolic syndrome and endothelial dysfunction on brachial artery ultrasound testing were at higher risk for cardiovascular events than those with either one alone [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognostic role of endothelial evaluation with brachial artery ultrasound testing was prospectively evaluated in 172 hypertensive subjects. After a mean follow-up of 95, a first nonfatal or fatal cardiovascular event occurred significantly more often in those below the median value for flow mediated vasodilatation than those above it [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Transplant vasculopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction is also associated with the development of transplant vasculopathy. In a study of 73 patients who underwent heart transplantation, the presence of endothelial dysfunction predicted the development of clinical end points, including angiographic vasculopathy or cardiac death (graft failure or sudden death) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/68\">",
"     68",
"    </a>",
"    ]. The presence of endothelial dysfunction had a sensitivity, specificity, and positive and negative predictive value of 100, 54, 31, and 100 percent, respectively, for the development of vasculopathy or cardiac death. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=see_link\">",
"     \"Pathogenesis of and risk factors for cardiac allograft vasculopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Preoperative evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Assessment of endothelial function by brachial ultrasound has been used for preoperative risk stratification in patients undergoing vascular surgery. The efficacy of brachial artery ultrasound for risk stratification was assessed in a study of 187 patients undergoing vascular surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/34\">",
"     34",
"    </a>",
"    ]. Low flow-mediated dilation was an independent predictor of a cardiac event at 30 days (odds ratio 9) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/34\">",
"     34",
"    </a>",
"    ] and of late events at 1.2 year follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The results from ongoing studies will provide further information about the clinical utility of this technique for preoperative risk stratification.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     POSSIBLE THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial dysfunction is induced by oxidized LDL [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/70\">",
"     70",
"    </a>",
"    ] and can be worsened by cigarette smoking. It can be reversed by L-arginine; with correction of hyperlipidemia by diet or by therapy with a statin, which increases the bioavailability of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]; with estrogen replacement, which increases the synthesis and release of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]; with antioxidants such as vitamin C or flavonoids contained in red wine and purple grape juice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]; or by inhibition of the renin-angiotensin system with an ACE inhibitor or angiotensin-I receptor blocker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link&amp;anchor=H9#H9\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\", section on 'Reversal of endothelial dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=see_link\">",
"     \"Actions of angiotensin II on the heart\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     L-arginine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intravenous or intracoronary administration of L-arginine, the physiologic precursor for NO, can acutely improve endothelium-dependent, but not endothelium-independent, vasodilation in patients with hypercholesterolemia or coronary atherosclerosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/2,78-80\">",
"     2,78-80",
"    </a>",
"    ]. The stereoisomer, D-arginine, is ineffective [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/78,79\">",
"     78,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The longer term effects of oral L-arginine have also been evaluated. Among patients with heart failure, oral L-arginine improved endothelial function, arterial compliance, and functional status [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are conflicting data from small randomized trials on the effect of oral therapy with L-arginine in patients with coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/82-85\">",
"     82-85",
"    </a>",
"    ]. A randomized trial of 30 patients on appropriate medical therapy for coronary heart disease found that one month of L-arginine therapy (9 g per day) did not improve NO bioavailability, had no effect on serum cell adhesion molecules (an index of NO regulated markers of inflammation), and had no effect on flow-mediated dilation of the brachial artery (an index of NO bioactivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/82\">",
"     82",
"    </a>",
"    ]. In another report, L-arginine did not improve endothelial dysfunction in patients with type 1 diabetes who had no evidence of coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, L-arginine had clinical benefit in a randomized study of 36 patients with stable class II and III angina [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/84\">",
"     84",
"    </a>",
"    ]. Compared to placebo, two weeks of therapy with a medical food bar enriched with L-arginine and other nutrients known to enhance endothelial dysfunction (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    ; vitamins B6, B12, C, and E; niacin; and phytoestrogens) improved flow-mediated vasodilation, treadmill exercise time, and quality of life scores without any effect on the ECG manifestations of ischemia.",
"   </p>",
"   <p>",
"    The potential benefits associated with L-arginine therapy are presumably mediated by increased NO activity. In addition to improved endothelial function, other changes that have been described include lower plasma endothelin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/85\">",
"     85",
"    </a>",
"    ], increased apoptosis of vascular cells in intimal lesions, leading to regression of atherosclerosis and decreased symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/86\">",
"     86",
"    </a>",
"    ], and prevention of the progression of atherosclerotic plaques [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     N-acetylcysteine",
"    </span>",
"    &nbsp;&mdash;&nbsp;N-acetylcysteine (NAC), a thiol, is a pharmacologic precursor of L-cysteine. It can potentiate the activity of NO and may promote scavenging of free radicals. One study of 16 patients with atherosclerosis found that NAC supplements improved coronary and peripheral endothelium-dependent vasodilation; the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    was not affected, while the response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    was potentiated only in the coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Lipid lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some but not all studies have found that endothelial dysfunction can be attenuated or abolished with the use of a statin. This issue is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link&amp;anchor=H9#H9\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\", section on 'Reversal of endothelial dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fibrate therapy also improves fasting and postprandial endothelial function in patients with type 2 diabetes. The mechanism for this may be an increase in HDL and an attenuation of postprandial lipemia and the associated oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/89\">",
"     89",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=see_link\">",
"     \"Lipid lowering with fibric acid derivatives\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Low fat/Mediterranean diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;A low fat diet is usually the first step in treating hypercholesterolemia. A Mediterranean diet reduces serum LDL-cholesterol and lowers the risk of cardiovascular events in patients with a myocardial infarction. These benefits are associated with an improvement in endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'Lifestyle modification'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link\">",
"     \"Dietary fat\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Aerobic exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular aerobic exercise is associated with a reduced risk of cardiovascular events, especially in middle-aged and older adults; it also can modify many of the traditional risk factors for coronary disease, including endothelial dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=see_link\">",
"     \"Overview of the benefits and risks of exercise\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=see_link\">",
"     \"Exercise and fitness in the prevention of cardiovascular disease\"",
"    </a>",
"    .) As an example, one study of 68 healthy men, aged 22 to 35 and 50 to 76, who were either sedentary or endurance-exercise trained, found that endurance-trained men did not have an age-associated decline of endothelium-dependent vasodilation; in addition, regular aerobic exercise restored the loss of endothelium-dependent vasodilation in previously sedentary middle-aged and older healthy men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Weight loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with endothelial dysfunction, possibly related to an increase in cytokine concentrations, which results from enhanced expression and release by adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/93\">",
"     93",
"    </a>",
"    ]. Some of these cytokines, such as tumor necrosis factor alpha and interleukin-6, can influence endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/94\">",
"     94",
"    </a>",
"    ]. Among premenopausal obese women, that weight loss has been associated with a significant reduction in cytokine levels and an improvement in endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3641?source=see_link\">",
"     \"Obesity, weight reduction, and cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Antioxidants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with hypercholesterolemia, vitamin C, folate, and 5-methyltetrahydrofolate, the active form of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    , can improve endothelial function; improvement occurs without changes in plasma lipids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Vitamin C can also restore coronary microcirculatory responsiveness and impaired coronary flow reserve in smokers with normal coronary arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/98\">",
"     98",
"    </a>",
"    ]. Vitamin C and folate may act by reducing oxidative stress and preventing the degradation of nitric oxide. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=see_link\">",
"     \"Vitamin supplementation in disease prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another mechanism by which folate improves endothelial dysfunction may be by a reduction in serum levels of homocysteine. Elevated levels of homocysteine promote endothelial dysfunction by their toxic effects on the endothelium, likely mediated by an increase in oxidative stress [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/99\">",
"     99",
"    </a>",
"    ] and inhibition of NO synthesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Young patients with type I diabetes and endothelial dysfunction have reduced plasma and LDL vitamin E content; vitamin E supplementation restores the endothelial function of conduit and resistance vessels in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/101,102\">",
"     101,102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=see_link\">",
"     \"Nutritional antioxidants in coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Flavonoids, found in red wine, grape juice, and tea, also have antioxidant properties and may prevent the oxidation of LDL and improve endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/103\">",
"     103",
"    </a>",
"    ]. The intake of tea flavonoids is associated with a reduction in cardiovascular disease events [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/104\">",
"     104",
"    </a>",
"    ], possibly as a result of the improvement in endothelial dysfunction in patients with coronary artery disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/105\">",
"     105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=see_link\">",
"     \"Cardiovascular benefits and risks of moderate alcohol consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/40/25223?source=see_link\">",
"     Allopurinol",
"    </a>",
"    therapy rapidly reverses endothelial dysfunction in smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/106\">",
"     106",
"    </a>",
"    ]. The drug-induced inhibition of xanthine oxidase may lead to reduced oxygen free radical production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    may also improve endothelial dysfunction in the presence of atherosclerosis, possibly via inhibition of one or more cyclooxygenase-dependent vasoconstrictors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/107\">",
"     107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=see_link\">",
"     \"NSAIDs: Mechanism of action\"",
"    </a>",
"    .) This can result in vasodilation and reduction in thrombosis, providing a potential mechanism for the beneficial effects of aspirin in atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Estrogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial cells have estrogen receptors, suggesting that estrogen may have a direct effect on endothelial function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/108\">",
"     108",
"    </a>",
"    ]. Consistent with this hypothesis are the observations that estrogen therapy enhances endothelium-dependent vasodilatation in postmenopausal women with hypercholesterolemia or atherosclerotic arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/109\">",
"     109",
"    </a>",
"    ]. A potential mechanism for this beneficial effect is enhanced endothelial synthesis and release of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/73,74,110\">",
"     73,74,110",
"    </a>",
"    ]. Another potential mechanism is a reduction in coronary endothelin-1 levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/111\">",
"     111",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=see_link\">",
"     \"Postmenopausal hormone therapy and cardiovascular risk\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Concurrent administration of progesterone offsets the beneficial effects of estrogen on endothelial function, without altering its LDL-lowering and antioxidant effects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Selective estrogen receptor modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     Tamoxifen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6390?source=see_link\">",
"     raloxifene",
"    </a>",
"    are selective estrogen receptor modulators, which have estrogen-like activity on some of the plasma cardiovascular risk factors, for example a decrease in low density lipoprotein and fibrinogen. One study of 31 men with documented coronary heart disease found that 56 days of tamoxifen therapy produced a significant increase in endothelium-dependent flow mediated vasodilatation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/113\">",
"     113",
"    </a>",
"    ]. In an animal model, raloxifene improved hypertension-induced endothelial dysfunction by increasing the bioavailability of NO [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=see_link\">",
"     \"Mechanisms of action of selective estrogen receptor modulators\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Phytoestrogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phytoestrogens, which are found in soy protein, have properties that are similar to estrogen, including an effect on cholesterol levels and inhibition of low density lipoprotein oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/115\">",
"     115",
"    </a>",
"    ]. One study of normal subjects found that the phytoestrogen genistein produced NO dependent vasodilation with similar potency to estradiol [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/116\">",
"     116",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link&amp;anchor=H3#H3\">",
"     \"Lipid lowering with diet or dietary supplements\", section on 'Soy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Testosterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone may also improve endothelial dysfunction. One small series of 13 patients with coronary heart disease found that testosterone, at physiologic concentrations, induced coronary artery dilatation and increased coronary blood flow [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/117\">",
"     117",
"    </a>",
"    ]. However, this did not appear to be mediated by endothelium-dependent responses, since acetylcholine-induced changes in coronary artery blood flow were not affected by testosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Blockade of the renin-angiotensin system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Angiotensin converting enzyme (ACE) inhibitors may improve endothelial dysfunction, but this benefit may not be seen in all drugs in this class. In one report,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/29/24024?source=see_link\">",
"     quinapril",
"    </a>",
"    , which has high tissue specificity for ACE, but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , improved endothelial dysfunction in patients with coronary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/118\">",
"     118",
"    </a>",
"    ]. The efficacy of quinapril was also evaluated in the TREND trial of men with coronary disease but without heart failure, hypertension, or lipid abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/119\">",
"     119",
"    </a>",
"    ]. The administration of quinapril improved endothelial dysfunction at six months.",
"   </p>",
"   <p>",
"    There are conflicting data as to whether ACE inhibition with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/22/20839?source=see_link\">",
"     enalaprilat",
"    </a>",
"    improves endothelial dysfunction in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/120,121\">",
"     120,121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/122-124\">",
"     122-124",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/118\">",
"     118",
"    </a>",
"    ] studies have shown an improvement in endothelial dysfunction following the administration of an angiotensin II receptor blocker in patients with atherosclerosis or diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Endothelin receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated levels of endothelin may play a role in endothelial dysfunction seen in heart failure and hypertension and, as noted above, in the transient dysfunction induced by mental stress. In a small series of patients with these problems, endothelin receptor blockade produced an improvement in endothelial dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/23,125,126\">",
"     23,125,126",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11592?source=see_link\">",
"     \"Role of endothelin in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Other forms of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous other interventions have been investigated for their potential in reversing endothelial dysfunction. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"       Nifedipine",
"      </a>",
"      , which may have antioxidant effects and effects on endothelial nitric oxide synthase expression and activity. In a study of 343 patients undergoing percutaneous coronary intervention, endothelium dependent vasodilatation was assessed with intracoronary acetylcholine after six months of therapy with nifedipine, cerivastatin, or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/127\">",
"       127",
"      </a>",
"      ]. Nifedipine but not cerivastatin reduced vasoconstriction to acetylcholine.",
"     </li>",
"     <li>",
"      Supplementation of taurine supplementation, a semi-essential amino acid [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/128\">",
"       128",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thermal therapy in a sauna for 15 to 30 minutes once daily [",
"      <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/129,130\">",
"       129,130",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Prognosis after treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;A recent study in patients with coronary artery disease showed that persistent impairment of endothelial vasomotor function despite optimized therapy to reduce risk factors has an adverse impact on clinical outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/39/23162/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H201322445\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The arterial endothelium is a monolayer of cells that carries out multiple important tasks. Endothelial dysfunction is seen in a variety of pathological conditions, with atherosclerosis being the most prominent. It is also found in patients with hypercholesterolemia, diabetes, hypertension, heart failure, cigarette smoking, and aging. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Blood vessels dilate in response to sheer stress, a process called flow-mediated vasodilation (FMD); measurement of FMD is a clinical method for evaluating endothelial function. Impairment of FMD is seen in the early stages of atherosclerotic vascular disease. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Endothelial physiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Association with atherosclerosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While endothelial dysfunction is associated with impaired clinical outcomes, tests of endothelial function are not currently recommended for use as surrogate markers in clinical practice.",
"     </li>",
"     <li>",
"      Improvement of endothelial function is a desirable therapeutical goal, and several therapeutic interventions have shown promise in this regard. However, only a few of these (ie, statins) have been systematically assessed in large, prospective, randomized, controlled studies.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/1\">",
"      Janssens SP, Shimouchi A, Quertermous T, et al. Cloning and expression of a cDNA encoding human endothelium-derived relaxing factor/nitric oxide synthase. J Biol Chem 1992; 267:14519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/2\">",
"      B&ouml;ger RH, Bode-B&ouml;ger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98:1842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/3\">",
"      Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/4\">",
"      Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation 2004; 109:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/5\">",
"      Steudel W, Ichinose F, Huang PL, et al. Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene. Circ Res 1997; 81:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/6\">",
"      Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004; 109:III27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/7\">",
"      Sch&auml;chinger V, Britten MB, Elsner M, et al. A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation. Circulation 1999; 100:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/8\">",
"      Lieberman EH, Gerhard MD, Uehata A, et al. Flow-induced vasodilation of the human brachial artery is impaired in patients &lt;40 years of age with coronary artery disease. Am J Cardiol 1996; 78:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/9\">",
"      Clarkson P, Celermajer DS, Powe AJ, et al. Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation 1997; 96:3378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/10\">",
"      Lundman P, Eriksson MJ, St&uuml;hlinger M, et al. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001; 38:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/11\">",
"      Al Suwaidi J, Higano ST, Holmes DR Jr, et al. Obesity is independently associated with coronary endothelial dysfunction in patients with normal or mildly diseased coronary arteries. J Am Coll Cardiol 2001; 37:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/12\">",
"      Shinozaki K, Hirayama A, Nishio Y, et al. Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol 2001; 38:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/13\">",
"      Arcaro G, Cretti A, Balzano S, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 2002; 105:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/14\">",
"      Balletshofer BM, Rittig K, Enderle MD, et al. Endothelial dysfunction is detectable in young normotensive first-degree relatives of subjects with type 2 diabetes in association with insulin resistance. Circulation 2000; 101:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/15\">",
"      Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol 1996; 28:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/16\">",
"      M&auml;kimattila S, Virkam&auml;ki A, Groop PH, et al. Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation 1996; 94:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/17\">",
"      Gaenzer H, Neumayr G, Marschang P, et al. Effect of insulin therapy on endothelium-dependent dilation in type 2 diabetes mellitus. Am J Cardiol 2002; 89:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/18\">",
"      M&auml;kimattila S, M&auml;ntysaari M, Groop PH, et al. Hyperreactivity to nitrovasodilators in forearm vasculature is related to autonomic dysfunction in insulin-dependent diabetes mellitus. Circulation 1997; 95:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/19\">",
"      Piatti P, Fragasso G, Monti LD, et al. Acute intravenous L-arginine infusion decreases endothelin-1 levels and improves endothelial function in patients with angina pectoris and normal coronary arteriograms: correlation with asymmetric dimethylarginine levels. Circulation 2003; 107:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/20\">",
"      Celermajer DS, Sorensen KE, Spiegelhalter DJ, et al. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol 1994; 24:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/21\">",
"      Egashira K, Inou T, Hirooka Y, et al. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation 1993; 88:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/22\">",
"      Ghiadoni L, Donald AE, Cropley M, et al. Mental stress induces transient endothelial dysfunction in humans. Circulation 2000; 102:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/23\">",
"      Spieker LE, H&uuml;rlimann D, Ruschitzka F, et al. Mental stress induces prolonged endothelial dysfunction via endothelin-A receptors. Circulation 2002; 105:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/24\">",
"      Brevetti G, Martone VD, de Cristofaro T, et al. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/25\">",
"      Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95:1747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/26\">",
"      B&ouml;ger RH, Bode-B&ouml;ger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95:2068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/27\">",
"      Diodati JG, Dakak N, Gilligan DM, Quyyumi AA. Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans. Circulation 1998; 98:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/28\">",
"      Tiefenbacher CP, Bleeke T, Vahl C, et al. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/29\">",
"      Ito A, Tsao PS, Adimoolam S, et al. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999; 99:3092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/30\">",
"      Valkonen VP, P&auml;iv&auml; H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/31\">",
"      Mangin EL Jr, Kugiyama K, Nguy JH, et al. Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta. Circ Res 1993; 72:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/32\">",
"      Vergnani L, Hatrik S, Ricci F, et al. Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production : key role of L-arginine availability. Circulation 2000; 101:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/33\">",
"      Landmesser U, Merten R, Spiekermann S, et al. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 2000; 101:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/34\">",
"      Kaye DM, Ahlers BA, Autelitano DJ, Chin-Dusting JP. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 2000; 102:2707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/35\">",
"      Boltwood MD, Taylor CB, Burke MB, et al. Anger report predicts coronary artery vasomotor response to mental stress in atherosclerotic segments. Am J Cardiol 1993; 72:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/36\">",
"      Lacy CR, Contrada RJ, Robbins ML, et al. Coronary vasoconstriction induced by mental stress (simulated public speaking). Am J Cardiol 1995; 75:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/37\">",
"      Adams MR, Robinson J, McCredie R, et al. Smooth muscle dysfunction occurs independently of impaired endothelium-dependent dilation in adults at risk of atherosclerosis. J Am Coll Cardiol 1998; 32:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/38\">",
"      Liuba P, Karnani P, Pesonen E, et al. Endothelial dysfunction after repeated Chlamydia pneumoniae infection in apolipoprotein E-knockout mice. Circulation 2000; 102:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/39\">",
"      Hingorani AD, Cross J, Kharbanda RK, et al. Acute systemic inflammation impairs endothelium-dependent dilatation in humans. Circulation 2000; 102:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/40\">",
"      Fichtlscherer S, Rosenberger G, Walter DH, et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/41\">",
"      Blum A, Tamir S, Mualem K, et al. Endothelial dysfunction is reversible in Helicobacter pylori-positive subjects. Am J Med 2011; 124:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/42\">",
"      Beckman JA, Thakore A, Kalinowski BH, et al. Radiation therapy impairs endothelium-dependent vasodilation in humans. J Am Coll Cardiol 2001; 37:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/43\">",
"      Chow AY, Chin C, Dahl G, Rosenthal DN. Anthracyclines cause endothelial injury in pediatric cancer patients: a pilot study. J Clin Oncol 2006; 24:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/44\">",
"      Boulanger CM, Scoazec A, Ebrahimian T, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104:2649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/45\">",
"      Hill JM, Zalos G, Halcox JP, et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003; 348:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/46\">",
"      Schmidt-Lucke C, R&ouml;ssig L, Fichtlscherer S, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111:2981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/47\">",
"      Shaffer RG, Greene S, Arshi A, et al. Flow cytometric measurement of circulating endothelial cells: the effect of age and peripheral arterial disease on baseline levels of mature and progenitor populations. Cytometry B Clin Cytom 2006; 70:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/48\">",
"      Mohler ER 3rd, Shi Y, Moore J, et al. Diabetes reduces bone marrow and circulating porcine endothelial progenitor cells, an effect ameliorated by atorvastatin and independent of cholesterol. Cytometry A 2009; 75:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/49\">",
"      Bahlmann FH, DeGroot K, Duckert T, et al. Endothelial progenitor cell proliferation and differentiation is regulated by erythropoietin. Kidney Int 2003; 64:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/50\">",
"      Shaffer RG, Greene S, Arshi A, et al. Effect of acute exercise on endothelial progenitor cells in patients with peripheral arterial disease. Vasc Med 2006; 11:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/51\">",
"      M&eacute;ndez-Ferrer S, Lucas D, Battista M, Frenette PS. Haematopoietic stem cell release is regulated by circadian oscillations. Nature 2008; 452:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/52\">",
"      Viswambharan H, Carvas JM, Antic V, et al. Mutation of the circadian clock gene Per2 alters vascular endothelial function. Circulation 2007; 115:2188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/53\">",
"      Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/54\">",
"      Roman MJ, Naqvi TZ, Gardin JM, et al. Clinical application of noninvasive vascular ultrasound in cardiovascular risk stratification: a report from the American Society of Echocardiography and the Society of Vascular Medicine and Biology. J Am Soc Echocardiogr 2006; 19:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/55\">",
"      Anderson TJ, Uehata A, Gerhard MD, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/56\">",
"      Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117:2467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/57\">",
"      Hamburg NM, Palmisano J, Larson MG, et al. Relation of brachial and digital measures of vascular function in the community: the Framingham heart study. Hypertension 2011; 57:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/58\">",
"      Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 2002; 106:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/59\">",
"      Su Y, Liu XM, Sun YM, et al. Endothelial dysfunction in impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes mellitus. Am J Cardiol 2008; 102:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/60\">",
"      Kuvin JT, Patel AR, Sliney KA, et al. Peripheral vascular endothelial function testing as a noninvasive indicator of coronary artery disease. J Am Coll Cardiol 2001; 38:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/61\">",
"      Halcox JP, Donald AE, Ellins E, et al. Endothelial function predicts progression of carotid intima-media thickness. Circulation 2009; 119:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/62\">",
"      Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009; 120:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/63\">",
"      Suwaidi JA, Hamasaki S, Higano ST, et al. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/64\">",
"      Sch&auml;chinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/65\">",
"      Halcox JP, Schenke WH, Zalos G, et al. Prognostic value of coronary vascular endothelial dysfunction. Circulation 2002; 106:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/66\">",
"      Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 2008; 156:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/67\">",
"      Muiesan ML, Salvetti M, Paini A, et al. Prognostic role of flow-mediated dilatation of the brachial artery in hypertensive patients. J Hypertens 2008; 26:1612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/68\">",
"      Hollenberg SM, Klein LW, Parrillo JE, et al. Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation 2001; 104:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/69\">",
"      Wenzel RR, Duthiers N, Noll G, et al. Endothelin and calcium antagonists in the skin microcirculation of patients with coronary artery disease. Circulation 1996; 94:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/70\">",
"      Anderson TJ, Meredith IT, Charbonneau F, et al. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation 1996; 93:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/71\">",
"      Harrison DG, Armstrong ML, Freiman PC, Heistad DD. Restoration of endothelium-dependent relaxation by dietary treatment of atherosclerosis. J Clin Invest 1987; 80:1808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/72\">",
"      John S, Schlaich M, Langenfeld M, et al. Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study. Circulation 1998; 98:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/73\">",
"      Stefano GB, Prevot V, Beauvillain JC, et al. Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia. Circulation 2000; 101:1594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/74\">",
"      Chen Z, Yuhanna IS, Galcheva-Gargova Z, et al. Estrogen receptor alpha mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Invest 1999; 103:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/75\">",
"      Levine GN, Frei B, Koulouris SN, et al. Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 1996; 93:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/76\">",
"      Stein JH, Keevil JG, Wiebe DA, et al. Purple grape juice improves endothelial function and reduces the susceptibility of LDL cholesterol to oxidation in patients with coronary artery disease. Circulation 1999; 100:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/77\">",
"      Hashimoto M, Kim S, Eto M, et al. Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery. Am J Cardiol 2001; 88:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/78\">",
"      Creager MA, Gallagher SJ, Girerd XJ, et al. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992; 90:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/79\">",
"      Quyyumi AA, Dakak N, Diodati JG, et al. Effect of L-arginine on human coronary endothelium-dependent and physiologic vasodilation. J Am Coll Cardiol 1997; 30:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/80\">",
"      Thorne S, Mullen MJ, Clarkson P, et al. Early endothelial dysfunction in adults at risk from atherosclerosis: different responses to L-arginine. J Am Coll Cardiol 1998; 32:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/81\">",
"      Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/82\">",
"      Blum A, Hathaway L, Mincemoyer R, et al. Oral L-arginine in patients with coronary artery disease on medical management. Circulation 2000; 101:2160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/83\">",
"      Mullen MJ, Wright D, Donald AE, et al. Atorvastatin but not L-arginine improves endothelial function in type I diabetes mellitus: a double-blind study. J Am Coll Cardiol 2000; 36:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/84\">",
"      Maxwell AJ, Zapien MP, Pearce GL, et al. Randomized trial of a medical food for the dietary management of chronic, stable angina. J Am Coll Cardiol 2002; 39:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/85\">",
"      Lerman A, Burnett JC Jr, Higano ST, et al. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. Circulation 1998; 97:2123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/86\">",
"      Wang BY, Ho HK, Lin PS, et al. Regression of atherosclerosis: role of nitric oxide and apoptosis. Circulation 1999; 99:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/87\">",
"      B&ouml;ger RH, Bode-B&ouml;ger SM, Brandes RP, et al. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin. Circulation 1997; 96:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/88\">",
"      Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol 2001; 37:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/89\">",
"      Evans M, Anderson RA, Graham J, et al. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000; 101:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/90\">",
"      Ryan M, McInerney D, Owens D, et al. Diabetes and the Mediterranean diet: a beneficial effect of oleic acid on insulin sensitivity, adipocyte glucose transport and endothelium-dependent vasoreactivity. QJM 2000; 93:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/91\">",
"      Fuentes F, L&oacute;pez-Miranda J, S&aacute;nchez E, et al. Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men. Ann Intern Med 2001; 134:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/92\">",
"      DeSouza CA, Shapiro LF, Clevenger CM, et al. Regular aerobic exercise prevents and restores age-related declines in endothelium-dependent vasodilation in healthy men. Circulation 2000; 102:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/93\">",
"      Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999; 19:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/94\">",
"      Bhagat K, Vallance P. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation 1997; 96:3042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/95\">",
"      Ziccardi P, Nappo F, Giugliano G, et al. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/96\">",
"      Ting HH, Timimi FK, Haley EA, et al. Vitamin C improves endothelium-dependent vasodilation in forearm resistance vessels of humans with hypercholesterolemia. Circulation 1997; 95:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/97\">",
"      Verhaar MC, Wever RM, Kastelein JJ, et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia. A randomized placebo-controlled trial. Circulation 1999; 100:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/98\">",
"      Kaufmann PA, Gnecchi-Ruscone T, di Terlizzi M, et al. Coronary heart disease in smokers: vitamin C restores coronary microcirculatory function. Circulation 2000; 102:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/99\">",
"      Chambers JC, Ueland PM, Obeid OA, et al. Improved vascular endothelial function after oral B vitamins: An effect mediated through reduced concentrations of free plasma homocysteine. Circulation 2000; 102:2479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/100\">",
"      St&uuml;hlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001; 104:2569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/101\">",
"      Skyrme-Jones RA, O'Brien RC, Luo M, Meredith IT. Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes. J Am Coll Cardiol 2000; 35:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/102\">",
"      Skyrme-Jones RA, O'Brien RC, Berry KL, Meredith IT. Vitamin E supplementation improves endothelial function in type I diabetes mellitus: a randomized, placebo-controlled study. J Am Coll Cardiol 2000; 36:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/103\">",
"      Chou EJ, Keevil JG, Aeschlimann S, et al. Effect of ingestion of purple grape juice on endothelial function in patients with coronary heart disease. Am J Cardiol 2001; 88:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/104\">",
"      Sesso HD, Gaziano JM, Buring JE, Hennekens CH. Coffee and tea intake and the risk of myocardial infarction. Am J Epidemiol 1999; 149:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/105\">",
"      Duffy SJ, Keaney JF Jr, Holbrook M, et al. Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease. Circulation 2001; 104:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/106\">",
"      Guthikonda S, Sinkey C, Barenz T, Haynes WG. Xanthine oxidase inhibition reverses endothelial dysfunction in heavy smokers. Circulation 2003; 107:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/107\">",
"      Husain S, Andrews NP, Mulcahy D, et al. Aspirin improves endothelial dysfunction in atherosclerosis. Circulation 1998; 97:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/108\">",
"      Venkov CD, Rankin AB, Vaughan DE. Identification of authentic estrogen receptor in cultured endothelial cells. A potential mechanism for steroid hormone regulation of endothelial function. Circulation 1996; 94:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/109\">",
"      Gilligan DM, Quyyumi AA, Cannon RO 3rd. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994; 89:2545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/110\">",
"      Thompson LP, Pinkas G, Weiner CP. Chronic 17beta-estradiol replacement increases nitric oxide-mediated vasodilation of guinea pig coronary microcirculation. Circulation 2000; 102:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/111\">",
"      Webb CM, Ghatei MA, McNeill JG, Collins P. 17beta-estradiol decreases endothelin-1 levels in the coronary circulation of postmenopausal women with coronary artery disease. Circulation 2000; 102:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/112\">",
"      Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001; 104:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/113\">",
"      Clarke SC, Schofield PM, Grace AA, et al. Tamoxifen effects on endothelial function and cardiovascular risk factors in men with advanced atherosclerosis. Circulation 2001; 103:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/114\">",
"      Wassmann S, Laufs U, Stamenkovic D, et al. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002; 105:2083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/115\">",
"      Lissin LW, Cooke JP. Phytoestrogens and cardiovascular health. J Am Coll Cardiol 2000; 35:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/116\">",
"      Walker HA, Dean TS, Sanders TA, et al. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17beta-estradiol. Circulation 2001; 103:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/117\">",
"      Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation 1999; 100:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/118\">",
"      Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). J Am Coll Cardiol 2000; 35:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/119\">",
"      Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/120\">",
"      O'Driscoll G, Green D, Rankin J, et al. Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 1997; 100:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/121\">",
"      Mullen MJ, Clarkson P, Donald AE, et al. Effect of enalapril on endothelial function in young insulin-dependent diabetic patients: a randomized, double-blind study. J Am Coll Cardiol 1998; 31:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/122\">",
"      Prasad A, Tupas-Habib T, Schenke WH, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101:2349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/123\">",
"      Hornig B, Landmesser U, Kohler C, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase. Circulation 2001; 103:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/124\">",
"      Cheetham C, Collis J, O'Driscoll G, et al. Losartan, an angiotensin type 1 receptor antagonist, improves endothelial function in non-insulin-dependent diabetes. J Am Coll Cardiol 2000; 36:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/125\">",
"      Berger R, Stanek B, H&uuml;lsmann M, et al. Effects of endothelin a receptor blockade on endothelial function in patients with chronic heart failure. Circulation 2001; 103:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/126\">",
"      Cardillo C, Campia U, Kilcoyne CM, et al. Improved endothelium-dependent vasodilation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002; 105:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/127\">",
"      ENCORE Investigators. Effect of nifedipine and cerivastatin on coronary endothelial function in patients with coronary artery disease: the ENCORE I Study (Evaluation of Nifedipine and Cerivastatin On Recovery of coronary Endothelial function). Circulation 2003; 107:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/128\">",
"      Fennessy FM, Moneley DS, Wang JH, et al. Taurine and vitamin C modify monocyte and endothelial dysfunction in young smokers. Circulation 2003; 107:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/129\">",
"      Imamura M, Biro S, Kihara T, et al. Repeated thermal therapy improves impaired vascular endothelial function in patients with coronary risk factors. J Am Coll Cardiol 2001; 38:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/130\">",
"      Kihara T, Biro S, Imamura M, et al. Repeated sauna treatment improves vascular endothelial and cardiac function in patients with chronic heart failure. J Am Coll Cardiol 2002; 39:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/39/23162/abstract/131\">",
"      Kitta Y, Obata JE, Nakamura T, et al. Persistent impairment of endothelial vasomotor function has a negative impact on outcome in patients with coronary artery disease. J Am Coll Cardiol 2009; 53:323.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1532 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-335F5A8ACC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23162=[""].join("\n");
var outline_f22_39_23162=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H201322445\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDOTHELIAL PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ASSOCIATION WITH ATHEROSCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Abnormal nitric oxide metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Role of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anthracycline chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Microparticles",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Endothelial progenitor cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16028800\">",
"      Genetics of endothelial function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      BRACHIAL ARTERY ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pretest issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Ultrasound machine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Ultrasound protocol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16028819\">",
"      Peripheral artery tonometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CLINICAL USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Low to intermediate risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Higher-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Transplant vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Preoperative evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      POSSIBLE THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      L-arginine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      N-acetylcysteine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Lipid lowering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Low fat/Mediterranean diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Aerobic exercise",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Weight loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Antioxidants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Estrogen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Phytoestrogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Blockade of the renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Endothelin receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Other forms of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Prognosis after treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H201322445\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1532\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1532|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?20/17/20767\" title=\"algorithm 1\">",
"      Pathogenesis of atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1532|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/32/12800\" title=\"diagnostic image 1A\">",
"      Endothelial dysfunction CHD I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?42/41/43679\" title=\"diagnostic image 1B\">",
"      Endothelial dysfunction CHD II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/38/26223\" title=\"diagnostic image 1C\">",
"      Endothelial dysfunction CHD III",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/2/17443\" title=\"diagnostic image 2\">",
"      Endothelial function and brachial artery ultrasound",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1532|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/10/15535\" title=\"figure 1\">",
"      Impaired coronary artery vasoreactivity predicts CV events",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1532|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/50/812\" title=\"table 1\">",
"      Endothelial dysfunction factors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36825?source=related_link\">",
"      Actions of angiotensin II on the heart",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/40/44679?source=related_link\">",
"      Association between Helicobacter pylori infection and duodenal ulcer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27658?source=related_link\">",
"      C-reactive protein in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19864?source=related_link\">",
"      Cardiac syndrome X: Angina pectoris with normal coronary arteries: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/33/31258?source=related_link\">",
"      Cardiovascular benefits and risks of moderate alcohol consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/36/25160?source=related_link\">",
"      Chlamydophila (Chlamydia) pneumoniae infection as a potential etiologic factor in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/28/14793?source=related_link\">",
"      Exercise and fitness in the prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7800?source=related_link\">",
"      Lipid lowering with fibric acid derivatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/2/7210?source=related_link\">",
"      Mechanisms of action of selective estrogen receptor modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1336?source=related_link\">",
"      NSAIDs: Mechanism of action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26456?source=related_link\">",
"      Nutritional antioxidants in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3641?source=related_link\">",
"      Obesity, weight reduction, and cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/46/28394?source=related_link\">",
"      Overview of the benefits and risks of exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34394?source=related_link\">",
"      Overview of the possible risk factors for cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/25/44441?source=related_link\">",
"      Pathogenesis of and risk factors for cardiac allograft vasculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/36/29258?source=related_link\">",
"      Postmenopausal hormone therapy and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25528?source=related_link\">",
"      Psychosocial factors in coronary and cerebral vascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/20/11592?source=related_link\">",
"      Role of endothelin in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11785?source=related_link\">",
"      The coronary microcirculation in disease states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/10/36009?source=related_link\">",
"      The endothelium: A primer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/46/36586?source=related_link\">",
"      Vitamin supplementation in disease prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_39_23163="Causes uvulitis";
var content_f22_39_23163=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F82234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F82234&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infectious and noninfectious causes of uvulitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Group A streptococcus (",
"        <em>",
"         Streptococcus pyogenes",
"        </em>",
"        )*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Fusobacterium nucleatum",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Prevotella intermedia",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Streptococcus pneumoniae",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <em>",
"         Candida albicans",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Noninfectious causes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trauma (during airway or other instrumentation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inhalation of irritants (including steam and cannabis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Allergic reaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Angioedema (Quincke's edema)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Most common cause. Other bacterial etiologies are from case reports.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23163=[""].join("\n");
var outline_f22_39_23163=null;
var title_f22_39_23164="DSM-IV-TR diagnostic criteria for hypomania";
var content_f22_39_23164=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F70757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F70757&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    DSM-IV-TR diagnostic criteria for hypomania",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        A distinct period of persistently elevated, expansive, or irritable mood, lasting at least 4 days, that is clearly different from the usual nondepressed mood.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         B.",
"        </strong>",
"        During the period of mood disturbance, three (or more) of the following symptoms have persisted (four if the mood is only irritable) and have been present to a significant degree:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1) Inflated self-esteem or grandiosity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2) Decreased need for sleep (eg, feels rested after only 3 hours of sleep)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3) More talkative than usual or pressure to keep talking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4) Flight of ideas or subjective experience that thoughts are racing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5) Distractibility (ie, attention too easily drawn to unimportant or irrelevant external stimuli)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        6) Increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        7) Excessive involvement in pleasurable activities that have a high potential for painful consequences (eg, engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         C.",
"        </strong>",
"        The episode is associated with an unequivocal change in functioning that is uncharacteristic of the person when not symptomatic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D.",
"        </strong>",
"        The disturbance in mood and the change in functioning are observable by others.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         E.",
"        </strong>",
"        The episode 1) is not severe enough to cause marked impairment in social or occupational functioning, 2) does not necessitate hospitalization, and 3) does not have psychotic features.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         F.",
"        </strong>",
"        The symptoms are not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication, or other treatment) or a general medical condition (eg, hyperthyroidism).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Note",
"        </strong>",
"        : Hypomanic-like episodes that are clearly caused by somatic antidepressant treatment (eg, medication, ECT, light therapy) should not count toward a diagnosis of bipolar II disorder.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Text Revision, Fourth Edition (Copyright 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23164=[""].join("\n");
var outline_f22_39_23164=null;
var title_f22_39_23165="GISSI risk index post MI";
var content_f22_39_23165=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59209&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    GISSI-prevenzione risk of death assessment scoring",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\" rowspan=\"2\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Risk points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Females",
"       </td>",
"       <td class=\"subtitle2\">",
"        Males",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Age, Years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        &lt;45",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -11",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        45 to 49",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        50 to 54",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        55 to 59",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        60 to 64",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        65 to 69",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        70 to 74",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        75",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Complications after myocardial infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Left ventricular dysfunction",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electrical instability",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Residual myocardial ischaernia",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Diabetes",
"       </td>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Hypertension",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Smoker",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Intermittent claudication",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Leukocyte count ( x 1000/&micro;L)",
"       </td>",
"       <td>",
"        &lt;7.0",
"       </td>",
"       <td>",
"        -4",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7.0 to 7.9",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8.0 to 8.9",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;9.0",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Fibrinogen (mg /dL)",
"       </td>",
"       <td>",
"        &lt;400",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;400",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        HDL-cholesterol (mg/dL)",
"       </td>",
"       <td>",
"        &gt;55",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        41 to 55",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        36 to 40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;35",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        Heart rate (beats/min)",
"       </td>",
"       <td>",
"        &le;64",
"       </td>",
"       <td>",
"        -2",
"       </td>",
"       <td>",
"        -1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        65 to 69",
"       </td>",
"       <td>",
"        -3",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        70 to 74",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &ge;75",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Marchioli R, Avanzini F, Barzi F. Eur Heart J 2001; 22:2085.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23165=[""].join("\n");
var outline_f22_39_23165=null;
var title_f22_39_23166="Steps in management of postpartum hemorrhage";
var content_f22_39_23166=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57307&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sequential steps in managing postpartum hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         Assemble team and notify appropriate departments",
"        </strong>",
"        <strong>",
"         &nbsp;(obstetrics, nursing, anesthesiology, blood bank, laboratory)",
"        </strong>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Initiate uterine massage and establish large bore (two 16 or 18-gauge,&nbsp;ideally&nbsp;14-gauge) &nbsp;intravenous access",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Administer oxygen (10-15 liters/minute) by face mask. Anesthesia team should evaluate airway and breathing, intubate if indicated.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Fluid resuscitation:",
"        </strong>",
"        Infuse crystalloid (at least 3 liters for each liter of estimated blood loss)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Transfusion:",
"        </strong>",
"        If hemodynamics do not improve&nbsp;with 2 to 3 liters of&nbsp;crystalloid administration and bleeding continues, administer blood products, initially two units packed red blood cells. For massive transfusion,&nbsp;administer",
"        <span style=\"font-family: verdana,sans-serif; font-size: 10pt;\">",
"         red blood cells, fresh frozen plasma, and apheresis platelets in a ratio of 6:4:1 or 4:4:1.",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Administer uterotonic drugs* to reverse atony:",
"        </strong>",
"        It should be possible to determine within 30 minutes whether uterotonic&nbsp;treatment will reverse atony.&nbsp; If it&nbsp;does not, prompt invasive intervention is usually warranted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         <strong>",
"          Initiate oxytocin:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Begin with oxytocin 40&nbsp;units in 1 liter of normal saline or Ringer's lactate.&nbsp; Using an intravenous infusion pump, start at 10 to 40 milliunits per minute.&nbsp; Adjust rate to&nbsp;achieve and maintain uterine contraction",
"          <sup>",
"           [1]",
"          </sup>",
"          ; 80&nbsp;units in 1 liter of normal saline or Ringer's lactate may be given for a short time.",
"          <sup>",
"           [2]",
"          </sup>",
"          Expect rapid response.&nbsp;",
"         </li>",
"         <li>",
"          Avoid rapid intravenous bolus injection of oxytocin",
"         </li>",
"         <li>",
"          If no intravenous access, give 10 units intramuscularly;&nbsp;expect response within 3 to 5 minutes",
"         </li>",
"         <li>",
"          There are no absolute contraindications to oxytocin for PPH",
"         </li>",
"         <li>",
"          Carbetocin (where available",
"          <sup>",
"           &bull;",
"          </sup>",
"          )&nbsp;100 mcg slow intravenous injection as single dose. A long acting analogue of oxytocin,&nbsp;carbetocin is a&nbsp;potential alternative if&nbsp;titrable oxytocin intravenous infusion is not feasible. &nbsp;",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         <strong>",
"          Add ergot:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Methylergonovine (methylergometrine) 0.2 mg intramuscularly (including intramyometrial) every two to four hours up to a maximum of 1 mg (five doses). Expect response within 2 to 5 minutes.",
"          <ul>",
"           <li>",
"            Do&nbsp;",
"            <strong>",
"             not",
"            </strong>",
"            give intravenously",
"           </li>",
"           <li>",
"            Avoid&nbsp;in women with hypertension, Raynaud's phenomenon, or scleroderma&nbsp;",
"           </li>",
"           <li>",
"            If first dose ineffective, quickly add a different uterotonic agent (eg, carboprost tromethamine)",
"           </li>",
"          </ul>",
"         </li>",
"         <li>",
"          Ergonovine (ergometrine), where available",
"          <sup>",
"           &bull;",
"          </sup>",
"          , is an alternative to methylergonovine; its&nbsp;actions and contraindications are similar to methylergonovine&nbsp;(see above).",
"          <sup>",
"           [3]",
"          </sup>",
"          <ul>",
"           <li>",
"            Ergonovine (ergometrine) 0.2 mg intramuscularly; may be repeated once in 15 minutes",
"           </li>",
"           <li>",
"            If required, additional doses of 0.2 mg intramuscularly may be given every four hours",
"            <sup>",
"             [3]",
"            </sup>",
"           </li>",
"          </ul>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        <p>",
"         <strong>",
"          Add prostaglandin:",
"         </strong>",
"        </p>",
"        <ul>",
"         <li>",
"          Carboprost tromethamine (PGF",
"          <sub>",
"           2",
"          </sub>",
"          alpha,&nbsp;Hemabate&reg;) 250 mcg intramuscularly every 15 to 90 minutes, as needed, to a&nbsp;maximum of 2 mg (eight doses). Peak plasma level&nbsp;is about&nbsp;30 minutes after injection.",
"          <ul>",
"           <li>",
"            Do&nbsp;",
"            <strong>",
"             not",
"            </strong>",
"            give intravenously",
"           </li>",
"           <li>",
"            Avoid in women with asthma/bronchospasm or hypertension",
"           </li>",
"           <li>",
"            Relatively contraindicated in renal or hepatic insufficiency or reduced cardiac output",
"           </li>",
"           <li>",
"            Can cause tachycardia, pyrexia, diarrhea",
"           </li>",
"          </ul>",
"         </li>",
"         <li>",
"          Misoprostol (PGE",
"          <sub>",
"           1",
"          </sub>",
"          ) 400 to 600 mcg sublingually or 800 to 1000 mcg rectally as a single dose.",
"          <sup>",
"           &Delta;&nbsp;&nbsp;",
"          </sup>",
"          The mean time to peak concentration is about 30 minutes&nbsp;after sublingual administration&nbsp;versus 40 to 60 minutes after rectal administration.",
"          <ul>",
"           <li>",
"            Can be given to women with hypertension or asthma/bronchospasm. Monitor for pyrexia.",
"           </li>",
"           <li>",
"            Unlikely to be useful if carboprost has been given and was not effective",
"           </li>",
"          </ul>",
"         </li>",
"         <li>",
"          Dinoprostone (PGE",
"          <sub>",
"           2",
"          </sub>",
"          ) 20 mg suppository intravaginally or rectally, is an alternative to misoprostol.&nbsp; Expect response within 10 minutes. May be repeated at 2 hour intervals.",
"          <ul>",
"           <li>",
"            Avoid in women who are hypotensive. Pyrexia is common",
"           </li>",
"           <li>",
"            Stored frozen, must be thawed to room temperature",
"           </li>",
"          </ul>",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Inspect the vagina and cervix for lacerations; repair as necessary. Evacuate any retained products of conception. Replace uterus if inverted.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Tamponade&nbsp;bleeding",
"        </strong>",
"        <strong>",
"         from the uterine cavity.&nbsp;",
"        </strong>",
"        &nbsp;Options include&nbsp;Bakri or BT-Cath balloon, Sengstaken-Blakemore tube, Foley catheter balloon, or packing if medical therapy fails and prior to, or in conjunction with, preparations for surgery or transarterial embolization.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Recombinant factor VIIa:&nbsp;",
"        </strong>",
"        Consider recombinant activated factor VIIa (off-label use) for management of intractable hemorrhage and coagulopathy.&nbsp; Risk of thromboembolism. High cost. See \"Management of postpartum hemorrhage at vaginal delivery\" section \"Recombinant activated factor VIIa\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Perform transarterial embolization&nbsp;if the woman is stable and there is time for personnel and facilities to mobilize",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        <strong>",
"         Perform laparotomy if the above measures fail.",
"        </strong>",
"        Surgical approaches that are quick, relatively easy, and effective should be tried first. In utilizing these measures, the surgeon should be cognizant of the amount of blood loss and the stability of the patient, and should perform hysterectomy rather than resort to temporizing measures if her cardiovascular status is unstable or if it appears that the anesthesiologist will not be able to keep up with her fluid needs. Options include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Ligate bleeding sites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perform uterine artery ligation, including the utero-ovarian arcade",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Place a B-Lynch stitch or other uterine compression suture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Perform hysterectomy - Hysterectomy is the last resort, but should not be delayed in women who have disseminated intravascular coagulation and require prompt control of uterine hemorrhage to prevent death",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Suture deep pelvic bleeders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Tamponade pelvic bleeding with pelvic packing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PG: prostglandin, PPH: Postpartum hemorrhage",
"     <br>",
"      * All uterotonic agents can cause nausea and vomiting.",
"      <br>",
"       &bull; Not available in US.&nbsp; Available in Canada, UK, EU and elsewhere.",
"       <br>",
"        &Delta; Oral tablets may be given per rectum or as a micro-enema prepared from oral misoprostol tablets dissolved in 5 mL saline.",
"        <sup>",
"         [4]",
"        </sup>",
"        <br>",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References: [1] American College of Obstetricians and Gynecologists Committee on Practice Bulletins&mdash;Obstetrics Postpartum hemorrhage (ACOG Practice Bulletin, number 76, issued October 2006). Obstet Gynecol 2006; 108: 1039&ndash;47. &nbsp;[2] Ramanathan G, Arulkumaran S. Postpartum hemorrhage. J Obstet Gynaecol Can 2006; 28: 967&ndash;73. [3] WHO guidelines for the management of postpartum haemorrhage and retained placenta (issued 2009). &nbsp;[4] Bugalho A, Daniel A, Faundes A, et al: Misoprostol for prevention of postpartum hemorrhage. Int J Gynecol Obstet 2001; 73:1-6.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23166=[""].join("\n");
var outline_f22_39_23166=null;
var title_f22_39_23167="TEE ASD";
var content_f22_39_23167=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/79348/atsepdet_conv.mp4?title=TEE+ASD\" style=\"width:312px;height:224px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transesophageal echocardiogram of an atrial septal defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 314px; height: 209px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a large defect in the mid interatrial septum compatible with a ostium secundum atrial septal defect (ASD).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_39_23167=[""].join("\n");
var outline_f22_39_23167=null;
